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Abstract 
The Drosophila Toll receptor is crucial for dorsoventral patterning in embryos, and also for the 
fly’s innate immune response. Toll also functions during central nervous system development, 
and promotes the survival and targeting of neurons. There are nine Toll paralogues in 
Drosophila, and it is unknown whether any of these also function in the CNS. Toll’s ligand, 
Spz, has an NGF domain. NGF is a vertebrate neurotrophin - a growth factor that regulates the 
development and function of the nervous system. Drosophila Neurotrophin 1 (DNT1), 
identified by homology to the vertebrate neurotrophin BDNF, and DNT2 are paralogues of spz. 
The three DNTs – DNT1, DNT2 and spz – are structural and functional homologues of 
vertebrate neurotrophins, and they promote neuronal survival, targeting and synaptogenesis in 
Drosophila. However, the receptors for DNT1 and DNT2 are unknown. 
Here, using a combination of in situ hybridisations and reporters that drive GFP expression, I 
show that Toll-7 and Toll-6 are expressed in CNS neurons, in all stages. By generating null 
mutant flies and gain-of-function transgenic flies, I show that Toll-7 and Toll-6 genetically 
interact with DNT1 and DNT2, resulting in a synergistic and specific decrease in viability of the 
DNT-Toll double mutants at 18°C compared to the single mutants. Loss of function Toll-7 and 
Toll-6 mutants display abnormal adult locomotion behaviour, and increased apoptosis and 
motor axon targeting defects in embryos. Expressing activated forms of Toll-7 and Toll-6 in 
neurons rescues naturally occurring cell death in the embryonic central nervous system, and 
rescues the semi-lethality of Toll-7Toll-6 double mutants. Remarkably, expressing activated 
receptors in neurons rescues the DNT1DNT2 double mutant semi-lethality at 18°C, and rescues 
the excess CNS cell death of DNT1 and DNT2 mutant embryos. Using signalling in S2 cell 
culture as a readout for ligand binding, I demonstrate that recombinant DNT1 can activate 
NFκB signalling through Toll-7, and DNT2 through Toll-7 and Toll-6. 
Altogether, my data show that Toll-7 and Toll-6 function in the Drosophila CNS as DNT 
receptors. This evidence of a link between the Toll and Neurotrophin families provides novel 
insights into CNS development, and into the evolution of the nervous and immune systems. 
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CHAPTER 1 
INTRODUCTION 
 
One of the fundamental questions in neurobiology is how is the brain built. This question 
encompasses two different concepts. Firstly, in an individual, what controls the development 
of a brain, from a fertilised egg to a behaving adult?  And secondly, over evolution, how has 
the complex brain evolved from a simpler ancestral nervous system? It is the emergence and 
elaboration of signalling mechanisms over evolution, and the expression of genes during 
neural development, that underlie the complexity and diversity of animal nervous systems. 
Therefore, by investigating the evolution of the complex brain, we can better understand the 
mechanisms by which it develops. 
Vertebrate neurotrophins are key signalling molecules that control the development and 
function of the nervous system. They are target-derived trophic factors that promote the 
targeting and survival of neurons, matching innervation to the organs’ requirements (Levi-
Montalcini, 1987). And by modulating neuronal morphology and excitability, they influence 
the functioning of the nervous system throughout life (Huang and Reichardt, 2001). 
Consistent with their central roles in brain development and functioning, dysfunction in 
neurotrophin signalling is responsible for a wide range of neurological and psychiatric 
illnesses, including Alzheimer’s disease, anxiety and depression (Chao et al., 2006). It was 
initially thought the neurotrophins were a vertebrate innovation, and that they were 
responsible for increased complexity seen in vertebrate nervous systems (Jaaro et al., 2001, 
Barde, 1994). However, there is now abundant evidence that members of the neurotrophin 
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family and their receptors are present throughout the invertebrates (DeLotto and DeLotto, 
1998, Mizuguchi et al., 1998, van Kesteren et al., 1998, Ormond et al., 2004, Benito-Gutiérrez 
et al., 2006, Bothwell, 2006, Hallböök et al., 2006, Zhu et al., 2008). In Drosophila, 
functional homology between the Drosophila neurotrophins (DNTs) and their vertebrate 
counterparts has been demonstrated. DNTs promote neuronal survival and targeting, as well 
as influencing synaptic structural plasticity and adult behaviour (Zhu et al., 2008, Sutcliffe et 
al., Submitted). Therefore, neurotrophin signalling is a conserved mechanism for nervous 
system development, from flies to humans. 
To better understand how Drosophila neurotrophins regulate nervous system development 
and function, it is essential that their receptors are identified. Of the DNTs, only the receptor 
for Spätzle is known: Toll (Weber et al., 2003). And Toll promotes neuronal survival and 
targeting in the central nervous system (CNS) (Zhu et al., 2008, Halfon et al., 1995, Rose et 
al., 1997). The receptors for DNT1 and DNT2 remain to be identified. In this thesis, I present 
evidence that Toll paralogues, Toll-7 and Toll-6, are expressed in the Drosophila nervous 
system, and promote neuronal survival and targeting. Furthermore, I show that Toll-7 and 
Toll-6 mutants genetically interact with DNT1 and DNT2 mutants, and that expressing 
constitutively active receptors in neurons can rescue DNT mutant phenotypes. Finally, 
evidence is provided that shows DNTs can activate cell signalling through Toll-7 and Toll-6. 
It is hoped that this work will contribute to a deeper understanding of how the nervous system 
develops. And the characterisation of Tolls – homologues of vertebrate innate immune 
receptors – as neurotrophin receptors raises intriguing questions about the relationship 
between the immune and nervous systems. 
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1.1 Drosophila Toll 
Toll is a type I transmembrane protein, with an extracellular N-terminus, a transmembrane 
domain, and the C-terminus intracellular. The ectodomain is made up of leucine-rich repeats 
(LRRs), which are divided into two blocks. The first block contains 15 LRRs, and is capped 
at the C-terminal end by a cysteine-rich cluster (CRC); the second block contains 3 LRRs, and 
is capped by N-terminal and C-terminal CRCs (protein architecture obtained from the UniProt 
database, accession number P08953) (Fig 1.1). The intracellular region of Toll contains a 
Toll/Interleukin -1 Receptor (TIR) domain. TIR domains do not possess intrinsic catalytic 
activity, but can initiate intracellular signalling through the recruitment of adapter proteins.  
Toll is maternally expressed in early embryos, and also zygotically expressed later in 
embryogenesis. At the syncytial blastoderm stage, maternal Toll is uniformly distributed at 
the plasma membrane, and expression diminishes during cellularisation (Gerttula et al., 1988, 
Hashimoto et al., 1991). Zygotic Toll is expressed in the gut, salivary glands and epidermis 
(Gerttula et al., 1988). Toll is expressed in migrating cells, and Toll protein localises to the 
sites of contact between cells, including the fused epidermal layers at the dorsal midline and 
at segment borders (Hashimoto et al., 1991). Toll is also expressed in embryonic muscle, 
where it localises to the points of contact between adjacent muscles (Halfon et al., 1995). 
Finally, Toll is expressed in embryonic neurons, and Toll-Gal4>UAS-GAP-GFP labels 
neurons in the larval and adult CNS (Zhu et al., 2008, Sutcliffe, 2010). 
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1.1.1 Toll in dorsoventral patterning 
The Toll gene was first identified as a key component of the dorsoventral patterning pathway 
in Drosophila early embryos (Anderson and Nüsslein-Volhard, 1984). Toll is a member of the 
‘dorsal-group’ of maternal effect genes, and acts downstream of nudel, pipe, gastrulation 
defective (gd), snake, easter, and spätzle (spz) and upstream of dorsal (Anderson et al., 1985). 
The Toll signalling pathway in dorsoventral patterning is well understood, and results in a 
gradient of activated Dorsal, a Drosophila NFκB homologue (Moussian and Roth, 2005) 
(Fig 1.1). 
Dorsoventral patterning starts in the maternal egg chamber, where the somatic expression of 
Nudel, Pipe and Windbeutel initiate the establishment of ventral cell fates (Stein et al., 1991). 
Pipe has sulfotransferase activity, although its substrate remains unknown, and is expressed 
on the ventral side of the follicular epithelium, (Zhu et al., 2005, Nilson and Schüpbach, 1998, 
Stein et al., 2008). Nudel, a multi-domain protein with proteolytic activity, is uniformly 
expressed (LeMosy et al., 1998). Downstream of Pipe and Nudel, in the perivitelline space, a 
proteolytic cascade sequentially activates Gd, Snake and Easter (Dissing et al., 2001). Nudel 
initiates the cascade, and Pipe restricts Snake activity to the ventral side of the embryo 
(Dissing et al., 2001, Han et al., 2000, LeMosy et al., 2001, Cho et al., 2010). 
The final proteolytic step is the generation of mature Spz from its inactive pro-peptide form 
by Easter, after which it binds Toll (DeLotto and DeLotto, 1998, Stein et al., 1991, Schneider 
et al., 1994, Weber et al., 2003). Cleaved Spz is a dimer, and binding of one Spz dimer to Toll 
induces receptor dimerization, resulting in a 2:2 signalling complex (Gangloff et al., 2008). 
Downstream signalling follows the endocytosis of this complex (Huang et al., 2010). 
5 
 
Toll has an intracellular TIR domain, which recruits adapter proteins to the bound receptor to 
activate Dorsal (Fig 1.1). These adapters all contain a Death-Domain, a domain involved in 
protein-protein interactions, and comprise MyD88, Tube and Pelle (Kambris et al., 2003, 
Hecht and Anderson, 1993). MyD88 and Tube are bound via their death domains, and localise 
to the plasma membrane (Sun et al., 2004). The death domain of Pelle then binds that of 
Tube, though it is unclear whether the formation of the MyD88/Tube/Pelle trimer requires 
Toll (Sun et al., 2004, Moncrieffe et al., 2008). Upon binding of Spz, Toll’s TIR domain 
forms a homotypic interaction with the TIR domain of MyD88, resulting in the recruitment 
and activation of the adapter multimer (Sun et al., 2002). Pelle also carries a kinase domain 
and triggers the activation of Dorsal, possibly through interaction with dTRAF2 (Shen et al., 
2001). dTRAF2 is required for Toll signalling in immunity, though the survival of dTRAF2 
null mutant flies to adulthood indicates it is not essential for embryogenesis (Cha et al., 2003). 
In the absence of signalling, Dorsal is found in the cytoplasm in a complex with the IκB 
homologue Cactus (Whalen and Steward, 1993). Ventrally-restricted Toll signalling leads to 
the degradation of Cactus and the nuclear localisation of Dorsal to direct gene expression 
(Bergmann et al., 1996, Reach et al., 1996). The phosphorylation of both Dorsal and Cactus is 
required for the nuclear localisation of Dorsal (Gillespie and Wasserman, 1994, Drier et al., 
1999), while further modifications are likely to target Cactus for proteasome-mediated 
degradation (Fernandez et al., 2001). 
In the nucleus, Dorsal functions as a transcription factor to promote or repress gene 
expression. At high concentrations (ventrally) it activates the transcription of twist and snail, 
which specify the mesoderm; at low concentrations (laterally) it activates sim to specify the 
mesectoderm, and rho and sog transcription to specify the neuroectoderm; and throughout all 
ventral and lateral regions, it represses zen, which specifies the dorsal ectoderm (Moussian 
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and Roth, 2005, Stathopoulos and Levine, 2002, Huang et al., 1997). Thus, the gradient of 
nuclear Dorsal, triggered by ventrally restricted Toll signalling, establishes the dorsoventral 
axis in Drosophila embryogenesis. 
1.1.2 Toll in immunity 
Spz also activates Toll in the innate immune response (Lemaitre et al., 1996). In this context, 
Toll signalling is activated in response to invasion by Gram-positive bacteria and fungi 
(Valanne et al., 2011) (Fig 1.1). Pathogens are recognised by two families of pathogen 
recognition receptors (PRR): Peptidoglycan recognition proteins (PGRP) and Gram-negative 
binding proteins (GNBP), which can be membrane-associated or circulating in the 
haemolymph (Ferrandon et al., 2007). Different members of these families can detect Gram-
positive or -negative bacteria, or fungi. Binding of one of these proteins to the pathogen 
triggers a proteolytic cascade that results in the activation of Spz and its binding to Toll. 
However, the proteases involved in this pathway are not the same as those used in 
dorsoventral patterning. 
The first serine protease in the immune cascade is ModSP, and responds to PRR binding to 
both bacterial and fungal pathogens (Buchon et al., 2009). ModSP functions upstream of 
Grass, the next protease in the cascade, but may not activate it directly (Buchon et al., 2009). 
Parallel to ModSP and Grass are the protease Persephone and its serpin inhibitor Necrotic, 
and Persephone is also able to activate Toll signalling (Levashina et al., 1999, Ligoxygakis et 
al., 2002b). Persephone responds to ‘danger signals’ associated with infection, and activates 
Toll independently of PRRs and Grass (Gottar et al., 2006, El Chamy et al., 2008). Grass and 
Persephone pathways next converge on Spheroide, Sphinx1/2 and Spirit: four proteins with 
sequence similarity to serine proteases of which only one, Spirit, is thought to be catalytically 
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active (Kambris et al., 2006). Downstream of Spheroide, Sphinx1/2 and Spirit is Spätzle 
Processing Enzyme (SPE); and SPE directly cleaves Spz, releasing the Cys-knot to bind to 
Toll (Jang et al., 2006). 
The intracellular signalling cascade activated by Toll during dorsoventral patterning, is also 
activated in the innate immune response (Gay and Gangloff, 2007). However, in immunity, 
Dif is activated, another Drosophila NFκB (Manfruelli et al., 1999, Meng et al., 1999). In the 
larva, Dif and Dorsal show redundancy, but in the adult, Dif is required for an immune 
response (Rutschmann et al., 2000). The target genes of the NFκB signalling pathway on 
immune challenge include those encoding anti-microbial peptides, such as Drosomycin, an 
anti-fungal peptide (Lemaitre et al., 1996). 
The immune response to Gram-negative bacteria in Drosophila uses a different signalling 
pathway. Different PRRs signal via IMD to activate Relish (Rel), a third NFκB homologue 
(Ferrandon et al., 2007). However, there is evidence for cross-talk between these two 
signalling pathways. Activating upstream components of the Toll and IMD pathways together 
produces a synergistic effect on antimicrobial peptide expression (Tanji et al., 2007). 
Moreover, the NFκB paralogues can form heterodimers; the Dif-Rel heterodimer is a much 
more potent activator of Drosomycin expression than the Dif homodimer (Han and Ip, 1999, 
Tanji et al., 2010). 
1.1.3 Toll in the nervous system 
In addition to its well-defined roles in dorsoventral patterning and immunity, Toll is also 
involved in the development of the epidermis, muscle and nervous system. Loss of Toll 
expression in the epidermis results in disrupted muscle development; similar muscle 
phenotypes are seen in spz, tube and pelle mutants (Halfon and Keshishian, 1998). And in 
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Toll mutant larvae, the muscle defects are associated with misrouting of motor axons, and loss 
of motor neurons (Halfon et al., 1995). Halfon and colleagues predicted that the non-cell-
autonomous effect of Toll could be due to a secreted factor acting on neurons. Toll mutant 
embryos also show axon targeting defects. The expression of Toll in muscles 15, 16 and 17 
prevents the inappropriate targeting of the RP3 motor axon (Rose et al., 1997). Targeting of 
RP3 to muscles 6 and 7 is promoted by Fasciclin III (FasIII), and the growth cone evaluates 
the relative amounts of Toll and FasIII it encounters before establishing a synapse (Rose and 
Chiba, 1999). In this context, muscle-expressed Toll inhibits the intimate membrane 
interactions between the growth cone and the muscle that are required for synapse formation 
(Suzuki et al., 2000). Toll is also required for cell survival in the embryonic CNS, as Toll 
mutant embryos have increased apoptosis in the developing ventral nerve cord (VNC) (Zhu et 
al., 2008). Therefore, Toll can have cell-autonomous functions in neurons, where it promotes 
neuronal survival and targeting. However, the upstream activating events and downstream 
signalling pathways of Toll have not been as well characterised in the nervous system as in 
dorsoventral patterning and innate immunity.  
1.1.4 Other Toll functions 
Toll has additional functions in Drosophila development, which have been less extensively 
explored. For example, Toll is required for the formation of the dorsal vessel, the Drosophila 
heart (Wang et al., 2005). Toll is expressed on the lateral surfaces of adjoining cardioblasts, 
and its effects were attributed to roles in cell adhesion (Wang et al., 2005, Keith and Gay, 
1990). Toll also regulates haematopoiesis in the fly, and Spz was not shown to be involved in 
this process (Qiu et al., 1998). 
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1.1.5 Other Drosophila Tolls 
Drosophila Toll belongs to a family of nine paralogues. These are Toll, 18 wheeler (18w), 
Toll-3 (also called MstProx), Toll-4, Toll-5 (also called Tehao), Toll-6, Toll-7, Toll-8 (also 
called Tollo), and Toll-9. Nearly all of the Drosophila paralogues share the same protein 
architecture, with two extracellular blocks of LRRs and an intracellular TIR domain (Tauszig 
et al., 2000, Imler and Hoffmann, 2001). The main difference between the Toll paralogues is 
in the number of LRRs. The exception is Toll-9, which has a single block of LRRs in the 
ectodomain, compared to the two blocks seen in the other Tolls (Imler and Hoffmann, 2001). 
Toll-9 is more closely related to the vertebrate Toll-like receptors (TLRs) than other 
Drosophila Tolls. 
Of the Toll paralogues in the fly, 18w has been the most studied. It is expressed in stripes in 
the early embryo, and is found in multiple organs as the embryo develops (Eldon et al., 1994). 
Loss of function results in semi-lethality, and adult escapers have deformed legs, wings and 
antennae (Eldon et al., 1994). 18w is involved in cell migration in the ovary and the salivary 
gland, and can interact with Rho-GTPase signalling (Kleve et al., 2006, Kolesnikov and 
Beckendorf, 2007). Like Toll, 18w can influence the innate immune response, though this is 
primarily due to its role in the development of the fat body, which produces anti-microbial 
peptides (Williams et al., 1997, Ligoxygakis et al., 2002a). Toll-5 (Tehao) can interact with 
Toll, synergistically activating Dorsal in S2 cells, though its in vivo functions remain to be 
determined (Luo et al., 2001). Toll-8 is expressed in the wing imaginal disc, where it 
antagonises Dpp signalling (Kim et al., 2006). In the imaginal disc epithelium, Toll-8 
interacts with Rel during sensory organ development, and is involved in neuronal 
specification (Ayyar et al., 2007). Toll-8 has also been shown to induce expression of the 
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neuronal Horse Radish Peroxidase (HRP) epitope, however a normal HRP labelling pattern in 
Toll-8 mutant embryos indicates that additional factors are involved (Seppo et al., 2003, Yagi 
et al., 2010). Expression of Toll-9 in cultured cells and in larval fat bodies results in the 
constitutive expression of anti-microbial peptides (Ooi et al., 2002, Bettencourt et al., 2004). 
This effect is attributed to a tyrosine residue that recapitulates the activating mutation in the 
Toll10b allele. However, the lack of a phenotype in Toll-9 mutant flies calls into question the in 
vivo function of Toll-9 (Narbonne-Reveau et al., 2011). Finally, over-expressing or mutating 
18w, Toll-6, Toll-7 and Toll-8 can lead to morphological defects in tissues derived from 
various imaginal discs, including leg and wing defects, extra bristles, and rough eye 
phenotypes (Yagi et al., 2010). 
Of the Toll paralogues, Toll-7 and Toll-6 are also expressed in the embryonic CNS (Kambris 
et al., 2002). However, nothing is known about their function in the nervous system. 
Moreover, the ligands for the Toll paralogues have not been identified, and little is known 
about the intracellular pathways they activate. Since Toll promotes neuronal development, it 
is compelling to test whether Toll-7 and Toll-6 also carry out neuronal functions, and to 
investigate the ligands of these Toll paralogues. 
1.2 Human Toll-Like Receptors 
A search for human homologues of Drosophila Toll led to the discovery of hToll, which was 
found to signal through NFκB to induce the expression of inflammatory cytokines (Medzhitov 
et al., 1997). An earlier screen of cDNA clones also identified rsc786 as a Toll homologue 
(Nomura et al., 1994, Mitcham et al., 1996). rsc786 (renamed TLR1), hToll (TLR4), were the 
first members of an emerging family of TLRs (Rock et al., 1998). The human TLR family is 
now made up of 10 members, and represents a key pathogen-sensing system for both innate 
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and adaptive immune responses (Takeda et al., 2003). The protein structure of TLRs is 
homologous to that of Drosophila Toll-9, with a single block of extracellular LRRs and a 
single juxtamembrane CRC, and an intracellular TIR domain. 
TLR4 is activated in response to lipopolysaccharide (LPS), a marker of Gram-negative 
bacteria, which requires the co-receptors CD14 and MD2 (Miyake, 2003). TLR4 mutant 
alleles are associated with a reduced responsiveness to LPS and increased risk of infection in 
mice and humans (Poltorak et al., 1998, Qureshi et al., 1999, Arbour et al., 2000). Unlike 
Drosophila Toll, vertebrate TLRs are directly activated by pathogen-associated molecular 
patterns (PAMPs), including those associated with Gram-positive and -negative bacteria, 
fungi and viruses (Gay and Gangloff, 2007). However, once TLRs are activated, the 
intracellular signalling molecules are homologous to those activated by Drosophila Toll, 
culminating in the activation of NFκB and the expression of inflammatory cytokines (Gay and 
Gangloff, 2007). In addition, a TLR-3, -7, -8 and -9 form signalling endosomes, and through 
IRF transcription factors induce the expression of type I interferons (Kumar et al., 2009). As 
well as directly detecting PAMPs, TLRs are activated by an array of endogenous ligands, 
some of which are normally intracellular and are released during necrosis (Sloane et al., 
2010). These ‘damage-associated molecular patterns’ (DAMPs) induce an inflammatory 
response through TLRs with the aim of repairing tissue damage, although prolonged 
activation is associated with inflammatory disease and cancer (Chen and Nuñez, 2010). 
As well as mediating the release of pro-inflammatory cytokines as part of the innate immune 
response, TLRs represent the link between the innate and adaptive immune system in 
vertebrates. It has long been known that an adaptive immune response (through the 
recruitment of T- and B-cells) can only occur if the innate immune system has been engaged. 
This was proposed as a mechanism to ensure the adaptive immune system only responds to 
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pathogens, and not to ‘self’ antigens (Janeway, 1989). It is now know that TLRs play a central 
role in the activation of the adaptive immune response. TLRs induce the expression of co-
stimulatory molecules on antigen-presenting cells, which are required for the activation of T-
cells (Iwasaki and Medzhitov, 2004). In this way, only cells that have recognised a pathogen 
(through TLR binding of PAMPs) are able to activate T-cells and initiate an adaptive immune 
response.  In addition, a number of the cytokines released following TLR activation are 
responsible for the recruitment and differentiation of a wide range of immune cells.  
1.2.1 TLRs in the nervous system 
TLRs have been primarily studied in the context of the immune system, and outside the brain. 
However, the CNS is not completely isolated from the immune system, and TLRs play a key 
role in the regulation of innate immunity in neural tissue (Rivest, 2009). TLRs are widely 
expressed in CNS glia, in particular the resident innate immune cells – microglia (Jack et al., 
2005). TLR signalling in microglia represents a major mechanism of pathogen-recognition 
and engagement of the innate immune response in the CNS (Kong and Le, 2011, Lehnardt, 
2010). TLRs are also activated in CNS injury and disease, including Alzheimer’s disease 
(Downes and Crack, 2010, Salminen et al., 2009). TLRs mediate neuroprotection following 
infection and injury; however the inflammatory response mediated by TLRs can also be 
detrimental to the CNS, leading to neurodegeneration (Okun et al., 2009, Hanisch et al., 
2008). 
The expression and function of TLRs in neurons is less understood. Transcripts and protein 
for TLRs 1-9 have been detected in rodent neurons, (Mishra et al., 2006, Ma et al., 2006, 
Tang et al., 2008, Goethals et al., 2010). mRNA for all human ten TLRs has been detected in 
neurons (Zhou et al., 2009). Adding TLR-3 and -8 agonists to primary human neurons, and a 
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TLR-4 agonist to a neuronal cell line, induces the activation of a reporter plasmid, indicating 
the expression of functional TLR proteins (Zhou et al., 2009, Peltier et al., 2010). Moreover, 
TLR-3 has been detected by immunocytochemistry on a neuronal cell line, and TLR-3 and 
TLR-4 have been detected by immunohistochemistry on human neuronal explants (Préhaud et 
al., 2005, Jackson et al., 2006, Wadachi and Hargreaves, 2006). In most of these studies, 
neuronal TLRs were found to carry out immune functions, effecting inflammatory responses 
to infection or injury. This indicates that, to some extent, neurons are immunologically 
competent, and could contribute to the defence of the nervous system from pathogens. 
Evidence is accumulating that neuronal TLRs carry out additional functions, separate from 
those relating to immunity, that relate more directly to neuronal development and physiology 
(Okun et al., 2011). During embryogenesis, neuronal progenitor cells (NPCs) express TLR-2 
and TLR-3, both of which negatively regulate the proliferation of NPCs (Okun et al., 2010b, 
Lathia et al., 2008). Similarly, TLR-4 prevents proliferation in retinal progenitor cells 
(Shechter et al., 2008). In adult neurogenesis, the data are less clear. In one study, TLR-2 was 
found to promote neurogenesis, while TLR-4 continued to suppress the proliferation and 
differentiation of NPCs (Rolls et al., 2007). However, a second study did not record any effect 
on proliferation or differentiation of NPCs by TLR-2 or -4, although it noted that adult NPCs 
could respond to TLR agonists by releasing cytokines (Covacu et al., 2009). In all of these 
studies, the downstream signalling of TLRs was to NFκB. 
There is also evidence that TLRs can function in neurons. Neuronal expression of TLR-3 is 
concentrated in the growth cone, and activation by a synthetic ligand 
polyinosinic:polycytidylic acid (poly I:C) results in growth cone collapse and inhibition of 
neurite extension (Cameron et al., 2007). Activation of TLR-3 in vivo was associated with 
decreased axon number and behavioural deficits (Cameron et al., 2007). TLR-8 is enriched in 
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axons, and activating it with resiquimod inhibits neurite growth, as well as inducing apoptosis 
(Ma et al., 2006). The inhibition of neuronal outgrowth and the induction of cell death occur 
independently following TLR-8 stimulation. Remarkably, the effects of activating axonal 
TLR-3 and -8 do not require the nuclear localisation of NFκB (Ma et al., 2006, Cameron et 
al., 2007). This raises intriguing the possibilities that NFκB could function at the membrane, 
or that TLRs can also activate additional signalling pathways. 
Most research has focussed on activation of neuronal TLRs by pathogens, but less is known 
about the role of endogenous ligands. High-Mobility Group Protein B1 (HMGB1, also called 
HMG1 and amphoterin) is emerging as a candidate endogenous TLR ligand with neuronal 
functions. HMGB1 was discovered through its properties of promoting neurite outgrowth, 
which are mediated by the receptor RAGE (Rauvala and Pihlaskari, 1987, Hori et al., 1995). 
HMGB1 has also been shown to bind TLR2 and TLR4 to activate NFκB in macrophages, 
although this has not yet been demonstrated in neurons (Park et al., 2004, Park et al., 2006). 
In zebrafish, HMGB1 is required for the development of the forebrain, where it promotes cell 
survival, though the receptor it binds was not identified (Zhao et al., 2011). Interestingly, 
HMGB1 induces expression of AMIGO, a CNS receptor with extracellular homology to the 
vertebrate neurotrophin receptor, Trk (Kuja-Panula et al., 2003). Moreover, HMGB1 
signalling through TLR4 induces Matrix Metalloproteinase 9 (MMP9) expression, and it 
potentiates the activity of Tissue Plasminogen Activator (tPA). These two extracellular 
proteases are involved in regulating neurotrophin processing (Qiu et al., 2010, Roussel et al., 
2011, Bruno and Cuello, 2006). Therefore HMGB1 may link the TLR and neurotrophin 
signalling pathways. 
TLRs also function in the adult nervous system. Loss of TLR-3-mediated neurogenesis in the 
adult hippocampus is associated with altered memory formation and anxiety behaviour in 
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mice (Okun et al., 2010a). In a model of stroke, TLR-2 and -4 promote cell death, and knock-
out mice show improved functional recovery (Tang et al., 2007). TLR-4 is upregulated in 
response to Amyloid β aggregates and mediates JNK-dependent neuronal death, and patients 
with Alzheimer’s disease show a reduction in TLR-4-positive neurons (Tang et al., 2008). 
And in a model of epilepsy, neuronal TLR-4 is upregulated after seizure induction, and TLR-
4 antagonists show anticonvulsant activity (Maroso et al., 2010). Much more research needs 
to be carried out on TLRs in the nervous system, to establish their neuronal functions, and 
determine their roles in health and disease. 
1.3 Neurotrophins 
Drosophila Toll, and its ligand Spz, have well characterised functions in dorsoventral 
patterning and innate immunity (Valanne et al., 2011, Moussian and Roth, 2005). Toll also is 
expressed in neurons, and promotes neuronal survival and targeting (Zhu et al., 2008, Halfon 
et al., 1995, Rose et al., 1997). Spz is a Drosophila neurotrophin, and functions in the CNS to 
promote cell survival and targeting, to regulate synaptic structural plasticity in the larval NMJ, 
and to influence adult behaviour (Zhu et al., 2008, Sutcliffe et al., Submitted). It is therefore 
compelling to explore the link between the neurotrophin and Toll families of proteins. 
1.3.1 Drosophila Neurotrophins 
For a long time, the existence of Neurotrophins in Drosophila was questioned. When the 
Drosophila genome was published, no neurotrophin homologues were found (Adams et al., 
2000). Although there is extensive apoptosis in the developing Drosophila nervous system, it 
was thought that cell survival was pre-determined, and not subject to non-cell-autonomous 
control (White et al., 1994, Truman, 1984). The small size of the fly’s CNS, its ‘hard-wired’ 
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development, and the apparent lack of neurotrophins lead to the theory that invertebrate brains 
are not subject to the trophic controls that characterise the mammalian CNS (Barde, 1994, 
Jaaro et al., 2001). However, there is evidence that neuronal number is plastic in Drosophila. 
In a population of wild-type embryos, there is variability in neuron number, and also in the 
number of cells undergoing apoptosis (Bossing et al., 1996, Schmidt et al., 1997, Rogulja-
Ortmann et al., 2007). In the developing eye, retinal photoreceptors require retrograde 
survival signals from the optic lobe, for which EGF receptors are necessary (Campos et al., 
1992, Baker and Yu, 2001). Conversely, optic lobe neurons require retinal axon input and 
glial trophic support for survival (Fischbach and Technau, 1984, Dearborn and Kunes, 2004, 
Xiong and Montell, 1995). Interactions between neurons and glia influence many aspects of 
neuronal function, and in the VNC, glia maintain neuronal survival (Edenfeld et al., 2005, 
Booth et al., 2000). Apoptosis is a conserved aspect of neurodevelopment, and while there are 
examples of pre-determined cell death, neurotrophism is a mechanism shared by flies and 
mammals (Buss et al., 2006, Miguel-Aliaga and Thor, 2009, Hidalgo and ffrench-Constant, 
2003, Hidalgo, 2002, Hidalgo et al., 2006). 
The first clue to identifying a Drosophila neurotrophin homologue came from structural 
studies. The crystallisation of NGF revealed a cystine-knot structure with subunits dimerising 
in parallel along their flat surface (McDonald et al., 1991). The amino acid sequence of Spz 
closely resembles the signal peptide, pro-domain, Cys-knot architecture of NGF (Morisato 
and Anderson, 1994). Moreover, the cysteine residues within the Cys-knot are similarly 
positioned to those of NGF. In 1998, two groups showed that the predicted structure of Spz 
was homologous to that of NGF, and that it could form parallel dimers like the vertebrate 
neurotrophins (Mizuguchi et al., 1998, DeLotto and DeLotto, 1998). This was later confirmed 
by crystallography (Hoffmann et al., 2008). Spz was also found to be a structural homologue 
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of the horseshoe crab Coagulogen, although Coagulogen forms end-on-end polymeric fibres 
after proteolytic activation (Bergner et al., 1996). A family of spz paralogues was identified in 
the Drosophila genome, and were originally proposed to be more closely related to 
coagulogen than to the vertebrate neurotrophins (Parker et al., 2001). Spz and Coagulogen 
share a common mechanism of activation, by a cascade of homologous serine proteases, 
which was likened to the blood clotting cascade found in mammals (Osaki and Kawabata, 
2004). Despite the divergent structures of the multimers, the homologous activation pathway 
in response to immune challenge caused attention to be directed to the similarities between 
Spz and Coagulogen. 
The Hidalgo lab re-examined the question by performing an unbiased search of the fly 
genome using PSI-BLAST and TBLASTN to identify distantly-related homologues of all 
vertebrate neurotrophin Cys-knots (Zhu et al., 2008). Using carp BDNF as the query resulted 
in the identification of DNT1, which was found to be a member of the spz family (spz2). 
Using FUGUE, which aligns protein sequences according to structural conservation (Shi et 
al., 2001), three members of the Spz family were found to be significantly homologous to 
human neurotrophins (Zhu et al., 2008). The Drosophila neurotrophins (DNTs) comprise 
DNT1 (spz2), DNT2 (spz5), and spz; and the DNTs are more closely related to the vertebrate 
neurotrophins than to coagulogen (Zhu et al., 2008). As well as being structural homologues 
of the vertebrate neurotrophins, the DNTs also carry out the same functions associated with 
canonical neurotrophins. They promote neuronal survival and targeting during development, 
are involved in synaptic structural plasticity at the neuromuscular junction (NMJ), and are 
required for normal adult behaviour (Zhu et al., 2008, Sutcliffe et al., Submitted). Zhu et al. 
demonstrated that neurotrophins are expressed in neuronal target tissues, function as cleaved 
mature Cys-knot growth factors, and act in a non-cell-autonomous manner. Therefore, the 
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neurotrophins are a conserved family of signalling molecule that link the structure and 
function of the nervous system, and are conserved from flies to humans. 
1.3.2 Vertebrate Neurotrophins 
Neurotrophins are a key family of signalling molecules that regulate multiple aspects of 
nervous system development and function, including cell survival, axon targeting and 
synaptic plasticity (Huang and Reichardt, 2001). The first neurotrophin to be discovered was 
Nerve Growth Factor (NGF). NGF is target-derived, exhibits trophic and tropic influences on 
developing neurons, and maintains neuronal survival throughout life (Levi-Montalcini, 1987). 
Brain-Derived Neurotrophic Factor (BDNF) is a second neurotrophic factor with structural 
and functional homology to NGF (Barde et al., 1982, Leibrock et al., 1989). And 
neurotrophin-3 (NT-3) and NT-4/5 complete the family of 4 proteins found in most 
vertebrates (Rosenthal et al., 1990, Maisonpierre et al., 1990b, Ernfors et al., 1990, Hohn et 
al., 1990, Hallböök et al., 1991, Berkemeier et al., 1991). The neurotrophins are found in all 
vertebrates, though NT-4/5 is absent from birds, and bony fishes possess an additional NT-
6/7, reflecting gene losses and duplications in those lineages (Hallböök et al., 2006). 
Neurotrophins belong to a large superfamily of proteins containing cystine-knots, which also 
include TGFβ, PDGF and hormone glycoproteins (Sun and Davies, 1995). However, position 
of the cysteine residues and the protein structure of the neurotrophins is different from other 
members of the superfamily. An important characteristic of the neurotrophins is the ‘head-to-
head’ orientation of the dimers, aligned along their long axis (Sun and Davies, 1995, 
McDonald et al., 1991). All neurotrophins form homodimers that are structurally very similar; 
and a number of heterodimers can form in vitro, though the biological significance of this is 
unknown (Wiesmann and de Vos, 2001). 
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Neurotrophins are translated as pre-pro-proteins, possessing a signal peptide, an N-terminal 
pro-domain, and a C-terminal Cys-knot (Bibel and Barde, 2000). Cleavage of the pro-domain 
releases the mature Cys-knot protein. All neurotrophins can be cleaved by furin and members 
of the PC family of serine proteases, and NGF can be cleaved by the kallikrein-family 
protease, γNGF (Seidah et al., 1996b, Seidah et al., 1996a, Edwards et al., 1988). NGF and 
BDNF are processed differently: NGF processing is directed towards constitutive secretion, 
while BDNF is also sorted into the regulated secretion pathway that is controlled by neuronal 
activity (Mowla et al., 1999). The pro-domains are required for neurotrophin processing, and 
are responsible for the differences in cleavage and sorting between NGF and BDNF (Suter et 
al., 1991, Nomoto et al., 2007). The processing and sorting of neurotrophins in vivo depends 
on the cell type and its endogenous proteases, and relates to the type of signalling required by 
the tissue (Lessmann et al., 2003). In addition, pro-neurotrophins can be released from cells, 
without cleavage of the pro-domain (Mowla et al., 1999). Extracellular pro-neurotrophins can 
be cleaved by Matrix Metalloproteases (MMPs) and plasmin (Lee et al., 2001). Tissue 
Plasminogen Activator (tPA) is a serine protease responsible for the generation of active 
plasmin from its precursor, and is secreted from neurons following electrical stimulation 
(Nagappan et al., 2009). Consequently, the cleavage of proBDNF by tPA/plasmin can also be 
regulated by neuronal activity, which can influence the establishment of long-term 
potentiation (LTP) – one of the functions of BDNF (Pang et al., 2004). 
1.4 Vertebrate Neurotrophin receptors 
1.4.1 p75NTR and Trks 
p75NTR is a membrane protein of 70-80kDa, and binds all four cleaved neurotrophins with 
relatively low affinity (Bothwell, 1995). p75NTR also binds pro-neurotrophins with high 
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affinity (Lee et al., 2001). The p75NTR protein contains four Cys-rich clusters in the 
ectodomain, and an intracellular death domain (Chao et al., 1986, Johnson et al., 1986, 
Radeke et al., 1987, Chapman, 1995) (Fig 1.2). p75NTR became the founding member of the 
TNF receptor superfamily (Smith et al., 1994). 
A second class of neurotrophin receptors are the Tropomyosin-Receptor-Kinase (Trk) family: 
TrkA, TrkB and TrkC. In their extracellular domains, Trk receptors consists of an N-terminal 
block of three LRRs flanked by CRCs, followed by two immunoglobulin (Ig) C2 domains 
(Martin-Zanca et al., 1989, Shelton et al., 1995) (Fig 1.2). Trks possess an intracellular 
tyrosine kinase domain, which is phosphorylated following neurotrophin binding (Klein et al., 
1991, Kaplan et al., 1991). 
Trk receptors are relatively promiscuous in their binding to neurotrophins. NGF preferentially 
binds to TrkA, BDNF and NT-4 to TrkB, and NT-3 to TrkC; to a lesser extent, NT-3 also 
activates TrkA and TrkB (Reichardt, 2006). However alternative splicing of Trk receptors can 
modulate their neurotrophin-binding affinities. The inclusion of a short stretch of amino acids 
in the juxtamembrane ectodomain of TrkA makes the receptor responsive to NT-3, and the 
longer version of TrkB is more sensitive to NT-3 and NT-4 (Clary and Reichardt, 1994, 
Strohmaier et al., 1996). The promiscuity of neurotrophin/Trk binding is unusual, and 
contrasts with the relatively specific interactions of most ligand/receptor pairs. 
1.4.2 Trk-p75NTR interactions and neurotrophin binding 
When they are expressed separately, p75NTR and TrkA bind NGF with a similar, relatively 
low affinity, but when they are co-expressed, high affinity binding is reported with increased 
receptor internalisation (Hempstead et al., 1991, Mahadeo et al., 1994, Chao, 2003). The co-
operation of p75NTR and TrkA in producing the high affinity binding has been mapped to the 
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transmembrane and intracellular domains of both proteins (Esposito et al., 2001). And the 
interaction of the TrkB intracellular domain with p75NTR is phosphorylation-dependent (Bibel 
et al., 1999). Moreover, the presence of p75NTR increases the specificity of neurotrophin 
binding to their preferred Trk receptor (Roux and Barker, 2002). However, other groups have 
shown that TrkA binds NGF with high-affinity independently of p75NTR, and it is unclear 
whether Trks directly bind to p75NTR during signalling (Klein et al., 1991, Jing et al., 1992, 
Bothwell, 1995, Roux and Barker, 2002, Wehrman et al., 2007, Barker, 2007). Further 
structural studies are needed determine how Trks and p75NTR together form the high affinity 
binding site. 
p75NTR directly binds to neurotrophin Cys-knot dimers. A systematic deletion analysis 
showed that all four cysteine-rich clusters of p75NTR are required for neurotrophin binding 
(Baldwin et al., 1992). This was confirmed by the crystal structure of the p75NTR 
ectodomain/NGF complex (He and Garcia, 2004). p75NTR binds the interface of neurotrophin 
dimers, and 2:2 binding depends on glycosylation of the receptor , (He and Garcia, 2004, 
Aurikko et al., 2005, Gong et al., 2008). Gong and colleagues showed that this disparity was 
due to structural differences in p75NTR resulting from glycosylation. 
The binding of neurotrophins to Trks requires the receptors’ second Ig domain, which also 
confers receptor-ligand specificity (Urfer et al., 1995). In agreement with this, a crystal 
structure shows the second Ig domain forms a complex with NGF, and there is symmetrical 
binding along the interface of the NGF dimer resulting in a 2:2 stoichiometry (Wiesmann et 
al., 1999). It is currently unclear how p75NTR and Trk receptors interact to form high-affinity 
neurotrophin binding sites (Aurikko et al., 2005, Wehrman et al., 2007, Zaccaro et al., 2001, 
Barker, 2007). 
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1.4.3 Sortilin 
Sortilin represents a third class of neurotrophin receptor. Sortilin contains an extracellular 
VPS10 domain, forming a β-propeller, and a short intracellular domain involved in vesicle 
trafficking (Petersen et al., 1997, Quistgaard et al., 2009) (Fig 1.2). Sortilin directly binds pro-
neurotrophins with higher affinity than the mature forms, and forms a signalling complex with 
p75NTR (Nykjaer et al., 2004, Teng et al., 2005, Yano et al., 2009, Feng et al., 2010). The 
precise mechanisms of neurotrophin binding and interactions with p75NTR and Trk receptors 
remain to be explored. 
1.5 Neurotrophin signalling 
1.5.1 p75NTR signalling pathways 
Because it lacks intrinsic catalytic activity, p75NTR initiates intracellular signalling through a 
number of adapter proteins, which interact either in the juxtamembrane region or in its death 
domain (Roux and Barker, 2002) (Fig 1.3). The interacting proteins Tumour Necrosis Factor 
Receptor-Associated Factor 6 (TRAF6), Neurotrophin Receptor-Interacting Factor (NRIF) 
and Neurotrophin Receptor-Interacting MAGE homologue (NRAGE) have been shown to 
activate JNK, a pro-apoptotic MAP kinase (Gentry et al., 2004, Salehi et al., 2002). The 
interaction of p75NTR with Neurotrophin Receptor-Associated Cell Death Executer (NADE) 
activates an alternative pro-apoptotic pathway through a 14-3-3 protein, while engagement of 
Schwann Cell Factor 1 (SC1) repressed Cyclin E (Kimura et al., 2001, Chittka et al., 2004). 
p75NTR-mediated activation of TRAF6 can also lead to the recruitment of Interleukin-1 
Receptor-Associated Kinase (IRAK) and the adapter protein p62, which together activate 
NFκB, a pro-survival transcription factor (Khursigara et al., 1999, Mamidipudi et al., 2002). 
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Signalling TRAF and IRAK proteins to activate NFκB is reminiscent of the Toll signalling 
pathway. 
Unbound p75NTR activates RhoA, resulting in reorganisation of the actin cytoskeleton 
(Yamashita et al., 1999). Neurotrophin binding to p75NTR blocks this pathway, therefore 
neurotrophin/p75NTR signalling negatively regulates RhoA. p75NTR has been shown to activate 
Ras, a small G-protein upstream of the pro-survival MAP kinase ERK (Blöchl et al., 2004). A 
further p75NTR-activated pathway involves sphingolipid metabolism, and the release of 
Ceramide. Ceramide can then interact with a broad range of signalling molecules, including 
NFκB, JNK, ERK and PI3K (Dobrowsky and Carter, 1998, Blöchl and Blöchl, 2007). 
1.5.2 Trk Receptor signalling pathways 
Ligand binding results in Trk receptor dimerisation, leading to the autophosphorylation of 
several tyrosine residues in its intracellular domain (Huang and Reichardt, 2003) (Fig 1.4). 
Two phospho-tyrosine residues are principally responsible for the engagement of Trk-
interacting proteins, and the activation of cell signalling cascades: Y490, which is close to the 
membrane and N-terminal to the kinase domain, and Y785, which lies outside the kinase 
domain at the C-terminal end of the receptor (residues numbered according to their positions 
in TrkA, and are conserved across all Trks). 
Neurotrophin binding of Trks activates PLCγ (Vetter et al., 1991). PLCγ is phosphorylated 
following neurotrophin binding, and induces the breakdown of PtdIns(4,5)P2 to IP3 and DAG, 
which are second messengers that can carry out a range of functions (see below) (Reichardt, 
2006). Y785, at the C-terminal of Trk receptors, serves as the docking point for PLCγ, and 
phosphorylation of this residue activates PLCγ (Obermeier et al., 1993, Loeb et al., 1994). 
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The juxtamembrane Y450 recruits Shc and Frs2, which activate signalling by two distinct 
pro-survival molecules (Stephens et al., 1994, Meakin et al., 1999). Activated Trk receptors 
signal through ERK, a member of the MAP kinase family. Recruitment of Shc activates the 
signalling pathway involving Grb2, SOS and Ras, which leads to the activation of Raf-1, 
MEK and ERK (English et al., 1999). The activation of ERK by Ras is relatively short-lived, 
however Trk receptors can initiate prolonged ERK signalling, through an alternative 
activation pathways (Huang and Reichardt, 2003). By signalling through Crk, C3G and Rap1, 
activation of MEK and ERK is via B-Raf (York et al., 1998). The longer-lasting activation of 
ERK has been shown to be initiated by FRS2, which can bind Y450 instead of Shc (Kao  et 
al., 2001). Alternatively, Trk signalling via an ankyrin-rich membrane-spanning protein 
(ARMS) can activate Crk, and has been shown to function independently of Y450 (Arévalo et 
al., 2004). 
Three mechanisms activate pro-survival PI3K/Akt signalling through Trks. As well as 
signalling through ERK, Ras can activate PI3K; NGF-TrkA signalling and electrical activity 
synergistically interact in neurons to evoke Ras-mediated Akt signalling (Rodriguez-Viciana 
et al., 1994, Vaillant et al., 1999). The second mechanism of Akt activation is through the 
binding of Gab1 to PI3K, which occurs downstream of Shc and Grb at Y450 (Holgado-
Madruga et al., 1997). And third, IRS-1, already known as an activator of PI3K signalling in 
response to insulin, is also phosphorylated by Trks (Backer et al., 1992, Yamada et al., 1997). 
1.5.3 Neurotrophins and cell survival 
Neurotrophins maintain the survival of neurons, and this is seen predominantly in vertebrate 
sensory and sympathetic neurons (Huang and Reichardt, 2001). The pro-survival effect is 
primarily mediated by mature neurotrophins binding Trk receptors, and activating pro-
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survival signalling pathways. Signalling through Akt mediates the pro-survival activity of 
neurotrophins, and this is achieved through transcriptional regulation as well as direct 
inhibition of pro-apoptotic molecules (Crowder and Freeman, 1998, Kaplan and Miller, 
2000). Akt activates NFκB to promote neuronal survival and differentiation, and inhibits Bad 
and Bax to block apoptosis. The activation of ERK in neurons is also pro-survival, although 
ERK is also involved in promoting neuronal differentiation (Creedon et al., 1996, Meakin et 
al., 1999). Consistent with their pro-survival functions, knock-out mice lacking any of the 
neurotrophins or Trks show a reduction in the number of neurons (Huang and Reichardt, 
2001). 
Pro-neurotrophins, signalling through p75NTR and Sortilin, induce apoptosis by activating 
JNK signalling (Lee et al., 2001, Nykjaer et al., 2004, Yano et al., 2009). And at high 
concentrations, in the absence of a Trk, mature neurotrophins can also signal through p75NTR 
to cause cell death (Bamji et al., 1998). A p75NTR-hypomorphic mouse has been shown to 
possess increased numbers of spinal cord neurons, consistent with a function in inducing cell 
death (Frade et al., 1996). However, the role of p75NTR in increasing neurotrophin affinity at 
Trk receptors (and therefore pro-survival signalling) complicates matters, and a different 
p75NTR-null mouse has a dramatically reduced neuronal cell number (von Schack et al., 2001). 
The opposite functions of mature neurotrophins promoting cell survival through Trks, and 
pro-neurotrophins promoting apoptosis through p75NTR, were consolidated into a ‘Yin and 
Yang’ model of neurotrophin action (Lu et al., 2005). However, it is unlikely that the situation 
is so straight-forward, since p75NTR is able to activate multiple pro-survival pathways 
In addition to its pro-apoptotic functions, p75NTR signals through NFκB to promote cell 
survival (Maggirwar et al., 1998, Hamanoue et al., 1999). When Trks and p75NTR are co-
expressed, the pro-survival signalling pathways activated by Trk block the p75NTR-mediated 
26 
 
apoptotic signals, while NFκB continues to signal (Yoon et al., 1998, Davey and Davies, 
1998). Thus, Trk signalling appears to trump p75NTR signalling in the control of cell survival. 
Activation of p75NTR, in the absence of Trk signalling, can prevent apoptosis through NFκB, 
regardless of any concomitant JNK signalling; ceramide generation can activate PI3K, and 
prevent apoptosis through Akt; and tyrosine residues present on the p75NTR death domain can 
become phosphorylated, bind Ras, and signal via the Shc/Grb2/SOS pathway to activate ERK 
(Hughes et al., 2001, Song and Posse de Chaves, 2003, Blöchl et al., 2004). In vivo, it is most 
likely that the true signalling pathways activated will depend on the cell context, the repertoire 
of receptors and signalling molecules present, and the balance of mature versus pro-
neurotrophins. 
1.5.4 Neurotrophins and cell shape 
Neurotrophins induce the neuronal differentiation of a phaeochromocytoma cell line (PC12), 
and promote neurite outgrowth from sensory neurons (Levi-Montalcini, 1987). Neuronal 
differentiation is often measured by the extent of neurite outgrowth from PC12 cells or 
cultured neurons, and can be uncoupled from pro-survival signalling pathways (Meakin and 
MacDonald, 1998). One model to explain this is the dual activation of ERK signalling. Short-
lived ERK activation through Ras promotes survival, whereas prolonged ERK activation 
through FRS2 and ARMS results in enhanced neurite outgrowth, and therefore differentiation 
(Meakin et al., 1999, Arévalo et al., 2004). NFκB is also involved in promoting neurite 
extension in response to neurotrophins (Gutierrez and Davies, 2011). Signalling through 
p75NTR, NFκB increases the length of dendrites, involving cross-talk with the Notch pathway; 
and activation of NFκB via Trk and Src promotes the growth of neuronal processes (Salama-
Cohen et al., 2005, Gavaldà et al., 2009). In vivo, systemic administration of NGF in mice 
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increases the size and complexity of sensory neurons, and BDNF injected into the optic 
tectum of tadpoles increases the axonal complexity of retinal ganglion cells (Ruit et al., 1990, 
Cohen-Cory and Fraser, 1995). 
In addition to promoting the formation and outgrowth of neurites, neurotrophins promote 
axon targeting, and can signal as chemoattractants (Campenot, 1977, Gundersen and Barrett, 
1979). Interestingly, the effects of the different neurotrophins are not equal: NGF- and BDNF-
mediated attraction is dependent on cAMP, while NT-3-mediated attraction is blocked on 
cGMP inhibition (Song and Poo, 1999). Intracellular activation of PI3K and PLCγ by Trk has 
been shown mediate the chemoattractive effects of NGF on the growth cone (Ming et al., 
1999). p75NTR can signal independently of Trks to promote axon extension. In the absence of 
neurotrophins, p75NTR activates RhoA, a small GTPase that promotes growth cone collapse; 
binding of neurotrophin reduced RhoA activity, and therefore increases neurite elongation 
(Yamashita et al., 1999, Gehler et al., 2004). However, the role of p75NTR in axon guidance is 
complicated by its interaction with the Nogo receptor (NgR) and LINGO. p75NTR acts as a co-
receptor with NgR and LINGO, and inhibits the growth of axons through myelin-rich 
environments (Wang et al., 2002, Mi et al., 2004). In this context, interaction of myelin 
components with p75NTR and NgR activates RhoA, therefore preventing axon growth 
(Yamashita and Tohyama, 2003). The regulation of neuronal differentiation and targeting by 
neurotrophins involves Trks and p75NTR, multiple intracellular signalling pathways, and can 
be influenced by additional extra- and intracellular factors. 
1.5.5 Neurotrophins and neural function 
Neurotrophins regulate multiple aspects of neural function, for example the influence of NGF 
on pain sensation. Firstly, NGF is preferentially required for the survival of nociceptive 
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neurons, and NGF and TrkA mutant mice exhibit severe sensory phenotypes, while the 
control of movement is less affected (Silos-Santiago et al., 1995, Smeyne et al., 1994, 
Crowley et al., 1994). Secondly, NGF/TrkA signalling induces the structural differentiation of 
pain-sensing neurons: TrkA is required for innervation of the skin, independently of its roles 
in cell survival (Patel et al., 2000). Thirdly, NGF induces the expression of calcitonin gene-
related peptide (CGRP) and substance P, markers of pain receptor differentiation and peptide 
neurotransmitters of nociceptive signals (Patel et al., 2000). And fourthly, TrkA signalling 
increases the sensitivity of the TRPV1 nociceptor to painful stimuli, through a PLCγ-
mediated depletion of inhibitory PtdIns(4,5)P2 (Chuang   et al., 2001). Similarly to their 
effects on sensory neurons, neurotrophins are involved in many aspects of autonomic nervous 
system function, from the survival and phenotypic specification of neurons to the control of 
neurotransmitter production and conductivity (Ernsberger, 2009). 
In the CNS, BDNF regulates synaptic transmission, where it promotes the induction of long-
term potentiation (LTP) in hippocampal neurons, and LTP is impaired in BDNF-mutant mice 
(Figurov et al., 1996, Korte et al., 1995, Patterson et al., 1996). LTP is a long-lasting 
sensitisation of a synapse by high-frequency stimulation, and results in enhanced synaptic 
transmission that lasts for days (Malenka and Nicoll, 1999). BDNF signalling through TrkB 
has been found to regulate a number of aspects of LTP (Minichiello, 2009). BDNF and TrkB 
expression are upregulated in hippocampal glutamatergic neurons after LTP induction 
(Patterson et al., 1992). Acting pre-synaptically, BDNF/Trk signalling can enhance glutamate 
release (Li et al., 1998, Xu et al., 2000). In the post-synaptic neuron, BDNF potentiates 
NMDA- and AMPA-type glutamate receptor activity, and can induce the transcription and 
translation of AMPA receptors (Levine et al., 1998, Caldeira et al., 2007). And BDNF is also 
required for the changes in dendritic spine morphology that characterise late stages of LTP 
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(Tanaka et al., 2008). PLCγ mediates the effects of TrkB activation, and is required both pre- 
and post-synaptically to enhance LTP (Minichiello et al., 2002, Gärtner et al., 2006). While it 
was not been shown to affect LTP, p75NTR can modulate dendritic morphology, AMPA 
receptor expression, and long-term depression (LTD – a reduction in synaptic excitability 
following low-frequency stimulation) (Zagrebelsky et al., 2005, Rösch et al., 2005). And pro-
BDNF, signalling through p75NTR, enhances LTD (Woo et al., 2005). Similarly to cell 
survival, mature and pro-neurotrophins are thought to evoke opposite responses by signalling 
through Trk or p75NTR:  the Yin-Yang model neurotrophin function (Lu et al., 2005). 
Defects in neurotrophin signalling can lead to neurological and psychiatric illness. NGF/TrkA 
signalling is essential for the development of the sensory and sympathetic nervous systems 
(Huang and Reichardt, 2001). Disruption of peripheral TrkA signalling in humans leads to 
Congenital Insensitivity to Pain with Anhidrosis (CIPA), a genetic disorder mapped to the 
TrkA gene (Indo et al., 1996). In the CNS, NGF is required for the survival and targeting of 
cholinergic neurons to the cortex, and exogenous NGF prevents age-associated degeneration 
of these neurons (Chen et al., 1997, Fischer et al., 1987). These studies also showed an 
association between NGF-mediated cholinergic neuron survival and improved memory 
function in rodents, consistent with the cholinergic model of Alzheimer’s disease (Bartus et 
al., 1982). Again, the opposing roles of pro- and mature NGF, and the balance between them, 
are thought to contribute cholinergic cell survival and to the pathology of Alzheimer’s 
disease, and the therapeutic delivery of NGF is being actively pursued as a potential treatment 
of the illness (Cuello et al., 2010, Covaceuszach et al., 2009). 
A polymorphism of BDNF is known in humans, and is associated with memory impairments 
(Egan et al., 2003). Mice heterozygous for BDNF, which is normally highly expressed in the 
hippocampus, also show learning deficits (Linnarsson et al., 1997). This mutation is a single 
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residue substitution in the BDNF pro-domain: the valine at position 66 is mutated to 
methionine. The result of this mutation is a reduced activity-dependent BDNF secretion 
through the regulated pathway, emphasising the importance of the pro-domain for 
neurotrophin processing (Egan et al., 2003, Suter et al., 1991). Knock-in mice with the 
equivalent mutation have reduced hippocampal volume, reduced dendritic complexity, and 
show increased anxiety-related behaviours (Chen et al., 2006). Similarly, human carriers of 
the Val66Met allele show reduced brain volume, memory impairments, and increased anxiety 
(Chen et al., 2008). 
1.5.6 Non-neuronal functions of Neurotrophins 
Neurotrophins play a role in early development, and have functions before the specification of 
neurons. In the chicken, the expression of TrkC is seen from the neural plate stage and TrkB 
from the neural tube stage, and both can influence cell proliferation and differentiation 
(Bernd, 2008). In chick and quail embryos, neurotrophins and their receptors are expressed 
during gastrulation and neurulation (Baig and Khan, 1996, Zhang et al., 1996). In the early 
quail embryo, TrkC is most prominently expressed; similarly, in rats, the TrkC ligand NT-3 is 
expressed early in embryogenesis (Zhang et al., 1996, Maisonpierre et al., 1990a). And even 
earlier in mouse development, shortly after fertilisation, BDNF/TrkB signalling has a role in 
the maturation of oocytes to pre-implantation embryos, and the development of the blastocyst 
(Kawamura et al., 2005, Kawamura et al., 2007). 
Vertebrate neurotrophins play roles in the development and function of other tissues. p75NTR 
and Trk receptors are expressed in the gut, skeletal muscle, heart, kidney and epidermis 
(Thomson et al., 1988, Tessarollo et al., 1993, Shelton et al., 1995). Pancreatic β-cells respond 
to neurotrophin signalling, and p75NTR is required for kidney development (Polak et al., 1993, 
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Sariola et al., 1991). In the skin, neurotrophins have pro-survival effects on melanocytes, and 
induce proliferation of keratinocytes (Yaar et al., 1994, Pincelli et al., 1994). Within the 
vasculature, neurotrophin signalling induces proliferation of endothelial cells and is 
angiogenic, and promotes the proliferation and migration of smooth muscle cells (Cantarella 
et al., 2002, Donovan et al., 1995). Neurotrophins and their receptors are up-regulated in 
vascular injury and disease, and it has been proposed that they play a role in a wide range of 
tissue repair paradigms (Donovan et al., 1995, Micera et al., 2007). 
Neurotrophins have effects on the immune system. NGF induces the proliferation and 
differentiation of mast cells (Aloe and Levi-Montalcini, 1977, Matsuda et al., 1991). This 
indicates that NGF can behave like a conventional immune cytokine, and that it may play an 
important role in the innate and adaptive immune systems (Levi-Montalcini et al., 1996). As 
well as responding to exogenous NGF, they also synthesise and release their own NGF, and 
that NGF induces mast cell degranulation (Leon et al., 1994, Mazurek et al., 1986). ProNGF 
has been shown to induce Natural Killer cell death, signalling through p75NTR and Sortilin 
(Rogers et al., 2010). The expression of neurotrophins and their receptors is now known 
across a wide range of immune cell types, and in almost all immunologically important 
tissues and organs (Vega et al., 2003); NGF has been associated with allergic and 
autoimmune disorders (Nockher and Renz, 2006a, Nockher and Renz, 2006b, Seidel et al., 
2010). 
Neurotrophins represent a possible mechanism for communication between the immune and 
nervous systems. Lymphoid tissues are extensively innervated by sympathetic neurons, and 
the spleen is a rich source of neurotrophins to support this innervation (Felten et al., 1985, 
Maisonpierre et al., 1990a). This represents a nervous-to-immune direction of 
communication, and could allow sympathetic modulation of an immune response. 
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Communication from immune-to-neural cells is well established, particularly in the context of 
pain (Moalem and Tracey, 2006). Here, peripheral immune cells degranulate in response to 
injury or infection, and the released peptides and neurotransmitters directly and indirectly 
activate afferent pain fibres. Moreover, mast cells are found in the brain, where they may 
influence neuronal activity or local immune responses, and have been implicated in multiple 
sclerosis pathogenesis (Silver et al., 1996). 
The complexity in neurotrophin processing and binding is reflected by their diverse – and 
often contradictory – effects on cell signalling. In many contexts, the ‘yin and yang’ model 
describes well the effects of pro- and mature neurotrophins in cell survival and synaptic 
signalling. However there are multiple instances when Trks and p75NTR carry out similar 
functions. Experiments on neurotrophin function are carried out in vitro, in cultured cell lines, 
in primary cell cultures, in tissue explants, and in vivo. This wide range of experimental 
paradigms generates a wealth of results that are frequently not comparable. Ultimately, cell 
context is likely to determine the true, in vivo functions of the neurotrophins. Using model 
organisms is a preferred method to investigate neurotrophin function. However, in the use of 
knock-out mice, it is often difficult to distinguish developmental from adult phenotypes. And 
neuronal phenotypes could be influenced by loss of neurotrophin signalling in other tissues, 
such as the immune system. Moreover, experiments in vertebrate models are expensive, can 
take a relatively long time to complete, and must satisfy strict ethical rules. The use of 
Drosophila lends itself to the investigation of neurotrophin function, since this family of 
growth factors is conserved. There are well-established techniques for gene knock-out or 
knock-in, which can be carried out relatively quickly, without ethical objection. To use 
Drosophila in neurotrophin research, it is essential that the DNT receptors are identified. 
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1.6 Invertebrate Neurotrophin receptors 
The identification of neurotrophins in Drosophila indicated that these molecules are part of a 
conserved mechanism for regulating neuronal structure and function. However, it is less clear 
whether neurotrophin receptors are similarly conserved between vertebrates and flies. 
Homologues of mammalian Trks and p75NTR are found across vertebrate and invertebrate 
deuterostome species, including the lancelet, acorn worm and sea urchin (Bothwell, 2006, 
Hallböök et al., 2006, Benito-Gutiérrez et al., 2006). 
1.6.1 Invertebrate Trk homologues 
Evidence of Trk homologues in protostomes includes cross-reactivity of neural tissue with 
anti-Trk antibodies. In the squid giant synapse, a protein that is labelled with anti-TrkA is 
phosphorylated on NGF application (Moreno et al., 1998). And the earthworm shows 
immunoreactivity to Trk and p75NTR in neurons and non-neuronal tissues (Lucini et al., 1999, 
Davoli et al., 2002). However, these sorts of cross-reactivity studies should be taken with 
caution, since antibodies have been found to bind non-specifically to an invertebrate plasma 
protein (Hahn et al., 1996). 
A significant advance in understanding the evolutionary origin of the Trk family came with 
the identification of a Trk homologue in the snail Lymnaea. Ltrk has an intracellular kinase 
domain that retains many of the residues unique to the Trk family of receptors, and has an 
extracellular domain that is very closely related to the Trks (van Kesteren et al., 1998, Beck et 
al., 2004). One difference is that the two extracellular IgC2 domains of vertebrate Trks are 
replaced with a single IgC1 domain in Ltrk. Ltrk is expressed extensively in juvenile and 
adult CNS neurons, and is required for neuronal survival and neurite outgrowth, indicating 
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that Trk functions have also been conserved (Bulloch et al., 2005, van Kesteren et al., 1998). 
In another snail, Aplysia, a receptor tyrosine kinase was found whose intracellular domain was 
most closely related to that of the Trks (Ormond et al., 2004). Because the EGF domain-
containing extracellular region shares no homology to the Trks, it was named ApTrkL 
(Aplysia Trk-Like). Like vertebrate Trks, it has functions in synaptic long-term facilitation 
through activation of ERK, though this is in response to 5-HT signalling (Ormond et al., 
2004). It is interesting to note that, although absent in the primitive deuterostome Amphioxus, 
and the protostome Aplysia, the C-terminal tyrosine responsible for PLCγ activation in 
vertebrate Trks is conserved in Lymnaea (van Kesteren et al., 1998). 
Trk homologues have been identified in the genome of the waterflea, Daphnia pulex (Wilson, 
2009). The water flea is a crustacean, and therefore an arthropod like Drosophila. 
Remarkably, Daphnia Trk is highly homologous to vertebrate Trks, sharing the same 
extracellular domains (including two IgC2 domains), a Trk-specific tyrosine kinase domain, 
and a C-terminal ‘PLCγ-docking’ tyrosine residue (Wilson, 2009). This study also found a 
Daphnia homologue to ApTrkL, sharing a common extracellular EGF domain, a Trk-like 
kinase domain, and C-terminal extension also seen in the Aplysia receptor. Wilson found Trk 
homologues in an additional snail (Lottia) and an annelid (Capitella), and TrkL homologues 
in Lottia and insects, including the honeybee, Apis (Wilson, 2009). This suggests that a Trk 
was present in the bilateral ancestor of protostomes and deuterostomes, and that a TrkL gene 
likely emerged in the protostomes. These data suggest that Trk was lost before the emergence 
of the insects, and that TrkL was lost in Drosophila. The true evolutionary origin of the Trks 
is likely to become clearer as more genomes are sequenced, and as their annotation improves. 
The in vivo functions of most invertebrate Trk homologues also remain to be demonstrated. 
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In flies, a receptor with an homologous kinase domain to Trk was sought, resulting in the 
identification of Dtrk (Pulido et al., 1992). However, it was noted at the time that the 
extracellular domain was not conserved with vertebrate Trks, and that there were some 
differences in the kinase domain. In fact, Dtrk lacks the juxtamembrane NPXY 
phosphotyrosine binding domain found in all vertebrate Trks (incorporating the Y450 of 
TrkA). Functional characterisation of Dtrk showed it to be involved in Semaphorin/Plexin 
signalling during axon guidance, and it was re-named Off-track (Winberg et al., 2001). In the 
meantime, two further neuronal receptor tyrosine kinases were identified in flies, with 
intracellular homology to vertebrate Trks: Dror and Dnrk (Wilson et al., 1993, Oishi et al., 
1997). The vertebrate Trk receptors belong to a superfamily sharing a homologous kinase 
domain, with divergent extracellular domains (Sossin, 2006). This group comprises the Rors 
(including Dror), the Musks (including Dnrk), the Discoidin receptors (including Drosophila 
Ddr), and the Trks. To date, no bona fide Trk homologue has been identified in flies. 
There are proteins that share a similar extracellular domain organisation with vertebrate Trks, 
possessing LRR domains flanked by CRCs, followed by Ig domains. These LIG proteins 
belong to a number of families, and are found in vertebrates, flies and nematodes (Vogel et 
al., 2003, Dolan et al., 2007). A family of vertebrate LIGs, the AMIGOS, promote neurite 
outgrowth and neuronal survival, and an unrelated LIG, Linx, positively regulates GDNF and 
NGF signalling in the developing nervous system (Kuja-Panula et al., 2003, Ono et al., 2003, 
Mandai et al., 2009). In flies, LIGs include the Kekkons (Keks), Lambik, and CG16974. Kek1 
and Kek2 are expressed in the CNS (Musacchio and Perrimon, 1996). Kek1 negatively 
regulates EGF signalling, while Kek5 negatively regulates BMP signalling (Ghiglione et al., 
1999, Alvarado et al., 2004, Evans et al., 2009). However, the CNS functions of these 
receptors have not been explored. Interestingly, the Keks are phylogenetically more related to 
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vertebrate Trks than to Lambik (Mandai et al., 2009). This suggests that the combination of 
LRR and Ig domains arose early in evolution, although relatively little is known about 
Drosophila LIG receptor signalling mechanisms. 
Trk receptors are modular, comprising distinct extracellular and intracellular catalytic 
domains. Over the course of evolution, these motifs may have been swapped, shared, and 
rearranged, and are now found in a vast array of different protein families. This ‘bricolage’ 
theory has been used to explain the building of the Trk receptor, and also the evolution of the 
superfamily of receptor tyrosine kinases (Benito-Gutiérrez et al., 2006, Sossin, 2006). As 
more invertebrate genomes are sequenced, and more functional studies are carried out, a 
clearer picture should emerge of when LRR, Ig and tyrosine kinases first came together, and 
how this receptor came to shape the development and function of the nervous system. 
1.6.2 Invertebrate p75NTR homologues 
p75NTR homologues have also been identified in invertebrates. There is one known TNFRSF 
member in Drosophila, called Wengen (Kanda et al., 2002). Wengen lacks a death domain, 
and it was suggested that the death domain-containing TNFR was a vertebrate innovation 
(Bridgham et al., 2003). Interestingly, Bridgham and colleagues proposed that the TNFRs in 
vertebrates could have recruited death-domain signalling from the Toll-like receptors in order 
to activate apoptotic pathways. Toll and its homologues are also well known to activate NFκB 
signalling, a potent pro-survival molecule. And Wengen can signal through Dorsal, an NFκB 
homologue (Kato et al., 2011). Wengen has also been found to be more similar to p75NTR than 
any other of the vertebrate TNFRSF members (Bothwell, 2006). Similarly to the Trks, the 
newly available sequences of a number of invertebrate species reveal a more ancient origin of 
p75NTR. TNFRSF members with death domains are found across all animals (Wiens and 
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Glenney, 2011). In the scallop (a mollusc), a TNFRSF member with a death domain has been 
cloned, and is involved in the immune response (Li et al., 2009). This receptor is similar to 
p75NTR, though is more closely related to other known invertebrate TNFRSF members. Other 
invertebrate p75NTR homologues have been identified from sequenced genomes, but lack 
functional characterisation. These include p75NTR homologues in the invertebrate 
deuterostomes, the lancelet, the acorn worm and the sea urchin (Bothwell, 2006, Robertson et 
al., 2006). p75NTR homologues are also found in protostome genomes, including another 
mollusc (Lottia), an annelid (Capitella) and the arthropod, Daphnia (Wilson, 2009). A 
TNFRSF member with homology to p75NTR, incorporating in intracellular death domain, has 
even been found in the cnidarian, Nematostella (Robertson et al., 2006). This suggests that 
p75NTR descends from an ancient receptor, originating before the emergence of bilateral 
animals, and that it is more ancient than the Trks. 
1.7 Drosophila as a model organism 
The Drosophila nervous system is a model to investigate many aspects of neuronal function, 
from neurogenesis to behaviour. The embryonic CNS consists of an anterior central brain, and 
a ventral nerve cord (VNC) that runs along the ventral midline of the embryo. The embryonic 
stem cells that give rise to the nervous system – the neuroblasts – first appear in stage 8, and 
delaminate from the ectoderm at stage 9 (stages according to Campos-Ortega and Hartenstein, 
1985). Neuroblasts undergo asymmetrical division to yield another neuroblast and a ganglion 
mother cell (GMC); the GMC divides to produce two neurons or glia, which begin to 
differentiate at stage 12 (Goodman and Doe, 1993). From stage 14 to 17, the VNC condenses, 
becoming shorter and thicker (Fig 1.5A, B). As neurons arise and differentiate, commissural 
pioneer axons cross the midline to create the commissures, and the longitudinal connective 
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tracts are pioneered anteriorly and posteriorly to connect each segment (Hidalgo and Brand, 
1997). There are two commissures (anterior and posterior) per segment that connect the 
longitudinal connectives, giving the embryonic neuropile a ladder-like appearance, and the 
neuropile occupies a dorsal position within the cell bodies of the VNC (Goodman and Doe, 
1993) (Fig 1.5C, D). Clusters of peripheral nervous system (PNS) cells arise from the 
ectoderm, and form the sensory organs (Jan and Jan, 1993). The sensory neurons differentiate 
from stage 13, and their axons project towards the CNS in anterior and posterior fascicles in 
each hemisegment (Fig 1.5D). At the same time, motor neurons project out of the CNS to the 
muscle along two fascicles per hemisegment (Goodman and Doe, 1993) (Fig 1.5D). The 
sensory and motor axons meet halfway, and their combined tracts form the segmental and 
intersegmental nerves. 
In the larva, the CNS continues to grow, particularly in the thoracic VNC and the optic lobes 
(Fig 1.5E). Neuroblasts that arose in the embryo undergo a second wave of division, and 
generate large numbers of immature, post-mitotic neurons (Prokop and Technau, 1991). 
During metamorphosis, a number of changes occur to produce the adult CNS. Many of the 
larval interneurons undergo re-modelling, and extend their axons and dendrites; immature 
neurons arising during post-embryonic neurogenesis differentiate, and send out axons to their 
targets; and cells that are no longer required are removed by apoptosis, particularly in the 
abdominal VNC (Truman, 1990). Also during metamorphosis, new sensory neurons enter the 
CNS from the periphery. The adult CNS is made up of a number of ganglia (Fig 1.5F). The 
larval VNC gives rise to the adult VNC and also the sub-oesophageal ganglion of the central 
brain. The larval brain hemispheres develop into the large optic lobes of the adult, and the 
supra-oesophageal ganglion of the central brain, which contains the central complex and the 
mushroom bodies (Hartenstein, 1993). 
Fig 1.5 - The Drosophila nervous system.
A B
C D
E F
(A) In stage 13 embryos, the CNS (blue) occupies the entire length of dorsal midline.
(B) By the end of embryogenesis at stage 17, the CNS has condensed. (C) The
neuropile (yellow) is located dorsally within the VNC, and nerves project to the
periphery. (D) Cartoon of a dissected embryo. The sensory neurons of the PNS project
into the CNS (left), and motor neurons project to the muscle (right), along two nerve
roots. (E) The larval CNS develops into (F) the adult CNS during metamorphosis. The larval
origins of the adult ventral nerve cord (dark blue), sub-oesophageal ganglion (yellow),
supra-oesophageal ganglion (red) and optic lobes (green) are indicated in (E).
PNS Motor
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1.8 Aims 
Toll-7 and Toll-6, paralogues of Toll, are expressed in the CNS, but their functions are 
unknown (Kambris et al., 2002). Toll is expressed in the Drosophila CNS, where it promotes 
cell survival and axon targeting (Zhu et al., 2008, Halfon et al., 1995). The ligand for Toll, 
Spz, functions as a Drosophila neurotrophin, a ligand family that also includes DNT1 and 
DNT2 (Zhu et al., 2008). However, the receptors for DNT1 and DNT2 are unknown, and 
Toll-7 and Toll-6 are appealing candidates. 
The aims of my thesis are to investigate the functions of Toll-7 and Toll-6 in the Drosophila 
nervous system, and to test whether they can serve as DNT receptors. To characterise Toll-7 
and Toll-6, my aims are: (1) To determine the expression patterns of Toll-7 and Toll-6 in 
embryos, and in the larval and adult CNS. (2) To generate Toll-7 and Toll-6 null alleles as 
tools to characterise their function. (3) To test the genetic interaction of mutant and gain-of-
function receptors with DNT mutants, using a lethality assay. This will show whether the 
Toll-7 and Toll-6 share common signalling pathways with the DNTs, and whether activated 
receptors can rescue a DNT mutant phenotype. (4) To investigate the functions of Toll-7 and 
Toll-6 in the nervous system, by examining their effects on adult locomotion, axon targeting 
and cell survival. This will show whether Toll-7 and Toll-6 are required for nervous system 
development and function, and indicate whether that have roles in common with the DNTs. 
(5) To generate recombinant DNT protein, and test in cell culture whether DNTs can activate 
signalling through Toll-7 and Toll-6. In this thesis, I aim to explore the intriguing connections 
between the neurotrophin and Toll families. 
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CHAPTER 2 
METHODS 
 
2.1 Genetics 
2.1.1 Fly strains 
Drosophila melanogaster were cultured on standard cornmeal agar medium, supplemented 
with dried yeast. Unless indicated, experiments were carried out at 25°C, in a 12 hour 
light/dark period. Stocks were maintained at 18°C, and transferred every 28 days. The stocks 
used and generated are given in Table 2.1. 
2.1.2 Genetic protocols 
Conventional genetic techniques were used to balance mutant alleles, Gal4 drivers and UAS 
transgenes on the 2nd and 3rd chromosomes (Protocols A-C, Fig 2.1). Alleles were combined 
by recombination on the 2nd chromosome following Protocol D (Fig 2.2) and on the 3rd 
chromosome following Protocol E (Fig 2.3). Double mutants on the 2nd and 3rd chromosomes 
were made following Protocol F (Fig 2.4). P-element transformant flies were mapped 
following Protocol G (Fig 2.5). P-element mobilisation for imprecise excision mutagenesis of 
Toll-7 followed Protocol H (Fig 2.6), and of Toll-6 followed Protocol I (Fig 2.7). Mutagenesis 
of Toll-7 was carried out by the Hidalgo lab technician, Janine Fenton, before I arrived in the 
lab. Toll-6 Mutagenesis was carried out with Janine Fenton and BSc student Sarah Quail. 
Transgenes were expressed in flies using the UAS/Gal4 system (Brand and Perrimon, 1993). 
To express genes in the CNS, elavGal4 and ChaGal4 lines were used, which drive expression 
(continued…)  
No. Genotype Source Protocol 
1 yw Hidalgo lab collection  
2 IF / CyOlacZ Hidalgo lab collection  
3 MKRS / TM6BlacZ Hidalgo lab collection  
4 IF / CyO ; MKRS / TM2 Hidalgo lab collection  
5 IF / CyOlacZ ; MKRS / TM6BlacZ Hidalgo lab collection  
6 en ; + / SM6aTM6B Hidalgo lab collection  
7 φC31;;ZH-attP-86Fa (J35) Bloomington  
8 yw ;  ; Δ2-3Sb / TM6 Hidalgo lab collection  
9 GE17034 (Toll-7 P-element) A gift from JL Imler  
10 GE26951 (Toll-6 P-element) A gift from JL Imler  
11 UAS GAP GFP A gift from A Chiba  
12 UAS mCD8 GFP Hidalgo lab collection  
13 UAS Histone GFP Hidalgo lab collection  
Driver lines 
14 elav Gal4 Hidalgo lab collection  
15 Cha Gal4 A gift from R Baines  
16 D42 (Toll-6) Gal4 / TM3 A gift from S Sanyal  
17 Toll-7 Gal4 / CyO G McIlroy, this work Transgenesis by 
BestGene Inc 
DNT mutants 
18 DNT1[41] / DNT1[41] Hidalgo lab collection  
19 Df4342 / TM6BlacZ Hidalgo lab collection  
20 DNT2[e03444] / DNT2[e03444] Hidalgo lab collection  
21 Df6092 / TM6BlacZ Hidalgo lab collection  
22 spz[2] / TM6BlacZ Bloomington  
23 DNT1[41]DNT2[e03444] / TM6BlacZ Hidalgo lab collection  
24 DNT1[41]spz[2] / TM6BlacZ Hidalgo lab collection  
25 DNT2[e03444]spz[2] / TM6BlacZ Hidalgo lab collection  
Toll-7 single mutants 
26 Toll-7[P8] / CyOlacZ J Fenton Hop-out line 9 
27 Toll-7[P8] ; + / SM6aTM6B G McIlroy, this work C using lines 6 and 26 
28 Toll-7[P114] / CyOlacZ J Fenton Hop-out line 9 
29 Toll-7[P114] ; + / SM6aTM6B G McIlroy, this work C using lines 6 and 28 
30 Df(2R)BSC22 / SM6a Bloomington  
31 Df(2R)BSC22 / CyOlacZ G McIlroy, this work A using lines 2 and 30 
(continued…)  
No. Genotype Source Protocol 
Toll-6 single mutants 
32 Toll-6[26] / TM6BlacZ G McIlroy, this work Hop-out of line 10 
33 Toll-6[31] / TM6BlacZ G McIlroy, this work Hop-out of line 10 
34 Df(3L)XG4 / TM3 Bloomington  
35 Df(3L)XG4 / TM6BlacZ G McIlroy, this work B using lines 3 and 34 
Toll-7 and Toll-6 double mutants 
36 Toll-7[P8] / CyOlacZ ; Toll-6[26] / TM6BlacZ G McIlroy, this work F using lines 26 and 32 
37 Toll-7[P8] ; Toll-6[26] / SM6aTM6B G McIlroy, this work C using lines 6 and 36 
38 Toll-7[P114] / CyOlacZ ; Toll-6[31] / TM6BlacZ G McIlroy, this work F using lines 28 and 33 
39 Toll-7[P114] ; Toll-6[31] / SM6aTM6B G McIlroy, this work C using lines 6 and 38 
Toll-7, Toll-6, and DNT double mutants 
40 Toll-7[P114] / CyOlacZ ; DNT1[41] / TM6BlacZ G McIlroy, this work F using lines 18 and 28 
41 Toll-7[P114] ; DNT1[41] / SM6aTM6B G McIlroy, this work C using lines 6 and 40 
42 Toll-7[P114] / CyOlacZ ; DNT2[e03444] / TM6BlacZ G McIlroy, this work F using lines 20 and 28 
43 Toll-7[P114] ; DNT2[e03444] / SM6aTM6B G McIlroy, this work C using lines 6 and 43 
44 Toll-7[P8] / CyOlacZ ; spz[2] / TM6BlacZ G McIlroy, this work F using lines 22 and 26 
45 Toll-7[P8] ; spz[2] / SM6aTM6B G McIlroy, this work C using lines 6 and 44 
46 DNT1[41]Toll-6[26] / TM6BlacZ G McIlroy, this work E using lines 18 and 32 
47 DNT2[e03444]Toll-6[26] / TM6BlacZ G McIlroy, this work E using lines 20 and 32 
48 Toll-6[26]spz[2] / TM6BlacZ G McIlroy, this work E using lines 22 and 32 
DNT and elav Gal4 driver combined lines 
49 DNT1[41]elav Gal4 / TM6BlacZ Hidalgo lab collection  
50 DNT2[e03444]elav Gal4 / TM6BlacZ G McIlroy, this work E using lines 14 and 20 
51 spz[2]elav Gal4 / TM6BlacZ B Sutcliffe, Hidalgo lab   
52 DNT1[41]DNT2[e03444]elav Gal4 / TM6BlacZ B Sutcliffe, Hidalgo lab   
Toll-7, Toll-6, and Cha Gal4 driver combined lines 
53 Toll-7[P8]Cha Gal4 / CyOlacZ G McIlroy, this work D using lines 15 and 26 
54 Toll-7[P8]Cha Gal4 / CyOlacZ ; Toll-6[26] / 
TM6BlacZ 
G McIlroy, this work F using lines 32 and 53 
55 Toll-7[P8]Cha Gal4 ; Toll-6[26] / SM6aTM6B G McIlroy, this work C using lines 6 and 54 
No. Genotype Source Protocol 
Activated receptor lines 
56 UAS Toll[10b] A gift from YT Ip  
57 UAS Toll-7[ΔLRR] / TM6BlacZ G McIlroy, this work Transgenesis into line 7 
58 UAS Toll-7[Cys-Tyr] / CyO G McIlroy, this work Transgenesis by 
BestGene Inc 
59 UAS Toll-6[ΔLRR] /TM6BlacZ G McIlroy, this work Transgenesis into line 7 
60 UAS Toll-6[Cys-Tyr] / TM2 G McIlroy, this work Transgenesis by 
BestGene Inc 
Activated receptor and DNT mutant lines 
61 UAS Toll-7[Cys-Tyr] / CyOlacZ ; DNT1[41] / TM6B G McIlroy, this work F using lines 18 and 58 
62 Df6092UAS Toll-6[Cys-Tyr] / TM6BlacZ G McIlroy, this work E using lines 21 and 60 
63 spz[2]UAS Toll-7[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 22 and 57 
64 spz[2]UAS Toll-6[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 22 and 59 
Activated receptor and DNT double mutant lines 
65 UAS Toll[10b] / CyOlacZ ; DNT1[41]DNT2[e03444] / 
TM6BlacZ 
G McIlroy, this work F using lines 23 and 56 
66 DNT1[41]DNT2[e03444]UAS Toll-7[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 23 and 57 
67 UAS Toll-7[Cys-Tyr] / CyOlacZ ; DNT1[41]DNT2[e03444] / 
TM6BlacZ 
G McIlroy, this work F using lines 23 and 58 
68 DNT1[41]DNT2[e03444]UAS Toll-6[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 23 and 59 
69 DNT1[41]DNT2[e03444]UAS Toll-6[Cys-Try] / TM6BlacZ G McIlroy, this work E using lines 23 and 60 
Activated receptor, and Toll-7 or Toll-6 mutant lines 
70 Toll-6[26]UAS Toll-7[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 32 and 57 
71 Toll-7[P8]UAS Toll-7[Cys-Tyr] / CyOlacZ G McIlroy, this work D using lines 26 and 58 
72 Toll-6[26]UAS Toll-6[ΔLRR] / TM6BlacZ G McIlroy, this work E using lines 32 and 59 
Activated receptor, and Toll-7 and Toll-6 double mutant lines 
73 Toll-7[P8] / CyOlacZ ; Toll-6[26]UAS Toll-7[ΔLRR] / 
TM6BlacZ 
G McIlroy, this work F using lines 26 and 70 
74 Toll-7[P8] ; Toll-6[26]UAS Toll-7[ΔLRR] / SM6aTM6B G McIlroy, this work C using lines 6 and 73 
75 Toll-7[P8]UAS Toll-7[Cys-Tyr] / CyolacZ ; Toll-6[31] / 
TM6BlacZ 
G McIlroy, this work F using lines 33 and 71 
76 Toll-7[P8]UAS Toll-7[Cys-Tyr] ; Toll-6[31] / SM6aTM6B G McIlroy, this work C using lines 6 and 75 
77 Toll-7[P8] / CyOlacZ ; Toll-6[26]UAS Toll-6[ΔLRR] / 
TM6BlacZ 
G McIlroy, this work F using lines 26 and 72 
78 Toll-7[P8] ; Toll-6[26]UAS Toll-6[ΔLRR] / SM6aTM6B G McIlroy, this work C using lines 6 and 77 
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in all neurons and in cholinergic neurons, respectively. Expression constructs were cloned 
downstream of UAS and transformed into flies. When the Gal4 fly line and the UAS line 
were crossed, neuronally expressed Gal4 bound to the UAS elements to drive the expression 
of the transgene. Similarly, Toll-7 and Toll-6 Gal4 lines were used to drive expression of 
membrane-bound GFP, to reveal the morphology of those cells. 
2.1.3 Transgenesis 
To prepare transformation constructs containing ΔLRR activated receptors, 10μg plasmid 
DNA was precipitated by adding a 10% volume of 3M sodium acetate pH5.2 and 2x volume 
ethanol, chilling for 10 minutes at -20°C, and centrifuging for 10 minutes at 13000rpm. The 
pellet was washed in 70% ethanol, and air dried. The DNA was dissolved in 20μl injection 
buffer (0.1mM NaH2PO4, 5mM KCl, filtered to 0.2μm (Pall Acrodisc)) to give a final 
concentration of 0.5μg/μl. For microinjection, glass micropipettes (outer diameter 1mm, inner 
diameter 0.78mm, Clark) were pulled using a PC-10 Micropipette Puller (Narishige), and 
were loaded with the DNA solution. Flies carrying an attP site at cytogenetic location 86F 
(line J35, genotype: φC31;;ZH-attP-86Fa) were bred in a large cage with a grape-juice agar 
base to collect the embryos, which was changed every 45 minutes to synchronise egg laying. 
Embryos were collected before the cellular blastoderm stage, were briefly dechorionated in a 
10% sodium hypochlorite (VWR) solution, and washed thoroughly with water. Embryos were 
aligned, and attached to a glass coverslip (VWR) with heptane glue (Scotch tape adhesive 
dissolved in heptane). Embryos were desiccated in air for 10 minutes before injection. DNA 
was injected into the posterior end of the embryos, prior to pole cell formation, using an 
MN-153 micro-manipulator (Narishige) an IM-30 microinjector (Narishige) and JunAir 3-4 
air compressor. The embryos were then covered by a layer of halocarbon oil 700 (Sigma), and 
42 
 
kept in a humid large petri dish until hatching. First instar larvae were collected, and 
transferred to fly food supplemented with wet yeast paste (Red Star). All steps from egg 
laying to collection of eclosing adults took place at 18°C. Adult flies eclosing from injected 
embryos (G0) were crossed to yw flies, and transformants were identified in the F1 progeny by 
their red eyes. Stocks were established using Protocol G (Fig 2.5). For UAS-Toll-7ΔLRR, 2080 
embryos were injected, of which 146 hatched as larvae and 26 eclosed as adults. Of the adult 
flies obtained, 5 were identified as transformants by their red eyes. For UAS-Toll-6ΔLRR, 1230 
embryos were injected, yielding 40 larvae and 13 adults. 2 transgenic fly lines were identified. 
UAS-Toll-7Cys-Tyr and UAS-Toll-6Cys-Tyr constructs were transformed using P-element 
Transposase into yw flies by BestGene Inc. The transgenes in the fly lines received from the 
company were mapped using Protocol G (Fig 2.5, materials and methods). The UAS-Toll-7Cys-Tyr 
line used was mapped to the 2nd chromosome, UAS-Toll-6Cys-Tyr to the 3rd. 
2.1.4 Survival Index 
Lethality was assessed at 18°C, in the progeny of heterozygous flies balanced with TM6B for 
mutant alleles on the 3rd chromosome, or SM6aTM6B for alleles on the 2nd chromosome. 
These balancer chromosomes are marked with Tb-, which means heterozygous pupae are 
identifiable from their shape (Fig 2.8A). As the progeny receive one copy of the chromosome 
from each parent, and TM6B/TM6B is embryonic lethal, the Mendelian expectation is that 1/3 
of the progeny will be homozygous and 2/3 heterozygous over TM6B (Fig 2.8B, C). The 
survival index (SI) is a measure of how mutant alleles affect viability:?
?? ? ? ?? ?????????? ???????????????????? ???????????? 
 
43 
 
For wild-type alleles:?
?? ? ? ? ?
? ?? ?
?? ?? ?
?? ? 
When the SI is below 1, there are fewer homozygotes than would be expected for wild-type, 
indicating that the mutant allele being tested reduces viability. If an allele is lethal, there are 
no homozygotes, and the SI is 0. 
2.2 Molecular biology 
The plasmids used during the course of the project are given in Table 2.2. The cloning of full-
length, wild-type Toll-7 and Toll-6, as well as pPTGAL-Toll-7 5kb upstream (used to generate 
the Toll-7-Gal4 fly line) are described in Chapter 3. The cloning of constitutively active 
receptors and DNT constructs for protein expression are described below. All primers used are 
referred to by number, and the sequences are given in Tables 2.3-2.7. 
2.2.1 Genomic DNA extraction 
15 adult flies were anaesthetised and kept chilled in an eppendorf tube. The genomic DNA 
was isolated using a Gentra Puregene Tissue Kit (Qiagen), according to the supplied 
instructions, and was stored at -20°C. To screen mutant fly lines, Single-Fly DNA 
preparations were made (Gloor et al., 1993). A single anaesthetised fly was placed in an 
eppendorf, squashed, incubated for 30 minutes at 37°C in squishing buffer (25mM NaCl, 
10mM Tris pH8, 1mM EDTA, 200μg/ml Proteinase K (Invitrogen), in water), followed by 
heat inactivation at 95°C for 2 minutes. 
TM6B
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Fig 2.8 - Mendelian segregation can be observed in pupae
Pupae
(A) TM6B pupae can be distinguished from Tb+ pupae by their shorter shape. (B) Following
a cross, progeny receive one copy of each chromosome from each parent (red and blue).
(C) When heterozygous flies are crossed, and the progeny pupae counted, 1/3 of the are
homozygous for chromosome m, while 2/3 of the progeny are heterozygous according to
Mendelian segregation. TM6B/TM6B homozygotes die during embryogenesis, and
therefore never pupate.
A
B
C
44 
 
2.2.2 Polymerase Chain Reaction (PCR) 
DNA was amplified by PCR from genomic DNA and cDNA plasmids. When high-fidelity 
was not required, BioTaq (Bioline) DNA polymerase was used. 50μl reaction volumes 
included 5μl 10x NH4 Buffer, 1.5μl 50mM MgCl2 solution, 1μl 10mM dNTP mix (Roche), 
5μl 3μM each primer, 1-3μl DNA template, 0.6μl BioTaq in water. A PTC-200 thermal cycler 
(MJ Research) was used to run the PCR, and temperature Program 1 was used when 
amplifying with BioTaq (Table 2.8). For high-fidelity cloning, Phusion (NEB) was used. Each 
50μl reaction contained 10μl 5x Buffer HF, 1μl 10mM dNTP mix, 5μl 3μM each primer, 1-
3μl DNA template, 0.5μl Phusion in water. When amplifying with Phusion, PCR Program 2 
was used (Table 2.9). 
Overlapping PCR was used to join two fragments of DNA that had been amplified separately, 
and had >40bp identical sequence at the point of overlap. 50μl reactions contained 0.5μl 
Phusion, 10μ 5x Buffer HF, 1μl 10mM dNTP mix, 5μl 3μM each primer directed at the 3’ and 
5’ ends of the final product, and the rest of the mix was made up of equimolar amounts of 
each fragment to be joined. Since Phusion DNA polymerase was used, PCR was run with 
Program 2 (Table 2.9). 
To confirm the presence of Toll-7 mutant alleles in putative recombinants, primers 7.2 and 7.4 
were used (Table 2.3), which flanked original P-element insertion site and the resulting 
genomic deletion. Similarly, to confirm the presence of Toll-6 mutant alleles in putative 
recombinants, primers 6.2 and 6.8 were used (Table 2.4). To confirm the presence of the 
DNT141 mutant allele in putative recombinants, primers 1.1 and 1.2 were used (Table 2.5), 
which identify the white gene in the DNT1 locus. And to confirm the presence of the 
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DNT2e03444 mutant allele, primers 2.1 and 2.2 were used (Table 2.6), which identify the P-
element in the DNT2 locus. 
2.2.3 Agarose gel electrophoresis and DNA purification 
To check the size of DNA fragments, and to purify amplified DNA for cloning, PCR products 
were run on 0.8%-1% agarose (Bioline) gels in TAE buffer + ethidium bromide (Sigma). 
DNA was mixed with 17% volume of 6x DNA loading buffer (0.25% bromophenol blue, 
0.25% xylene cyanol FF, 30% glycerol (Sigma) in water). Gels were run at 65V until the dye-
front had travelled to the end of the gel. 0.5μg of a 1kb ladder (NEB) was used as a molecular 
weight marker. DNA was visualised under UV light using a Gel Doc 2000 (BioRad). To 
extract the DNA, bands were cut from the gel using a razor blade, and DNA was purified 
using the QIAquick Gel Extraction kit (Qiagen) according to the kit instructions. DNA was 
eluted into 50μl 10mM Tris pH8. 
2.2.4 Gateway cloning 
A number of constructs were generated using Gateway cloning (Invitrogen). Gateway 
technology is based on the recombination of DNA across specific ‘att’ sites; the process of 
cloning a DNA fragment into an expression clone is summarised in (Fig 2.9). For expression 
in S2 cells, a destination vector with an Actin promoter and a C-terminal HA tag was used. 
For expression in flies following P-element transformation, the destination vector contained a 
UAS promoter, a C-terminal HA tag, P-element sequences, and the mini-white gene. For 
expression in flies following φC31 transformation, the destination vector contained a UAS 
promoter, a C-terminal FLAG tag, an attB site for transformation, and the mini-white gene. 
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When Gateway cloning was used (see Table 2.2), amplified DNA fragments included at the 5’ 
end an attB1 sequence, and at the 3’ end an attB2 sequence. 50fmol of purified PCR product 
was added to 50fmol (150ng) of the pDONR221 donor vector, and mixed with 2μl BP Clonase 
II enzyme (Invitrogen), to a total volume of 10μl in TE. The Clonase II enzyme reagent 
includes a 5x buffer. The reaction was incubated at 25°C overnight. Reactions were stopped 
by adding 1μg Proteinase K and incubating for 10 minutes at 37°C. This was then used to 
transform E.coli. For LR reactions, 150ng each of entry clone and destination vector were 
mixed in 8μl TE, and 2μl LR Clonase II enzyme (Invitrogen) was added. Reactions were 
incubated overnight at 25°C, and stopped with 1μg Proteinase K treatment for 10 minutes at 
37°C. This was then used to transform E. coli. 
2.2.5 Conventional restriction enzyme cloning 
Conventional cloning using restriction enzymes was also carried out to generate constructs 
(see Table 2.2). DNA fragments were amplified by PCR using primers containing restriction 
enzyme sites, and subsequently digested with the appropriate enzyme. Plasmids were digested 
with the same enzymes as the inserts. Digestion reactions were carried out in 15μl volumes, 
including 100-500ng DNA, 1.5μl of 10x buffer, and 0.5μl each enzyme (Roche), incubated at 
37°C for 3 hours, and inactivated by incubating at 65°C for 10 minutes. Cut fragments and 
vectors were purified from the reaction mix using the QIAquick PCR Purification kit 
(Qiagen) according to the instructions. DNA was eluted in 30μl 10mM Tris pH8. 
The DNA insert was ligated into the vector. A 3-fold molar excess of insert was mixed with 
the vector to a final DNA amount of 200-400ng, into 17μl water, to which 2μl 10x T4 buffer 
and 1μl T4 Ligase (NEB) were added. Ligation reactions were incubated overnight at 18°C, 
and inactivated at 65°C for 10 minutes. This was then used to transform E. coli. 
attB1 attB2Gene
PCR Product attP1 attP2ChlR ccdB
KanaR
pDONR
GeneattL1 attL2
KanaR
Entry Clone
attR1 attR2ChlR ccdB
By-Product
By-Product
attP1 attP2ChlR ccdB
KanaR
attR1 attR2ChlR ccdB
AmpR
Promoter
Destination
Vector
attB1 attB2Gene
AmpR
Promoter
Expression
Clone
BP Reaction
Select for
Kanamycin Resistance
Select for
Ampicillin Resistance
LR Reaction
Fig 2.9 - Gateway Cloning
During a BP reaction, recombination between attB sites in a PCR product and attP sites
in pDONR creates an entry clone. Entry clones are selected for with Kanamycin. The
toxic ccdB gene kills bacteria containing the empty pDONR. During an LR reaction,
recombination between attL and attR sites places the DNA fragment into an expression
clone. The expression clone is slelcted for with Ampicillin, non-recombined destination
vectors kill bacteria with the ccdB gene.
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2.2.6 Transformation of E. coli 
DNA clones were transformed into DH5α (Invitrogen) chemically competent E. coli cells. 
Large plasmids were transformed into One Shot OmniMAX cells (Invitrogen). 25μl of cells 
was thawed on ice, and 1μl plasmid DNA was added. The cells were incubated for 30 minutes 
on ice, heat-shocked for 30 seconds at 42°C, and returned to ice for 2 minutes. 500μl SOC 
medium was added, and E. coli were grown for 1 hour shaking at 225rpm at 37°C. 20μl and 
200μl of the culture were spread onto LB + agar plates, containing the relevant antibiotic for 
colony selection (50μg/ml ampicillin, 50μg/ml kanamycin, or 100μg/ml chloramphenicol, 
Sigma). Plates were incubated overnight at 37°C. 
To recombine pFastBac constructs into Bacmid DNA for protein expression with 
Baculovirus, DH10Bac (Invitrogen) E. coli were used, according to the manufacturer’s 
instructions. The transformed cells were spread on LB + agar plates containing 50μg/ml 
kanamycin, 7μg/ml gentamycin and 10μg/ml tetracycline for bacterial selection, and 
100μg/ml Bluo-gal and 40μg/ml IPTG for blue-white selection (Sigma). 
2.2.7 Amplification of plasmid DNA 
Single colonies were picked with a sterile pipette tip and inoculated into 2ml of LB medium 
containing the relevant antibiotic (see above), and miniprep cultures were grown overnight 
shaking at 225rpm, 37°C. 1.5ml of each culture was transferred to an eppendorf, the cells 
were pelleted by centrifuging at 13000rpm for 30 seconds, and the supernatant was discarded. 
Cells were re-suspended in 350μl STET (0.1M NaCl, 10mM Tris pH8, 1mM EDTA pH8, 5% 
Triton-X-100 (Sigma)) plus 30μl 5mg/ml Lysozyme (Sigma) solution. Samples were boiled at 
100°C for 1 minute, incubated on ice for 2 minutes, then centrifuged at 13000rpm for 20 
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minutes. The resulting pellet was removed, and DNA was precipitated with 200μl 5M 
ammonium acetate and 800μl isopropanol, and chilled at -20°C for 10 minutes. DNA was 
pelleted at 13000rpm for 15 minutes, washed with 80% ethanol in water, air dried, and 
dissolved in 50μl 10mM Tris pH8. 
Resultant clones were scrutinised with diagnostic restriction enzyme digests. Once a correct 
clone had been identified, 100μl from the miniprep LB culture was used to inoculate 50-
100ml of LB medium containing the relevant antibiotic (maxiprep). This was grown 
overnight shaking at 225rpm, 37°C. DNA was isolated from the cultures using a QIAfilter 
Plasmid Maxi kit (Qiagen), according to the kit instructions. 
2.2.8 DNA sequencing 
All constructs identified by diagnostic digests were sequenced. When using Gateway cloning, 
the ‘Entry’ clone was sequenced before transfers into destination vectors. In each sequencing 
reaction, 500ng plasmid DNA and 3pmol primer were made up to 10μl in water, and sent to 
the Genomics Facility, School of Biosciences, University of Birmingham for sequencing. The 
coding region and integration sites of each construct were sequenced. Toll-7 constructs were 
sequenced using primers 7.16-7.25 (Table 2.3); Toll-6 constructs were sequenced using 
primers 6.17-6.27 (Table 2.4); DNT1 constructs were sequenced with primers 1.16-1.22 
(Table 2.5); DNT2 constructs were sequenced with primers 2.10-2.12 (Table 2.6). To 
sequence the insertion site in plasmids, primers V.1 and V.2 were used in pDONR entry 
clones, and V.3 and V.4 were used in Baculovirus clones (Table 2.7). At least two 
overlapping sequences were obtained for every base, which were compared to the sequence 
predicted sequence from FlyBase, using the Kalign tool through the European Bioinformatics 
Institute website (www.ebi.ac.uk). 
 Name Description Source Cloning method
Gateway Vectors 
pDONR221 Gateway donor vector Invitrogen  
pUAS-gw-HA-attB Destination vector for Phi C31 transgenics with C-terminal 3xHA tag T Murphy  
pUAS-gw-FLAG Destination vector for transposase transgenics, with C-terminal 3xFLAG tag T Murphy  
pAct5C-gw-HA Destination vector for cell expression, C-terminal 3xHA tag T Murphy  
pAct5C-gw Destination vector for cell expression, no tags T Murphy  
Baculovirus Vectors 
pFastBac1 For Baculovirus, no tags Invitrogen  
pK503-9 For Baculovirus, pFastBac1 with N-terminal EGT signal peptide and FLAG tag A gift from N Gay  
Plasmids for cell culture 
pPsnail-Luc Firefly Luciferase downstream of snail promoter - Dorsal reporter A gift from AJ Courey  
pRenillaLuc Renilla Luciferase downstream of actin promoter - Luciferase control A gift from S Brogna  
pPac-FLAG-Dorsal Dorsal cDNA downstream of actin promoter A gift from AJ Courey  
pMT-Gal4 Gal4 under metallothionine promoter, copper-inducible Drosophila Genomics Resource Centre  
Toll-7 constructs 
pDONR-Toll-7 Full length Toll-7, no stop codon, Gateway entry clone G McIlroy, this work, see Chapter 3 Gateway cloning 
pAct5C-Toll-7-3HA Full length Toll-7 with C-terminal 3xHA, for S2 cell expression G McIlroy, this work, see Chapter 3 Gateway cloning 
pDONR-Toll-7[ΔLRR] Activated Toll-7[ΔLRR], no stop codon, Gateway entry clone G McIlroy, this work, see section 2.2.9 Gateway cloning 
pUAS-Toll-7[ΔLRR]-3HA-attB Activated Toll-7[ΔLRR] with C-terminal 3xHA, for φC31 transgenesis G McIlroy, this work, see section 2.2.9 Gateway cloning 
pDONR-Toll-7[Cys-Tyr] Activated Toll-7[Cys-Tyr], no stop codon, Gateway entry clone G McIlroy, this work, see section 2.2.9 Gateway cloning 
pUAS-Toll-7[Cys-Tyr]-3FLAG Activated Toll-7[Cys-Tyr] with C-terminal 3xFLAG, for P-element transgenesis 
and S2 cell expression 
G McIlroy, this work, see section 2.2.9 Gateway cloning 
pPTGAL-Toll-7 5kb upstream 5kb of Toll-7 regulatory region, upstream of Gal4, for P-element transgenesis G McIlroy, this work, see Chapter 3 Enzymatic cloning 
Toll-6 constructs 
pDONR-Toll-6 Full length Toll-6, no stop codon, Gateway entry clone G McIlroy, this work, see Chapter 3 Gateway cloning 
pAct5C-Toll-6-3HA Full length Toll-6 with C-terminal 3xHA, for S2 cell expression G McIlroy, this work, see Chapter 3 Gateway cloning 
pDONR-Toll-6[ΔLRR] Activated Toll-6[ΔLRR], no stop codon, Gateway entry clone G McIlroy, this work, see section 2.2.9 Gateway cloning 
pUAS-Toll-6[ΔLRR]-3HA-attB Activated Toll-6[ΔLRR] with C-terminal 3xHA, for φC31 transgenesis G McIlroy, this work, see section 2.2.9 Gateway cloning 
pDONR-Toll-6[Cys-Tyr] Activated Toll-6[Cys-Tyr], no stop codon, Gateway entry clone G McIlroy, this work, see section 2.2.9 Gateway cloning 
pUAS-Toll-6[Cys-Tyr]-3FLAG Activated Toll-6[Cys-Tyr] with C-terminal 3xFLAG, for P-element transgenesis 
and S2 cell expression 
G McIlroy, this work, see section 2.2.9 Gateway cloning 
  
Name Description Source Cloning method 
DNT1 protein expression constructs 
pK503-9-DNT1 CK DNT1 CK with N-terminal EGT signal peptide, FLAG tag, 6His 
and Thrombin site, for Baculovirus expression 
G McIlroy, this work, see section 2.2.11 Enzymatic cloning
pK503-9-DNT1 CK + CTD DNT1 CK + CTD with N-terminal EGT signal peptide, FLAG tag, 
6His and Thrombin site, for Baculovirus expression 
G McIlroy, this work, see section 2.2.11 Enzymatic cloning
pFastBac1-DNT1 Pro + CK DNT1 Pro-domain + CK with C-terminal TEV site and 6His, for 
Baculovirus expression 
G McIlroy, this work, see section 2.2.11 Enzymatic cloning
pFastBac1-Spz Pro-6HisTEV-DNT1 CK + CTD Spz pro-domain, 6His tag, TEV cleavage site, DNT1 CK + CTD, 
for Baculovirus expression 
G McIlroy, this work, see section 2.2.11 Enzymatic cloning
pDONR-DNT1 Pro-TEV6HisV5-DNT1 CK + CTD Full length DNT1 with internal TEV site, and 6His and V5 tags, 
Gateway entry clone 
G McIlroy, this work, see section 2.2.11 Gateway cloning 
pAct5C-DNT1 Pro-TEV6HisV5-DNT1 CK + CTD Full length DNT1 with internal TEV site, and 6His and V5 tags, 
for S2 cell expression 
G McIlroy, this work, see section 2.2.11 Gateway cloning 
DNT2 protein expression constructs 
pFastBac-DNT2 FL DNT2 full-length with C-terminal TEV site and 6His, for 
Baculovirus expression 
G McIlroy, this work, see section 2.2.12 Enzymatic cloning
pK503-9-DNT2 CK DNT2 CK with N-terminal EGT signal peptide, FLAG tag, 6His 
and Thrombin site, for Baculovirus expression 
G McIlroy, this work, see section 2.2.12 Enzymatic cloning
pDONR-DNT2 Pro-TEV6HisV5-DNT2 CK Full length DNT2 with internal TEV site, and 6His and V5 tags, 
Gateway entry clone 
G McIlroy, this work, see section 2.2.12 Gateway cloning 
pAct5C-DNT2 Pro-TEV6HisV5-DNT2 CK Full length DNT2 with internal TEV site, and 6His and V5 tags, 
for S2 cell expression 
G McIlroy, this work, see section 2.2.12 Gateway cloning 
 
Restriction enzyme sites in bold, Gateway sequences underlined, Cys-Tyr mutated codons in italics 
Number Original Name Sequence Description 
7.1 start-forw       ACCATGGCGGCAATCCTGCT 5' of Toll-7 just before ATG,  Forward 
7.2 1kbup-forw GCAAGATACGCATACGGAGA 1kb upstream of Toll-7 ATG, Forward 
7.3 3kbupforw GAGCCGGCGTCTGATAATAG 3kb upstream of Toll-7 ATG, Forward 
7.4 1kbreverse GGAACAGTCCTTTGGGAAGC 1kb downstream of Toll-7 ATG, Reverse 
7.5 3kbreverse CCAGTGCAGCACTGCCAGT 3kb downstream of Toll-7 ATG, Reverse 
7.6 1.6kbreverse TCCCCGCTCTATGCTCTGGAT 1.6kb downstream of Toll-7 ATG, Reverse 
7.7 2.1kbreverse TTACCACCCAGGTAAAATTCT 2.1kb downstream of Toll-6 ATG, Reverse 
7.8 Tl7attB1FwdTag GGGGACAAGTTTGTACAAAAAAGCAGGCT 
TCATGGCGGCAATCCTGCTGC 
5' of Toll-7 just before ATG,  with attB1 site, Forward 
7.9 Tl7attB2RevTag GGGGACCACTTTGTACAAGAAAGCTGGGT 
CCACCAGATACGCCTGAACAT 
End of Toll-7 coding region, with attB2 site, Reverse 
7.10 Tl7 SP-MluI Rev TCACGCGTTAACATGGCGCTGGCACTCGA End of Toll-7 Signal Peptide, with MluI site, Reverse 
7.11 Tl7MluII-TM+ICFwd TAACGCGTGAATCGTATATTCCCTTGCTG Start of Toll-7 TM and Intracelluar domain, with MluI site, Forward 
7.12 Tl7 C-Y Rev CTGCCAGTTCCCGAACTTGCGGCCATGTA 
GTAGATATCCTGGGCATCCTG 
Mutated Cys to Tyr, Reverse 
7.13 Tl7 C-Y Fwd TTGTCCAGGATGCCCAGGATATCTACTAC 
ATGGCCGCAAGTTCGGGAACT 
Mutated Cys to Tyr, Forward 
7.14 BamHITl7UpCRev ATCGATGGATCCGGTTTTGGGTGTTGTGC 
TTGGGGGGCCA 
Start of Toll-7, with BamHI site, Reverse 
7.15 NotITl7Up5Fwd ATATATGCGGCCGCAAGCTTGTGCTGATT 
TTTCGAAACTT 
5kb upstream of Toll-7, with NotI site,  Forward 
7.16 Toll7 0.4kbFwd TGCGTCTCATTGAGCGACAGC For sequencing of plasmids, 0.4kb into Toll-7, Forward 
7.17 Toll7 0.8kbFwd ATTCGCACTGCCGAGCAGATG For sequencing of plasmids, 0.8kb into Toll-7, Forward 
7.18 Toll7 1.2kbFwd ACTTCCAACCACGTGGATAAC For sequencing of plasmids, 1.2kb into Toll-7, Forward 
7.19 Toll7 1.6kbFwd CATGTTGCGCACTCTTGACCT For sequencing of plasmids, 1.6kb into Toll-7, Forward 
7.20 Toll7 2.0kbFwd TAAGCTTCAGGAGGAGATTCG For sequencing of plasmids, 2.0kb into Toll-7, Forward 
7.21 Toll7 2.4kbFwd TGGTGCTGCAGTGCGTCCTTT For sequencing of plasmids, 2.4kb into Toll-7, Forward 
7.22 Toll7 2.8kbFwd AATTGCGCACCCTTCATGGCT For sequencing of plasmids, 2.8kb into Toll-7, Forward 
7.23 Toll7 3.2kbFwd GACTTTAACGCCACAGGTGCT For sequencing of plasmids, 3.2kb into Toll-7, Forward 
7.24 Toll7 3.4kbFwd GAGAAGCTCTACGATGCCGTG For sequencing of plasmids, 3.4kb into Toll-7, Forward 
7.25 Toll7 3.8kbFwd AAATTGCGCTACGCACTGCCC For sequencing of plasmids, 3.8kb into Toll-7, Forward 
Restriction enzyme sites in bold, Gateway sequences underlined, Cys-Tyr mutated codons in italics 
Number Original Name Sequence Description 
6.1 UpReg5kb-For GTAAACACTTGCGGATGCTCA 5kb upstream of Toll-6 ATG, Forward 
6.2 UpReg2kb-For CCTTCTTGGTTGCATGTGCCA 2kb upstream of Toll-6 ATG, Forward 
6.3 UpReg1kb-For GATACCAGGACTACTTTAGGT 1kb upstream of Toll-6 ATG, Forward 
6.4 Start Fwd CGCAAACCCATTTTCCGGTG 5' of Toll-6 just before ATG,  Forward 
6.5 Mid-Rev GGAACTGGGTCCAATGCGCT 2kb downstream of Toll-6 ATG, Reverse 
6.6 Mid-Fwd GGATCTGGGCGAGAACATGA 2kb downstream of Toll-6 ATG, Forward 
6.7 End-Rev CACTGGTTGCGCAGTTTGTC End of Toll-6 coding region, Reverse 
6.8 Mid-Rev2 GGAGCTCAGGTTCAGGATCT 1.9kb downstream of Toll-6 ATG, Reverse 
6.9 UpReg1.5kb-For GGAGGCGTTCTGTTGGCTGA 1.5kb upstream of Toll-6 ATG, Forward 
6.10 UpReg3.5kb-For GCTGTCAGCTACACCATGCT 3.5kb upstream of Toll-6 ATG, Forward 
6.11 Tl6attB1FwdTag GGGGACAAGTTTGTACAAAAAAGCAGGCT 
TCATGATCTACTATATGCTAC 
5' of Toll-6 just before ATG,  with attB1 site, Forward 
6.12 Tl6attB2RevTag GGGGACCACTTTGTACAAGAAAGCTGGGT 
CCGCCCACAGGTTCTTCTGCT 
End of Toll-6 coding region, with attB2 site, Reverse 
6.13 Tl6SP-MluIRev ATACGCGTGTGGTGCTTGGTGGACAGCGA End of Toll-6 Signal Peptide,  with MluI site, Reverse 
6.14 Tl6MluI-TM+ICFwd ACACGCGTATCGAGGGACTGCTGCCCCTG Start of Toll-6 TM and Intracelluar domain,  with MluI site, Forward 
6.15 Toll6 C-Y Rev AGAACACTCGTAGCATTGTTGTAGATGTAG 
CTCACCCTGGAGGCATCTAT 
Mutated Cys to Tyr, Reverse 
6.16 Toll6 C-Y Fwd AGATCATAGATGCCTCCAGGGTGAGCTACA 
TCTACAACAATGCTACGAGT 
Mutated Cys to Tyr, Forward 
6.17 Toll6 0.4kbFwd CTGGATCAGCCGGAAATAGCC For sequencing of plasmids, 0.4kb into Toll-6, Forward 
6.18 Toll6 0.8kbFwd TGCACCCTGTCCGAGTTGTCT For sequencing of plasmids, 0.8kb into Toll-6, Forward 
6.19 Toll6 1.2kbFwd GAGGTGTACCTGCAGAATAAT For sequencing of plasmids, 1.2kb into Toll-6, Forward 
6.20 Toll6 1.6kbFwd ATCCGGATGCCTTCCGGAACT For sequencing of plasmids, 1.6kb into Toll-6, Forward 
6.21 Toll6 2.0kbFwd CCGATAATCGTTTGGAATCCT For sequencing of plasmids, 2.0kb into Toll-6, Forward 
6.22 Toll6 2.4kbFwd TTGGCTGCAGAAGATTAACCA For sequencing of plasmids, 2.4kb into Toll-6, Forward 
6.23 Toll6 2.8kbFwd TATGCGAACAACTCGAACGTG For sequencing of plasmids, 2.8kb into Toll-6, Forward 
6.24 Toll6 3.2kbFwd TCTACAACAATGCTACGAGTG For sequencing of plasmids, 3.2kb into Toll-6, Forward 
6.25 Toll6 3.4kbFwd TCCACCAACTGTCTAATGAAC For sequencing of plasmids, 3.4kb into Toll-6, Forward 
6.26 Toll6 3.8kbFwd ATCTGCGTACCAGCACCTGCA For sequencing of plasmids, 3.8kb into Toll-6, Forward 
6.27 Toll6 4.2kbFwd GGAGCATCAGCACCACCACAA For sequencing of plasmids, 4.2kb into Toll-6, Forward 
Restriction enzyme sites in bold, Gateway sequences underlined, 6His tags in blue, V5 tags in green, TEV and Thrombin protease sequences in red 
Number Original name Sequence Description 
1.1 White-Start-For       TCAAATACCCTTGGATCGAAGT Start of Mini-White gene, in DNT locus, Forward 
1.2 cDNAEnd-2_Rev         TTGCTAGAACTCTCGTGACA 30bp upstream of 3' UTR End of DNT1, Reverse 
1.3 SphIHTbDNT1CKFwd ACTACTGCATGCTCACCATCACCATCACCATCTGGTTCC 
GCGTGGATCTAAAAAGAGGCGTGAAGACGAAGGCAGC 
SphI-6His-Thrombin, start of DNT1 Cys knot, Forward 
1.4 HindIII DNT1 CK Rev GCCCAAGCTTTTAGCGATAACCATCCACTTGGCAGGAG End of DNT1 Cys knot, with HindIII site, Reverse 
1.5 HindIII DNT1 End Rev GCCCAAGCTTTTACTGGATAGACTGCCGGCGGTTGTGG End of DNT1 CTD, with HindIII site, Reverse 
1.6 SpeI DNT1 St Fwd GTACGTACTAGTATGAAAGCTGGCCGCGCCTTC Start of DNT1, with SpeI site Forward 
1.7 XhoI HT DNT1CK R AATTGGCTCGAGTTAATGATGATGATGATGATGGCCCTG 
AAAATACAGGTTTTCGCGATAACCATCCACTTGGCA 
XhoI-6His-TEV, at end of DNT1 Cys knot, Reverse 
1.8 SpzPro EcoRI St F GCATACTCGAATTCATGATGACGCCCATGTGGATA Start of Spz, with EcoRI site, Forward 
1.9 3His TEV R GCCCTGAAAATACAGGTTTTCGTGATGGTG 3His-TEV, Reverse 
1.10 TEV DNT1CK F GAAAACCTGTATTTTCAGGGCGAAGACGAAGGCAGCGC 
AGGTGGG 
TEV, start of DNT1 Cys knot, Forward 
1.11 DNT1 3’ XhoI End R GCATACTCCTCGAGTCACTGGATAGACTGCCGGCG End of DNT1, with XhoI site, Reverse 
1.12 attB1DNT1StF GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAAAG 
CTGGCCGCGCCT 
Start of DNT1, with attB1 site, Forward 
1.13 V56HTEVDNT1ProR AGGAGAGGGTTAGGGATAGGCTTACCATGGTGATGGTG 
ATGGTGGCCCTGAAAATACAGGTTTTCCCTCTTTTTGCTC 
AGGCTGAAGTCA 
End of DNT1 ProDomain, TEV-6His-V5, Reverse 
1.14 6HV5DNT1CKF AGGGCCACCATCACCATCACCATGGTAAGCCTATCCCTA 
ACCCTCTCCTCGGTCTCGATTCTACGCGTGAAGACGAAG 
GCAGCGCAGGTG 
Start of DNT1 Cys knot, TEV-6His-V5, Forward 
1.15 attB2DNT1EndR GGGGACCACTTTGTACAAGAAAGCTGGGTTCACTGGAT 
AGACTGCCGGCG 
End of DNT1, with attB2 site, Reverse 
1.16 DNT1 0.5kb Fwd GCTGCTTTTGCCCATAGTGTT For sequencing of plasmids, 0.5kb into DNT1, Forward 
1.17 DNT1 0.5 Rev TTGCGGGTAGAGCTCTTTATG For sequencing of plasmids,0.5kb into DNT1, Reverse 
1.18 DNT1 1kb Fwd TAGCCAGGAGGAGGAGAAGAT For sequencing of plasmids, 1kb into DNT1, Forward 
1.19 DNT1 1kb Rev CCTCCACCTCAGAGTATGACT For sequencing of plasmids, 1kb into DNT1, Reverse 
1.20 DNT1 1.5kb Rev TTCGTCTTCACGCCTCTTTTT For sequencing of plasmids, 1.5kb into DNT1, Reverse 
1.21 DNT1 2.1kb Fwd GATGATGACGAAGATCGCTAT For sequencing of plasmids, 2.1kb into DNT1, Forward 
1.22 DNT1 2.1kb Rev TACTTCTTGGAACTGGAACTG For sequencing of plasmids, 2.1 into DNT1, Reverse 
Restriction enzyme sites in bold, Gateway sequences underlined, 6His tags in blue, V5 tags in green, TEV and Thrombin protease sequences in red 
Number Original name Sequence Description 
2.1 White-End-Rev         ATGGTGGGCATAATAGTGTTGT End of Mini-White gene, in e03444 P-element, Reverse 
2.2 Spz5-EcoRI-Start For CGGAATTCATGCAAATCGACGGCGAATGA 5' of DNT2 just before ATG,  with EcoRI site, Forward 
2.3 NotI HT DNT2EndR ACAAATGCGGCCGCTTAATGATGATGATGATGATGGCCC 
TGAAAATACAGGTTTTCATTGGCGGCTATCGTGCAGACA 
NotI-6His-TEV at end of DNT2 Cys knot, Reverse 
2.4 SphIHTbDNT2CKFwd ACTACTGCATGCTCACCATCACCATCACCATCTGGTTCCG 
CGTGGATCTAGGACAAAGCGCCAAAGTCCGGGGCGC 
SphI-6His-Thrombin upstream of DNT2 Cys knot, Forward 
2.5 HindIII DNT2 End Rev GCCCAAGCTTTTAATTGGCGGCTATCGTGCAGACA End of DNT2 Cys knot, with HindIII site, Reverse 
2.6 attB1DNT2StF GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACAAA 
AAGTATTAAAC 
Start of DNT2, with attB1 site, Forward 
2.7 V56HTEVDNT2ProR AGGAGAGGGTTAGGGATAGGCTTACCATGGTGATGGTGATGGTGGCCCTG 
AAAATACAGGTTTTCTTGGCGCTTTGTCCTCGAACGCTTC 
End of DNT2 pro-domain, TEV-6His-V5, Reverse 
2.8 6HV5DNT2CKF AGGGCCACCATCACCATCACCATGGTAAGCCTATCCCTAACCCTCTCCTCGG 
TCTCGATTCTACGAGTCCGGGGCGCTCCACCCTCTGCC 
Start of DNT2 Cys knot, TEV-6His-V5, Forward 
2.9 attB2DNT2CKR GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATTGGCG 
GCTATCGTGCA 
End of DNT2, with attB2 site, Reverse 
2.10 DNT2 0.5kb Fwd TGGAAACCCGCTCTTTGTCAG For sequencing of plasmids, 0.5kb into DNT2, Forward 
2.11 DNT2 0.5kb Rev AGAAGATACGTGGGTGCTTCC For sequencing of plasmids, 0.5kb into DNT2, Reverse 
2.12 DNT2 0.9kb Rev TGATGAACTGCGATGTCGTCT For sequencing of plasmids, 0.9kb into DNT2, Reverse 
Number Original name Sequence Description 
V.1 M13_Forward           GTAAAACGACGGCCAGT M13 sequencing primer, Forward 
V.2 M13_Reverse           GGAAACAGCTATGACCA M13 sequencing primer, Reverse 
V.3 pFstBc B4MCSFwd TTCCGGATTATTCATACCGTC Just before Multi-cloning site of pFastBac1 vector, Forward 
V.4 SV40 Rev GTGTGGGAGGTTTTTTAAAGC Just after Multi-cloning site of various vectors within SV40 polyA, Reverse 
 
Program 1 – For BioTaq 
Temperature Time 
98°C 2 minutes  
98°C 30 seconds 
Tm-4°C 30 seconds 
68°C (1 minute / kb) + 1 minute 
98°C 30 seconds 
Tm-3°C 30 seconds 
68°C (1 minute / kb) 
72°C 15 minutes 
4°C Forever 
Tm is the lowest melting temperature of the primers used 
 
 
 
 
 
 
 
 
 
 
 
 
 
Program 2 – for Phusion 
Temperature Time  
98°C 2 minutes  
98°C 30 seconds 
Tm-3°C 30 seconds 
72°C (30 seconds / kb) 
72°C 15 minutes 
4°C Forever 
x10 
x25 
x35 
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2.2.9 Generation of a constitutively active Toll-7 and Toll-6 constructs 
To over-express constitutively active forms of Toll-7 and Toll-6, I generated constructs 
bearing activated receptors downstream of UAS in transformation vectors, following two 
different strategies. The first strategy followed the example of TollΔLRR: the endogenous signal 
peptide of each receptor was fused to the transmembrane domain, thereby removing the entire 
extracellular domain (Fig 2.10). For both receptors, the signal peptide was amplified from 
genomic DNA, incorporating a 5’ attB1 site and a 3’ MluI site (Toll-7: primers 7.8 and 7.10; 
Toll-6: primers 6.11 and 6.13).  The transmembrane + intracellular domains were separately 
amplified, incorporating a 5’ MluI site and a 3’ attB2 site (Toll-7: primers 7.9 and 7.11; Toll-
6: primers 6.12 and 6.14). Fragments were digested with MluI, and signal peptides were 
ligated to their respective transmembrane + intracellular fragments with T4 ligase. The 
constructs were then cloned into pDONR using Gateway BP Clonase. The correct clones were 
identified with restriction digests. Toll-7ΔLRR was digested with PstI and PvuI, and MluI (Fig 
2.11A); Toll-6ΔLRR was digested with HpaI and MluI (Fig 2.12A). Both clones were 
sequenced: neither the Toll-7ΔLRR nor Toll-6ΔLRR coding regions carried any additional 
mutations, and the sequence confirmed the signal peptide was correctly ligated in frame with 
the transmembrane + intracellular domains (Figs 2.11B and 2.12B). Gateway LR reactions 
between the pDONR-ΔLRR entry clones and the pUAS-gw-HA-attB destination vector were 
carried out to produce pUAS-Toll-7ΔLRR-HA-attB and pUAS-Toll-6ΔLRR-HA-attB, expression 
clones suitable for Drosophila transgenesis using the φC31 system. 
The second strategy taken followed the example of Toll10b: the cysteine that is mutated to 
tyrosine in Toll10b is conserved in Toll-7 and Toll-6, and equivalent amino acid substitutions 
were made (Fig 2.13). In Toll-7, the cysteine at position 993 was mutated to tyrosine, in Toll-6, 
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the cysteine was in position 1020. For both receptors, the signal peptide and extracellular 
domain up to the target cysteine were amplified from genomic DNA. An attB1 site was 
incorporated at the 5’ end, and the 3’ primer encoded the cysteine to tyrosine mutation (Toll-
7: primers 7.8 and 7.12; Toll-6: primers 6.11 and 6.15). Separately, the C-terminal half of the 
receptors were amplified, from the target cysteine until the end. The mutation was encoded in 
the 5’ primer, and an attB2 site was incorporated at the 3’ end (Toll-7: primers 7.9 and 7.13; 
Toll-6: primers 6.12 and 6.16). The two halves of each construct were connected in an 
overlapping PCR (Toll-7: primers 7.8 and 7.9; Toll-6: primers 6.11 and 6.12), and the 
resulting product was cloned into pDONR with BP Gateway cloning. The correct clones were 
identified with restriction digests. Toll-7Cys-Tyr was digested with ApaI and EcoRV (Fig 
2.14A); Toll-6Cys-Tyr was digested with BglII and XhoI (Fig 2.15A). Both clones were 
sequenced. The sequence of Toll-7Cys-Tyr confirmed that the targeted cysteine had been 
mutated to tyrosine (Fig 2.14B, C). Two additional point mutations were found: proline to 
leucine at position 58, and valine to isoleucine at position 251 (Fig 14C). Val251Ile is a 
conservative, hydrophobic mutation falling in the extracellular domain; Pro58Leu is a less 
conservative change, and lies at the N-terminal of the extracellular domain. Also, there was a 
loss of a glutamine residue at the C-terminal end of the protein, reducing a poly-glutamine 
tract from 13 to 12 residues (Fig 2.14C). There are no mutations in the TIR domain, and it is 
not anticipated that the mutations will impede the constitutive activation of Toll-7Cys-Tyr. The 
sequence of Toll-6Cys-Tyr confirmed that the targeted cysteine had been mutated to tyrosine 
(Fig 2.15B, C). In addition, two further point mutations were: threonine to alanine at position 
252, and serine to threonine at position 862 (Fig 2.15C). These are all small amino acid 
residues, serine and threonine are both polar, and the mutations fall in the extracellular 
domain. They do not fall within the signalling TIR domain, so are unlikely to interfere with 
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the constitutive activation of Toll-6Cys-Tyr. Gateway LR reactions between the pDONR-Cys-
Tyr entry clones and the pUAS-gw-FLAG destination vector were carried out to produce 
pUAS-Toll-7Cys-Tyr-FLAG and pUAS-Toll-6Cys-Tyr-FLAG, subsequently used for Drosophila 
transgenesis. 
2.2.10 Generation of clones for recombinant protein expression 
DNT1 and DNT2 constructs were made for protein expression with the Baculovirus system or 
in S2 cells. For Baculovirus, constructs containing an endogenous signal peptide from DNT1 
or DNT2 were cloned into pFastBac1 (Invitrogen), which contains the polyhedron promoter 
for high levels of expression, and Tn7 transposon sequenced for shuttling into the bacmid 
during DH10Bac cell transformation (Luckow et al., 1993). For Cys-knot (CK) versions, 
lacking the endogenous signal peptide, constructs were cloned into pK503-9 (Laukkanen et 
al., 1996). This is a modified pFastBac1, introducing an exogenous signal peptide and FLAG 
tag at the N-terminal of the protein. For expression in S2 cells, coding sequences were cloned 
downstream of an Actin promoter. Constructs contained a 6His tag, for NiNTA-affinity 
purification and identification by western blot; certain constructs contained additional epitope 
tags for identification, and TEV or Thrombin recognition sequences to allow subsequent 
proteolytic cleavage of the pro-domain or tags. The template for PCR of DNT1 fragments was 
cDNA3 (Zhu et al., 2008). The template for PCR of DNT2 fragments was the LD26258 EST, 
a full-length cDNA clone for DNT2 (Berkeley Drosophila Genome Project). 
2.2.11 Generation of DNT1 expression clones 
The DNT1 CK coding sequence was amplified from DNT1 cDNA by PCR. The forward 
primer 1.3 included a 5’ SphI enzyme site, a 6His epitope tag, and a Thrombin protease 
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Fig 2.10 - Cloning of ΔLRR constitutively active receptor constructs
Cloning strategy for ΔLRR constructs. The signal peptide and transmembrane + intracellular
domains were separately amplified by PCR, digested with MluI, and ligated with T4 Ligase.
The resulting construct was cloned into pDONR by a Gateway BP reaction.
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Fig 2.11 - Cloning of Toll-7ΔLRR
A
Toll-7ΔLRR was cloned into pDONR. (A) Restriction digests were used to identify the
correct clone. Enzyme sites are indicated on the map, and the DNA fragments are shown
to the right. Predicted sizes given below each lane. (B, over) The sequenced gene region,
compared to full-length Toll-7. Protein domains are shown, the deletion is indicated in red.
CRC, cysteine-rich clusters lie C-terminal (CT) and N-terminal (NT) to leucine-rich domains.
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3861 bp
Toll-7 TM+IC
Toll-7 SP
 
 
 
 
Tl7_Reference      MAAILLLLLGFSWSLAVESALAPKESESSASAMLGAGTGAAATVSLSGDYSSLLSNVPAA 60 
Tl7_DelLRR         MAAILLLLLGFSWSLAVESALAPKESESSASAML-------------------------- 34 
                   **********************************                           
 
Tl7_Reference      SPVPANPSQPSGPANQCSWSYNGTSSVHCALRLIERQPGLDLQGADGSSQLTIQCSELYL 120 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      FESTLPVAVFARLQTLEALRLDSCKLLQLPNNAFEGLATLKSLRLSTHNSEWGPTRTLEL 180 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      FPDSLGGLKQLTDLDLGDNNLRQLPSGFLCPVGNLQVLNLTRNRIRTAEQMGFADMNCGA 240 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      GSGSAGSELQVLDASHNELRSISESWGISRLRRLQHLNLAYNNLSELSGEALAGLASLRI 300 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      VNLSNNHLETLPEGLFAGSKELREIHLQQNELYELPKGLFHRLEQLLVVDLSGNQLTSNH 360 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      VDNTTFAGLIRLIVLNLAHNALTRIDYRTFKELYFLQILNLRNNSIGHIEDNAFLPLYNL 420 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      HTLNLAENRLHTLDDKLFNGLYVLSKLTLNNNLISVVEPAVFKNCSDLKELDLSSNQLNE 480 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      VPRALQDLAMLRTLDLGENQIRTFDNQSFKNLHQLTGLRLIDNQIGNITVGMFQDLPRLS 540 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      VLNLAKNRIQSIERGSFDKNFELEAIRLDRNFLADINGVFATLVSLLWLNLSENHLVWFD 600 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      YAFIPSNLKWLDIHGNYIEALGNYYKLQEEIRVKTLDASHNRITEIGPMSIPNTIELLFI 660 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      NNNLIGNVQPNAFVDKANLARVDLYANQLSKLQLQQLRVAPVVAPKPLPEFYLGGNPFEC 720 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      DCTMDWLQRINNLTTRQHPRVMDMANIECVMPHARGAAVRPLSGLRPQDFLCRYESHCFA 780 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      LCHCCDFDACDCEMTCPSNCTCYHDQIWSTNVVDCGGQQTTELPRRVPMDSSVVYLDGNN 840 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      FPVLKNHAFIGRKNLRALYVNGSQVAAIQNRTFASLASLQLLHLADNKLRTLHGYEFEQL 900 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      SALRELYLQNNQLTTIENATLAPLAALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLG 960 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Signal Peptide 
CRC-CT
CRC-NT LRR
LRR
Tl7_Reference      RNQWSCRCQFLQALTSYVADNALIVQDAQDIYCMAASSGTGSAALEDSSSNSGSLEKREL 1020 
Tl7_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl7_Reference      DFNATGAACTDYYSGGSMLQHGIPESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 1080 
Tl7_DelLRR         ----------------------TRESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 70 
                                           ************************************ 
 
Tl7_Reference      HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 1140 
Tl7_DelLRR         HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 130 
                   ************************************************************ 
 
Tl7_Reference      THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 1200 
Tl7_DelLRR         THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 190 
                   ************************************************************ 
 
Tl7_Reference      ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 1260 
Tl7_DelLRR         ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 250 
                   ************************************************************ 
 
Tl7_Reference      ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 1320 
Tl7_DelLRR         ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 310 
                   ************************************************************ 
 
Tl7_Reference      QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 1380 
Tl7_DelLRR         QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 370 
                   ************************************************************ 
 
Tl7_Reference      AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQQPNPTAVSGQQQGPH 1440 
Tl7_DelLRR         AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQQPNPTAVSGQQQGPH 430 
                   ************************************************************ 
 
Tl7_Reference      VQAYLV 1446 
Tl7_DelLRR         VQAYLV 436 
                   ****** 
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Fig 2.12 - Cloning of Toll-6ΔLRR
A
Toll-6ΔLRR was cloned into pDONR. (A) Restriction digests were used to identify the
correct clone. Enzyme sites are indicated on the map, and the DNA fragments are shown
to the right. Predicted sizes given below each lane. (B, over) The sequenced gene region,
compared to full-length Toll-6. Protein domains are given, and the deletion is indicated in
red. CRC, cysteine-rich clusters lie C-terminal (CT) and N-terminal (NT) to leucine-rich domains.
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4029 bp
pUC origin
attL1
attL2
Kanamycin
   Resistance
MluI
HpaI
MluI
MluI
HpaI
Toll-6 TM+IC
Toll-6 SP
Tl6_Reference      MIYYMLLILPVVLAQDQQHTTESLSTKHHQQQQLSHSNAIMGEAGVSNSQLMQPSTPART 60 
Tl6_DelLRR         MIYYMLLILPVVLAQDQQHTTESLSTKHH------------------------------- 29 
                   *****************************                                
 
Tl6_Reference      LRPLTAGAGGDPSLYDAPDDCHFMPAAGLDQPEIALTCNLRTVNSEFDTTNFSVIPAEHT 120 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      IALHILCNDEIMAKSRLEAQSFAHLVRLQQLSIQYCKLGRLGRQVLDGLEQLRNLTLRTH 180 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      NILWPALNFEIEADAFSVTRRLERLDLSSNNIWSLPDNIFCTLSELSALNMSENRLQDVN 240 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      ELGFRDRSKEPTNGSTESTSTTESAKKSSSSSTSCSLDLEYLDVSHNDFVVLPANGFGTL 300 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      RRLRVLSVNNNGISMIADKALSGLKNLQILNLSSNKIVALPTELFAEQAKIIQEVYLQNN 360 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      SISVLNPQLFSNLDQLQALDLSMNQITSTWIDKNTFVGLIRLVLLNLSHNKLTKLEPEIF 420 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      SDLYTLQILNLRHNQLENIAADTFAPMNNLHTLLLSHNKLKYLDAYALNGLYVLSLLSLD 480 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      NNALIGVHPDAFRNCSALQDLNLNGNQLKTVPLALRNMRHLRTVDLGENMITVMEDSAFK 540 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      GLGNLYGLRLIGNYLENITMHTFRDLPNLQILNLARNRIAVVEPGAFEMTSSIQAVRLDG 600 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      NELNDINGLFSNMPSLLWLNISDNRLESFDYGHVPSTLQWLDLHKNRLSSLSNRFGLDSE 660 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      LKLQTLDVSFNQLQRIGPSSIPNSIELLFLNDNLITTVDPDTFMHKTNLTRVDLYANQIT 720 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      TLDIKSLRILPVWEHRALPEFYIGGNPFTCDCNIDWLQKINHITSRQYPRIMDLETIYCK 780 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      LLNNRERAYIPLIEAEPKHFLCTYKTHCFAVCHCCEFDACDCEMTCPTNCTCFHDQTWST 840 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      NIVECSGAAYSEMPRRVPMDTSELYIDGNNFVELAGHSFLGRKNLAVLYANNSNVAHIYN 900 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      TTFSGLKRLLILHLEDNHIISLEGNEFHNLENLRELYLQSNKIASIANGSFQMLRKLEVL 960 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
 
Tl6_Reference      RLDGNRLMHFEVWQLSANPYLVEISLADNQWSCECGYLARFRNYLGQSSEKIIDASRVSC 1020 
Tl6_DelLRR         ------------------------------------------------------------ 
                                                                                
Signal Peptide 
CRC-CT
CRC-CT
CRC-NT
LRR
LRR
 
Tl6_Reference      IYNNATSVLREKNGTKCTLRDGVAHYMHTNEIEGLLPLLLVATCAFVAFFGLIFGLFCYR 1080 
Tl6_DelLRR         -----------------------------TRIEGLLPLLLVATCAFVAFFGLIFGLFCYR 58 
                                                  ***************************** 
 
Tl6_Reference      HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 1140 
Tl6_DelLRR         HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 118 
                   ************************************************************ 
 
Tl6_Reference      YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 1200 
Tl6_DelLRR         YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 178 
                   ************************************************************ 
 
Tl6_Reference      RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 1260 
Tl6_DelLRR         RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 238 
                   ************************************************************ 
 
Tl6_Reference      CLSGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 1320 
Tl6_DelLRR         CLSGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 298 
                   ************************************************************ 
 
Tl6_Reference      TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 1380 
Tl6_DelLRR         TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 358 
                   ************************************************************ 
 
Tl6_Reference      SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 1440 
Tl6_DelLRR         SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 418 
                   ************************************************************ 
 
Tl6_Reference      KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 1500 
Tl6_DelLRR         KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 478 
                   ************************************************************ 
 
Tl6_Reference      DEDEDHDQQKNLWA 1514 
Tl6_DelLRR         DEDEDHDQQKNLWA 492 
                   ************** 
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Fig 2.13 - Cloning of Cys-Tyr constitutively active receptor constructs
Cloning strategy for Cys-Tyr constructs. The N- and C-terminal halves of the receptors
were amplified separately, introducing the Cys-Tyr mutation in the primers. The fragments
were joined by overlapping PCR, and cloned into pDONR with a Gateway BP reaction.
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Toll-7          ALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLGRNQWSCRCQFLQALTSYVADNALIV 985 
Toll            NLTHLDISWNHLQMLNATVLGFLNRTMKWRSVKLSGNPWMCDCTAKP-LLLFTQDNFERI 773 
                  
 
Toll-7          QDAQDIYYMAASSGTGSAALEDSSSNSGSLEKRELDFNATGAACTDYYSGGSMLQHGIPE 1045 
Toll            GDRNEMMCVNAEMP--TRMVELSTNDICPAEKG--------------------------V 805 
                                             
 
Toll-7          SYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFAHYGVRVFGPRCE------ESEKLYD 1099 
Toll            FIALAVVIALTGLLAGFTAALYYKFQTEIKIWLYAHNLLLWFVTEED-----LDKDKKFD 860 
                      
Fig 2.14 - Cloning of Toll-7Cys-Tyr
A
B
Toll-7CysTyr was cloned into pDONR. (A) Restriction digests were used to identify the correct
clone. Enzyme sites are indicated on the map, DNA fragments are shown to the right. The
predicted fragment sizes are given below each lane. (B) An alignment of Toll and Toll-7
juxtamembrane regions, showing conservation of cysteine residues. The mutated cysteine is
highlighted in red, others in yellow. The transmembrane domain is underlined. (C, over) The
sequenced gene region, compared to the predicted Toll-7 sequence. Mutated residues
highlighted in red, including the targeted cysteine. Protein domains are given: CRC,
cysteine-rich clusters lie C-terminal (CT) and N-terminal (NT) to leucine-rich domains.
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Tl7_Reference      MAAILLLLLGFSWSLAVESALAPKESESSASAMLGAGTGAAATVSLSGDYSSLLSNVPAA 60 
Tl7_CysTyr         MAAILLLLLGFSWSLAVESALAPKESESSASAMLGAGTGAAATVSLSGDYSSLLSNVLAA 60 
                   ********************************************************* ** 
 
Tl7_Reference      SPVPANPSQPSGPANQCSWSYNGTSSVHCALRLIERQPGLDLQGADGSSQLTIQCSELYL 120 
Tl7_CysTyr         SPVPANPSQPSGPANQCSWSYNGTSSVHCALRLIERQPGLDLQGADGSSQLTIQCSELYL 120 
                   ************************************************************ 
 
Tl7_Reference      FESTLPVAVFARLQTLEALRLDSCKLLQLPNNAFEGLATLKSLRLSTHNSEWGPTRTLEL 180 
Tl7_CysTyr         FESTLPVAVFARLQTLEALRLDSCKLLQLPNNAFEGLATLKSLRLSTHNSEWGPTRTLEL 180 
                   ************************************************************ 
 
Tl7_Reference      FPDSLGGLKQLTDLDLGDNNLRQLPSGFLCPVGNLQVLNLTRNRIRTAEQMGFADMNCGA 240 
Tl7_CysTyr         FPDSLGGLKQLTDLDLGDNNLRQLPSGFLCPVGNLQVLNLTRNRIRTAEQMGFADMNCGA 240 
                   ************************************************************ 
 
Tl7_Reference      GSGSAGSELQVLDASHNELRSISESWGISRLRRLQHLNLAYNNLSELSGEALAGLASLRI 300 
Tl7_CysTyr         GSGSAGSELQLLDASHNELRSISESWGISRLRRLQHLNLAYNNLSELSGEALAGLASLRI 300 
                   **********:************************************************* 
 
Tl7_Reference      VNLSNNHLETLPEGLFAGSKELREIHLQQNELYELPKGLFHRLEQLLVVDLSGNQLTSNH 360 
Tl7_CysTyr         VNLSNNHLETLPEGLFAGSKELREIHLQQNELYELPKGLFHRLEQLLVVDLSGNQLTSNH 360 
                   ************************************************************ 
 
Tl7_Reference      VDNTTFAGLIRLIVLNLAHNALTRIDYRTFKELYFLQILNLRNNSIGHIEDNAFLPLYNL 420 
Tl7_CysTyr         VDNTTFAGLIRLIVLNLAHNALTRIDYRTFKELYFLQILNLRNNSIGHIEDNAFLPLYNL 420 
                   ************************************************************ 
 
Tl7_Reference      HTLNLAENRLHTLDDKLFNGLYVLSKLTLNNNLISVVEPAVFKNCSDLKELDLSSNQLNE 480 
Tl7_CysTyr         HTLNLAENRLHTLDDKLFNGLYVLSKLTLNNNLISVVEPAVFKNCSDLKELDLSSNQLNE 480 
                   ************************************************************ 
 
Tl7_Reference      VPRALQDLAMLRTLDLGENQIRTFDNQSFKNLHQLTGLRLIDNQIGNITVGMFQDLPRLS 540 
Tl7_CysTyr         VPRALQDLAMLRTLDLGENQIRTFDNQSFKNLHQLTGLRLIDNQIGNITVGMFQDLPRLS 540 
                   ************************************************************ 
 
Tl7_Reference      VLNLAKNRIQSIERGSFDKNFELEAIRLDRNFLADINGVFATLVSLLWLNLSENHLVWFD 600 
Tl7_CysTyr         VLNLAKNRIQSIERGSFDKNFELEAIRLDRNFLADINGVFATLVSLLWLNLSENHLVWFD 600 
                   ************************************************************ 
 
Tl7_Reference      YAFIPSNLKWLDIHGNYIEALGNYYKLQEEIRVKTLDASHNRITEIGPMSIPNTIELLFI 660 
Tl7_CysTyr         YAFIPSNLKWLDIHGNYIEALGNYYKLQEEIRVKTLDASHNRITEIGPMSIPNTIELLFI 660 
                   ************************************************************ 
 
Tl7_Reference      NNNLIGNVQPNAFVDKANLARVDLYANQLSKLQLQQLRVAPVVAPKPLPEFYLGGNPFEC 720 
Tl7_CysTyr         NNNLIGNVQPNAFVDKANLARVDLYANQLSKLQLQQLRVAPVVAPKPLPEFYLGGNPFEC 720 
                   ************************************************************ 
 
Tl7_Reference      DCTMDWLQRINNLTTRQHPRVMDMANIECVMPHARGAAVRPLSGLRPQDFLCRYESHCFA 780 
Tl7_CysTyr         DCTMDWLQRINNLTTRQHPRVMDMANIECVMPHARGAAVRPLSGLRPQDFLCRYESHCFA 780 
                   ************************************************************ 
 
Tl7_Reference      LCHCCDFDACDCEMTCPSNCTCYHDQIWSTNVVDCGGQQTTELPRRVPMDSSVVYLDGNN 840 
Tl7_CysTyr         LCHCCDFDACDCEMTCPSNCTCYHDQIWSTNVVDCGGQQTTELPRRVPMDSSVVYLDGNN 840 
                   ************************************************************ 
 
Tl7_Reference      FPVLKNHAFIGRKNLRALYVNGSQVAAIQNRTFASLASLQLLHLADNKLRTLHGYEFEQL 900 
Tl7_CysTyr         FPVLKNHAFIGRKNLRALYVNGSQVAAIQNRTFASLASLQLLHLADNKLRTLHGYEFEQL 900 
                   ************************************************************ 
 
Tl7_Reference      SALRELYLQNNQLTTIENATLAPLAALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLG 960 
Tl7_CysTyr         SALRELYLQNNQLTTIENATLAPLAALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLG 960 
                   ************************************************************ 
 
Signal Peptide 
CRC-CT
CRC-NT LRR
LRR
Tl7_Reference      RNQWSCRCQFLQALTSYVADNALIVQDAQDIYCMAASSGTGSAALEDSSSNSGSLEKREL 1020 
Tl7_CysTyr         RNQWSCRCQFLQALTSYVADNALIVQDAQDIYYMAASSGTGSAALEDSSSNSGSLEKREL 1020 
                   ******************************** *************************** 
 
Tl7_Reference      DFNATGAACTDYYSGGSMLQHGIPESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 1080 
Tl7_CysTyr         DFNATGAACTDYYSGGSMLQHGIPESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 1080 
                   ************************************************************ 
 
Tl7_Reference      HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 1140 
Tl7_CysTyr         HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 1140 
                   ************************************************************ 
 
Tl7_Reference      THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 1200 
Tl7_CysTyr         THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 1200 
                   ************************************************************ 
 
Tl7_Reference      ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 1260 
Tl7_CysTyr         ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 1260 
                   ************************************************************ 
 
Tl7_Reference      ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 1320 
Tl7_CysTyr         ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 1320 
                   ************************************************************ 
 
Tl7_Reference      QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 1380 
Tl7_CysTyr         QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 1380 
                   ************************************************************ 
 
Tl7_Reference      AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQQPNPTAVSGQQQGPH 1440 
Tl7_CysTyr         AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQ-PNPTAVSGQQQGPH 1439 
                   ********************************************* ************** 
 
Tl7_Reference      VQAYLV 1446 
Tl7_CysTyr         VQAYLV 1445 
                   ****** 
 
Transmembrane
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Toll-6CysTyr was cloned into pDONR. (A) Restriction digests were used to identify the correct
clone. Enzyme sites are indicated on the map, DNA fragments are shown to the right. The
predicted fragment sizes are given below each lane. (B) An alignment of Toll and Toll-6
juxtamembrane regions, showing conservation of cysteine residues. The mutated cysteine is
highlighted in red, others in yellow. The transmembrane domain is underlined. (C, over) The
sequenced gene region, compared to the predicted Toll-6 sequence. Mutated residues
highlighted in red, including the targeted cysteine. Protein domains are given: CRC,
cysteine-rich clusters lie C-terminal (CT) and N-terminal (NT) to leucine-rich domains.
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Toll-6          KLEVLRLDGNRLMHFEVWQLSANPY---LVEISLADNQWSCECGYLARFRNYLGQSSEKI 1012 
Toll            NLTHLDISWNHLQMLNATVLGFLNRTMKWRSVKLSGNPWMCDCTAKP-LLLFTQDNFERI 773 
                 
Toll-6          IDASRVSYIYNN---ATSVLREKNGTKCTLRDGVAHY---------------MHTNEIEG 1054 
Toll            GDRNEMMCVNAEMP--TRMVELSTNDICPAEKG--------------------------V 805 
                                      
Toll-6          LLPLLLVATCAFVAFFGLIFGLFCYRHELKIWAHSTNCLMNFCYKSPRFVDQLDKERPND 1114 
Toll            FIALAVVIALTGLLAGFTAALYYKFQTEIKIWLYAHNLLLWFVTEED-----LDKDKKFD 860 
                         
Fig 2.15 - Cloning of Toll-6Cys-Tyr
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Tl6_Reference      MIYYMLLILPVVLAQDQQHTTESLSTKHHQQQQLSHSNAIMGEAGVSNSQLMQPSTPART 60 
Tl6_CysTyr         MIYYMLLILPVVLAQDQQHTTESLSTKHHQQQQLSHSNAIMGEAGVSNSQLMQPSTPART 60 
                   ************************************************************ 
 
Tl6_Reference      LRPLTAGAGGDPSLYDAPDDCHFMPAAGLDQPEIALTCNLRTVNSEFDTTNFSVIPAEHT 120 
Tl6_CysTyr         LRPLTAGAGGDPSLYDAPDDCHFMPAAGLDQPEIALTCNLRTVNSEFDTTNFSVIPAEHT 120 
                   ************************************************************ 
 
Tl6_Reference      IALHILCNDEIMAKSRLEAQSFAHLVRLQQLSIQYCKLGRLGRQVLDGLEQLRNLTLRTH 180 
Tl6_CysTyr         IALHILCNDEIMAKSRLEAQSFAHLVRLQQLSIQYCKLGRLGRQVLDGLEQLRNLTLRTH 180 
                   ************************************************************ 
 
Tl6_Reference      NILWPALNFEIEADAFSVTRRLERLDLSSNNIWSLPDNIFCTLSELSALNMSENRLQDVN 240 
Tl6_CysTyr         NILWPALNFEIEADAFSVTRRLERLDLSSNNIWSLPDNIFCTLSELSALNMSENRLQDVN 240 
                   ************************************************************ 
 
Tl6_Reference      ELGFRDRSKEPTNGSTESTSTTESAKKSSSSSTSCSLDLEYLDVSHNDFVVLPANGFGTL 300 
Tl6_CysTyr         ELGFRDRSKEPANGSTESTSTTESAKKSSSSSTSCSLDLEYLDVSHNDFVVLPANGFGTL 300 
                   ***********:************************************************ 
 
Tl6_Reference      RRLRVLSVNNNGISMIADKALSGLKNLQILNLSSNKIVALPTELFAEQAKIIQEVYLQNN 360 
Tl6_CysTyr         RRLRVLSVNNNGISMIADKALSGLKNLQILNLSSNKIVALPTELFAEQAKIIQEVYLQNN 360 
                   ************************************************************ 
 
Tl6_Reference      SISVLNPQLFSNLDQLQALDLSMNQITSTWIDKNTFVGLIRLVLLNLSHNKLTKLEPEIF 420 
Tl6_CysTyr         SISVLNPQLFSNLDQLQALDLSMNQITSTWIDKNTFVGLIRLVLLNLSHNKLTKLEPEIF 420 
                   ************************************************************ 
 
Tl6_Reference      SDLYTLQILNLRHNQLENIAADTFAPMNNLHTLLLSHNKLKYLDAYALNGLYVLSLLSLD 480 
Tl6_CysTyr         SDLYTLQILNLRHNQLENIAADTFAPMNNLHTLLLSHNKLKYLDAYALNGLYVLSLLSLD 480 
                   ************************************************************ 
 
Tl6_Reference      NNALIGVHPDAFRNCSALQDLNLNGNQLKTVPLALRNMRHLRTVDLGENMITVMEDSAFK 540 
Tl6_CysTyr         NNALIGVHPDAFRNCSALQDLNLNGNQLKTVPLALRNMRHLRTVDLGENMITVMEDSAFK 540 
                   ************************************************************ 
 
Tl6_Reference      GLGNLYGLRLIGNYLENITMHTFRDLPNLQILNLARNRIAVVEPGAFEMTSSIQAVRLDG 600 
Tl6_CysTyr         GLGNLYGLRLIGNYLENITMHTFRDLPNLQILNLARNRIAVVEPGAFEMTSSIQAVRLDG 600 
                   ************************************************************ 
 
Tl6_Reference      NELNDINGLFSNMPSLLWLNISDNRLESFDYGHVPSTLQWLDLHKNRLSSLSNRFGLDSE 660 
Tl6_CysTyr         NELNDINGLFSNMPSLLWLNISDNRLESFDYGHVPSTLQWLDLHKNRLSSLSNRFGLDSE 660 
                   ************************************************************ 
 
Tl6_Reference      LKLQTLDVSFNQLQRIGPSSIPNSIELLFLNDNLITTVDPDTFMHKTNLTRVDLYANQIT 720 
Tl6_CysTyr         LKLQTLDVSFNQLQRIGPSSIPNSIELLFLNDNLITTVDPDTFMHKTNLTRVDLYANQIT 720 
                   ************************************************************ 
 
Tl6_Reference      TLDIKSLRILPVWEHRALPEFYIGGNPFTCDCNIDWLQKINHITSRQYPRIMDLETIYCK 780 
Tl6_CysTyr         TLDIKSLRILPVWEHRALPEFYIGGNPFTCDCNIDWLQKINHITSRQYPRIMDLETIYCK 780 
                   ************************************************************ 
 
Tl6_Reference      LLNNRERAYIPLIEAEPKHFLCTYKTHCFAVCHCCEFDACDCEMTCPTNCTCFHDQTWST 840 
Tl6_CysTyr         LLNNRERAYIPLIEAEPKHFLCTYKTHCFAVCHCCEFDACDCEMTCPTNCTCFHDQTWST 840 
                   ************************************************************ 
 
Tl6_Reference      NIVECSGAAYSEMPRRVPMDTSELYIDGNNFVELAGHSFLGRKNLAVLYANNSNVAHIYN 900 
Tl6_CysTyr         NIVECSGAAYSEMPRRVPMDTTELYIDGNNFVELAGHSFLGRKNLAVLYANNSNVAHIYN 900 
                   *********************:************************************** 
 
Tl6_Reference      TTFSGLKRLLILHLEDNHIISLEGNEFHNLENLRELYLQSNKIASIANGSFQMLRKLEVL 960 
Tl6_CysTyr         TTFSGLKRLLILHLEDNHIISLEGNEFHNLENLRELYLQSNKIASIANGSFQMLRKLEVL 960 
                   ************************************************************ 
 
Signal Peptide
CRC-CT
CRC-NT
LRR
LRR
Tl6_Reference      RLDGNRLMHFEVWQLSANPYLVEISLADNQWSCECGYLARFRNYLGQSSEKIIDASRVSC 1020 
Tl6_CysTyr         RLDGNRLMHFEVWQLSANPYLVEISLADNQWSCECGYLARFRNYLGQSSEKIIDASRVSY 1020 
                   ***********************************************************  
 
Tl6_Reference      IYNNATSVLREKNGTKCTLRDGVAHYMHTNEIEGLLPLLLVATCAFVAFFGLIFGLFCYR 1080 
Tl6_CysTyr         IYNNATSVLREKNGTKCTLRDGVAHYMHTNEIEGLLPLLLVATCAFVAFFGLIFGLFCYR 1080 
                   ************************************************************ 
 
Tl6_Reference      HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 1140 
Tl6_CysTyr         HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 1140 
                   ************************************************************ 
 
Tl6_Reference      YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 1200 
Tl6_CysTyr         YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 1200 
                   ************************************************************ 
 
Tl6_Reference      RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 1260 
Tl6_CysTyr         RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 1260 
                   ************************************************************ 
 
Tl6_Reference      CLSGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 1320 
Tl6_CysTyr         CLSGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 1320 
                   ************************************************************ 
 
Tl6_Reference      TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 1380 
Tl6_CysTyr         TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 1380 
                   ************************************************************ 
 
Tl6_Reference      SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 1440 
Tl6_CysTyr         SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 1440 
                   ************************************************************ 
 
Tl6_Reference      KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 1500 
Tl6_CysTyr         KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 1500 
                   ************************************************************ 
 
Tl6_Reference      DEDEDHDQQKNLWA 1514 
Tl6_CysTyr         DEDEDHDQQKNLWA 1514 
                   ************** 
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recognition sequence. The reverse primer 1.4 included a 3’ HindIII restriction site. The 
amplified fragment and the pK502-9 vector were digested with SphI and HindIII, and they 
were ligated with T4 ligase (Fig 2.16). To identify the correct clone, restriction digests were 
carried out with SphI and HindIII, and ScaI (Fig 2.17A). To confirm the clone, the entire 
coding region was sequenced, which revealed no mutations (Fig 2.17B). 
The DNA sequence encoding the DNT1 CK + C-terminal domain (CTD) was amplified from 
cDNA by PCR. Again, the forward primer 1.3 included a 5’ SphI site, 6His and Thrombin 
sequences, and the reverse primer 1.5 contained the 3’ HindIII site. The pK503-9 vector and 
the PCR product were digested with SphI and HindIII; the insert and vector were ligated 
using T4 Ligase (Fig 2.18). To identify the correct clone, restriction digests were carried out 
with EcoRV, and SphI and HindIII (Fig 2.19A). To confirm the clone, the coding region was 
sent for sequencing, which revealed no mutations (Fig 2.19B). 
DNT1 CK with its endogenous signal peptide and pro-domain, but lacking the CTD, was 
amplified from cDNA by PCR. The forward primer 1.6 contained a 5’ SpeI restriction site; 
the reverse primer 1.7 included the Tobacco etch virus (TEV) protease cleavage sequence, a 
6His tag, and a 3’ XhoI site. The PCR product and pFastBac1 vector were digested with SpeI 
and XhoI, ligated with T4 ligase (Fig 2.20). To identify the correct clone, restriction digests 
were carried out with XbaI and EcoRV, and XhoI and SpeI (Fig 2.21A). To confirm the 
clone, the coding region was sequenced, which revealed no mutations (Fig 2.21B). 
The DNT1 CK+CTD was also cloned downstream of the Spz signal peptide and pro-domain. 
The Spz signal peptide + pro-domain sequences were amplified from pFastBac-SpzSP+Pro-
6HisTEV-SpzCK (a gift from Dr Monique Gangloff, University of Cambridge), by PCR. The 
forward primer 1.8 included a 5’ EcoRI enzyme site; the reverse primer 1.9 contained a His 
53 
 
tag and the TEV cleavage site. The DNT1 CK+CTD sequence was separately amplified by 
PCR from cDNA. The forward primer 1.10 incorporated 6His and Thrombin sequences 
complementary to the Spz pro-domain; the reverse primer 1.11 contained a 3’ XhoI site. The 
two fragments were joined by overlapping PCR. The final fragment and the pFastBac vector 
were digested with EcoRI and XhoI, and were ligated with T4 ligase (Fig 2.22). To identify 
the correct clone, restriction digests were carried out with EcoRV, and BamHI (Fig 2.23A). 
To confirm the clone, the entire coding region was sequenced, which revealed no mutations 
(Fig 2.23B). 
To express DNT1 in S2 cells, the entire DNT1 coding sequence was cloned downstream of an 
actin promoter, incorporating a TEV cleavage sequence, and 6His and V5 tags between the 
pro-domain and the CK. The DNT1 signal peptide and pro-domain were amplified from 
cDNA by PCR. The forward primer 1.12 included a 5’ attB1 gateway cloning sequence; the 
reverse primer 1.13 included the TEV, 6His and V5 sequences. The DNT1 CK + CTD were 
separately amplified from cDNA by PCR. The forward primer 1.14 contained TEV, 6His and 
V5 sequences complementary to the pro-domain reverse primer; the reverse primer 1.15 
contained a 3’ attB2 Gateway cloning sequence. The two fragments were joined by 
overlapping PCR, and the insert was integrated into the pDONR plasmid using Gateway BP 
cloning (Fig 2.24). To identify the correct entry clone, restriction digests were carried out with 
XbaI and NotI, and EcoRV (Fig 2.25A). To confirm the clone, the entire coding region was 
sequenced, which revealed no mutations (Fig 2.25B). The resulting construct (DNT1 Pro-
domain – TEV-6His-V5 – CK+CTD) was then transferred to pActin-gw by Gateway LR 
cloning. 
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Fig 2.16 - Cloning Strategy for DNT1 CK
DNT1 CK was amplified by PCR from a cDNA template, with 6His, Thrombin (Tbn)
and restriction enzyme sequences included in the primers. The insert and the vector
were cut by restriction digest, and the insert was ligated in with T4 Ligase. Triangles
indicate restriction enzyme sites.
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Fig 2.17 - Identification of DNT1 CK clone
A
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
pUC origin
6His
Ampicillin
  Resistance
f1 origin
SV40 polyA
Tn7L
Tn7R
P-PH
Gentamycin
       Resistance
Thrombin
FLAG
EGT SP
ScaI
SphI
HindIII ScaI
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Predicted       MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSKKRREDEGSAGGMCQSVV 60 
Cloned          MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSKKRREDEGSAGGMCQSVV 60 
                ************************************************************ 
 
Predicted       RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 120 
Cloned          RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 120 
                ************************************************************ 
 
Predicted       LSWDKVRGLHVDIFKVPTCCSCQVDGYR 148 
Cloned          LSWDKVRGLHVDIFKVPTCCSCQVDGYR 148 
                **************************** 
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Fig 2.18 - Cloning Strategy for DNT1 CK + CTD
DNT1 CK + CTD was amplified by PCR from a cDNA template, with 6His, Thrombin (Tbn)
and restriction enzyme sequences included in the primers. The insert and the vector
were cut by restriction digest, and the insert was ligated in with T4 Ligase. Triangles
indicate restriction enzyme sites.
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Fig 2.19 - Identification of DNT1 CK + CTD clone
CTD
A
(A) Restriction digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown to the right. Predicted sizes are given below each lane.
(B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
pUC origin
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Tn7L
Tn7R
P-PH
Gentamycin
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Thrombin
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EGT SP
HindIII
EcoRV
SphI
EcoRV
DNT1 CK + CTD
 Predicted       MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSKKRREDEGSAGGMCQSVV 60 
Cloned          MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSKKRREDEGSAGGMCQSVV 60 
                ************************************************************ 
 
Predicted       RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 120 
Cloned          RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 120 
                ************************************************************ 
 
Predicted       LSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVINHSHNGYSTIN 180 
Cloned          LSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVINHSHNGYSTIN 180 
                ************************************************************ 
 
Predicted       EEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVGPYLSPPDDDED 240 
Cloned          EEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVGPYLSPPDDDED 240 
                ************************************************************ 
 
Predicted       RYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPPQHHQHHHLQYH 300 
Cloned          RYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPPQHHQHHHLQYH 300 
                ************************************************************ 
 
Predicted       RPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLPMPPMPIKQVPS 360 
Cloned          RPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLPMPPMPIKQVPS 360 
                ************************************************************ 
 
Predicted       HHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPFRPSAPLSGSGI 420 
Cloned          HHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPFRPSAPLSGSGI 420 
                ************************************************************ 
 
Predicted       SRRHYHNRRQSIQ 433 
Cloned          SRRHYHNRRQSIQ 433 
                ************* 
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Fig 2.20 - Cloning strategy for DNT1 Pro-domain + CK
DNT1 Pro-domain + CK was amplified by PCR from a cDNA template, with 6His, TEV and
restriction enzyme sequences included in the primers. The insert and the vector were
cut by restriction digest, and the insert was ligated in with T4 Ligase. Triangles indicate
restriction enzyme sites.
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Fig 2.21 - Identification of DNT1 Pro-domain + CK clone
(A) Restriction digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown to the right. Predicted sizes are given below each lane.
(B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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Tn7L
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Resistance
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SpeI
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  DNT1 SP +
Pro + CK
Predicted       MKAGRAFGCLFWALLYCVLYLDLVSGNSADDELMDFDFADSNDAAMEDWQLDDLEEAKKA 60 
Cloned          MKAGRAFGCLFWALLYCVLYLDLVSGNSADDELMDFDFADSNDAAMEDWQLDDLEEAKKA 60 
                ************************************************************ 
 
Predicted       EQAEKKLESNMLDFSVDLDEPEPEKQLPPFDWRERVLRNALAKALADEGLRQKFAEVLPI 120 
Cloned          EQAEKKLESNMLDFSVDLDEPEPEKQLPPFDWRERVLRNALAKALADEGLRQKFAEVLPI 120 
                ************************************************************ 
 
Predicted       LRMLSSQQRLALSALISAQMNAKKGHELKFEQVRMMFGNEKKLLLPIVFDIANLIKSSTR 180 
Cloned          LRMLSSQQRLALSALISAQMNAKKGHELKFEQVRMMFGNEKKLLLPIVFDIANLIKSSTR 180 
                ************************************************************ 
 
Predicted       KYINLGSDLASSALYHTPINRREDDLTPEESQQDDQLGTIAVEVEPKKVSTEEVQLESLE 240 
Cloned          KYINLGSDLASSALYHTPINRREDDLTPEESQQDDQLGTIAVEVEPKKVSTEEVQLESLE 240 
                ************************************************************ 
 
Predicted       DFFDEMGSEVLDPQMINEALTGDLHDNKTKTFKPENHGQRVRRSANEFVHKLTRSVPASV 300 
Cloned          DFFDEMGSEVLDPQMINEALTGDLHDNKTKTFKPENHGQRVRRSANEFVHKLTRSVPASV 300 
                ************************************************************ 
 
Predicted       TEQQLLGGIAGRTIKLNTTAFQQPSSQEEEKMASSNGGQSYSEVEDLAFAGLNGTEIPLS 360 
Cloned          TEQQLLGGIAGRTIKLNTTAFQQPSSQEEEKMASSNGGQSYSEVEDLAFAGLNGTEIPLS 360 
                ************************************************************ 
 
Predicted       ADERLDLQRNSAEETEEPLPSPEELIAGPRYRLGKRPLPGQKSGSPIKRKRVTSSLRGRP 420 
Cloned          ADERLDLQRNSAEETEEPLPSPEELIAGPRYRLGKRPLPGQKSGSPIKRKRVTSSLRGRP 420 
                ************************************************************ 
 
Predicted       KTAASSHKPVVTPPNKKCERFTSNMCIRTDDYPLEQIMGSIRRHKNAMSALLAEFYDKPN 480 
Cloned          KTAASSHKPVVTPPNKKCERFTSNMCIRTDDYPLEQIMGSIRRHKNAMSALLAEFYDKPN 480 
                ************************************************************ 
  
Predicted       NNLEFSDDFDDFSLSKKRREDEGSAGGMCQSVVRYARPQKAKSASGEWKYIVNTGQHTQT 540 
Cloned          NNLEFSDDFDDFSLSKKRREDEGSAGGMCQSVVRYARPQKAKSASGEWKYIVNTGQHTQT 540 
                ************************************************************ 
 
Predicted       LRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRLLSWDKVRGLHVDIFKVPTCCSCQVDGY 600 
Cloned          LRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRLLSWDKVRGLHVDIFKVPTCCSCQVDGY 600 
                ************************************************************ 
 
Predicted       RENLYFQGHHHHHH 614 
Cloned          RENLYFQGHHHHHH 614 
                ************** 
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Fig 2.22 - Cloning strategy for Spz Pro-domain - DNT1 CK + CTD
Spz signal peptide + pro-domain was amplified by PCR from cDNA, with restriction
enzyme, 6His and TEV sequences included in the primers. DNT1 CK + CTD was similarly
amplified by PCR. In third PCR reaction, the two fragments were joined and further
amplified. The insert and the vector were cut by restriction digest, and the insert was
ligated in with T4 Ligase. Triangles indicate restriction enzyme sites.
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Fig 2.23 - Identification of Spz Pro - DNT1 CK + CTD clone
A
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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Predicted       MMTPMWISLFKVLLLLFAFFATTSADSAPFMPIPTQHDDPTQKQKQNQNQSPIPETNRHY 60 
Cloned          MMTPMWISLFKVLLLLFAFFATTSADSAPFMPIPTQHDDPTQKQKQNQNQSPIPETNRHY 60 
                ************************************************************ 
 
 
Predicted       HQYHSLIQPDQYFKRTDTEVQSEQPIPPRHPSDTKYRPPQSPARPLRNDTKEHNPCAKDE 120 
Cloned          HQYHSLIQPDQYFKRTDTEVQSEQPIPPRHPSDTKYRPPQSPARPLRNDTKEHNPCAKDE 120 
                ************************************************************ 
 
 
Predicted       SQHLRNFCTNVDDYPDLSGLTHKLKNNFAKFFSNDLQPTDVSSRHHHHHHENLYFQGEDE 180 
Cloned          SQHLRNFCTNVDDYPDLSGLTHKLKNNFAKFFSNDLQPTDVSSRHHHHHHENLYFQGEDE 180 
                ************************************************************ 
 
 
Predicted       GSAGGMCQSVVRYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRS 240 
Cloned          GSAGGMCQSVVRYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRS 240 
                ************************************************************ 
 
 
Predicted       HCSQVYNYHRLLSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVI 300 
Cloned          HCSQVYNYHRLLSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVI 300 
                ************************************************************ 
 
 
Predicted       NHSHNGYSTINEEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVG 360 
Cloned          NHSHNGYSTINEEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVG 360 
                ************************************************************ 
 
 
Predicted       PYLSPPDDDEDRYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPP 420 
Cloned          PYLSPPDDDEDRYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPP 420 
                ************************************************************ 
 
 
Predicted       QHHQHHHLQYHRPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLP 480 
Cloned          QHHQHHHLQYHRPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLP 480 
                ************************************************************ 
 
 
Predicted       MPPMPIKQVPSHHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPF 540 
Cloned          MPPMPIKQVPSHHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPF 540 
                ************************************************************ 
 
 
Predicted       RPSAPLSGSGISRRHYHNRRQSIQ 564 
Cloned          RPSAPLSGSGISRRHYHNRRQSIQ 564 
                ************************ 
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Fig 2.24 - Cloning strategy for DNT1 for S2 cell expression
DNT1 signal peptide + pro-domain was amplified by PCR, as was the CK + CTD region,
from cDNA. TEV cleavage, 6His, V5 and Gateway attB cloning sequences were included
in the primers. The two fragments were joined by PCR, and amplified as a whole. The
complete insert was then cloned into DONR using the Gateway system. Crosses indicate
Gateway cloning sequences.
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Fig 2.25 - Identification of DNT1 clone for expression in S2 cells
A
CTD
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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Predicted       MKAGRAFGCLFWALLYCVLYLDLVSGNSADDELMDFDFADSNDAAMEDWQLDDLEEAKKA 60 
Cloned          MKAGRAFGCLFWALLYCVLYLDLVSGNSADDELMDFDFADSNDAAMEDWQLDDLEEAKKA 60 
                ************************************************************ 
 
Predicted       EQAEKKLESNMLDFSVDLDEPEPEKQLPPFDWRERVLRNALAKALADEGLRQKFAEVLPI 120 
Cloned          EQAEKKLESNMLDFSVDLDEPEPEKQLPPFDWRERVLRNALAKALADEGLRQKFAEVLPI 120 
                ************************************************************ 
 
Predicted       LRMLSSQQRLALSALISAQMNAKKGHELKFEQVRMMFGNEKKLLLPIVFDIANLIKSSTR 180 
Cloned          LRMLSSQQRLALSALISAQMNAKKGHELKFEQVRMMFGNEKKLLLPIVFDIANLIKSSTR 180 
                ************************************************************ 
 
Predicted       KYINLGSDLASSALYHTPINRREDDLTPEESQQDDQLGTIAVEVEPKKVSTEEVQLESLE 240 
Cloned          KYINLGSDLASSALYHTPINRREDDLTPEESQQDDQLGTIAVEVEPKKVSTEEVQLESLE 240 
                ************************************************************ 
 
Predicted       DFFDEMGSEVLDPQMINEALTGDLHDNKTKTFKPENHGQRVRRSANEFVHKLTRSVPASV 300 
Cloned          DFFDEMGSEVLDPQMINEALTGDLHDNKTKTFKPENHGQRVRRSANEFVHKLTRSVPASV 300 
                ************************************************************ 
 
Predicted       TEQQLLGGIAGRTIKLNTTAFQQPSSQEEEKMASSNGGQSYSEVEDLAFAGLNGTEIPLS 360 
Cloned          TEQQLLGGIAGRTIKLNTTAFQQPSSQEEEKMASSNGGQSYSEVEDLAFAGLNGTEIPLS 360 
                ************************************************************ 
 
Predicted       ADERLDLQRNSAEETEEPLPSPEELIAGPRYRLGKRPLPGQKSGSPIKRKRVTSSLRGRP 420 
Cloned          ADERLDLQRNSAEETEEPLPSPEELIAGPRYRLGKRPLPGQKSGSPIKRKRVTSSLRGRP 420 
                ************************************************************ 
 
Predicted       KTAASSHKPVVTPPNKKCERFTSNMCIRTDDYPLEQIMGSIRRHKNAMSALLAEFYDKPN 480 
Cloned          KTAASSHKPVVTPPNKKCERFTSNMCIRTDDYPLEQIMGSIRRHKNAMSALLAEFYDKPN 480 
                ************************************************************ 
 
Predicted       NNLEFSDDFDDFSLSKKRENLYFQGHHHHHHGKPIPNPLLGLDSTREDEGSAGGMCQSVV 540 
Cloned          NNLEFSDDFDDFSLSKKRENLYFQGHHHHHHGKPIPNPLLGLDSTREDEGSAGGMCQSVV 540 
                ************************************************************ 
 
Predicted       RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 600 
Cloned          RYARPQKAKSASGEWKYIVNTGQHTQTLRLEKCSNPVESCSYLAQTYRSHCSQVYNYHRL 600 
                ************************************************************ 
 
Predicted       LSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVINHSHNGYSTIN 660 
Cloned          LSWDKVRGLHVDIFKVPTCCSCQVDGYRQQFPPLSSIQAKDYSPQSPVINHSHNGYSTIN 660 
                ************************************************************ 
 
Predicted       EEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVGPYLSPPDDDED 720 
Cloned          EEDLDYAEESEEDELGLRYPSFNNRETNELYSSSNKVRVKLPGISSSVGPYLSPPDDDED 720 
                ************************************************************ 
 
Predicted       RYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPPQHHQHHHLQYH 780 
Cloned          RYGGYKSSSSSSKKYYSQVSRRRPQHSEARLDLDLAPSETHSDQEPPPPQHHQHHHLQYH 780 
                ************************************************************ 
 
Predicted       RPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLPMPPMPIKQVPS 840 
Cloned          RPQEELPSAYDFHRPQVYQPEREQLPLVRDPALSPVSAPVLASPAPPLPMPPMPIKQVPS 840 
                ************************************************************ 
 
Predicted       HHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPFRPSAPLSGSGI 900 
Cloned          HHQAHHQQPHHHLHQSTGKVAANRDPASMHHQPPRRPTQQWLPGQRRPFRPSAPLSGSGI 900 
                ************************************************************ 
 
Predicted       SRRHYHNRRQSIQ 913 
Cloned          SRRHYHNRRQSIQ 913 
                ************* 
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2.2.12 Generation of DNT2 expression clones 
The DNT2 CK was amplified from cDNA by PCR. The forward primer 2.4 incorporated a 5’ 
SphI site, and sequences for a 6His tag and Thrombin protease cleavage; the reverse primer 
2.5 contained a 3’ HindIII site. The insert and the pK503-9 vector were digested with SphI 
and HindIII, and ligated using T4 Ligase (Fig 2.26). To identify the correct clone, restriction 
digests were carried out with EcoRV and XhoI, and KspI (Fig 2.27A). To confirm the clone, 
the entire coding region was sequence, which revealed no mutations (Fig 2.27B). 
The DNT2 CK, with its endogenous signal peptide and pro-domain, was amplified from 
cDNA by PCR. The forward primer 2.2 contained a 5’ EcoRI restriction site; the reverse 
primer 2.3 included TEV, 6His and a 3’ NotI sequence. The insert and the pFastBac1 vector 
were digested with EcoRI and NotI, and ligated with T4 Ligase (Fig 2.28). To identify the 
correct clone, restriction digests were carried out with KspI, and EcoRI and NotI (Fig 2.29A). 
To confirm the clone, the entire coding region was sequenced, which revealed no mutations 
(Fig 2.29B). 
Finally, full-length DNT2 was cloned for expression in S2 cells, incorporating a TEV 
cleavage site and 6His and V5 epitope tags between the pro-domain and the CK. The DNT2 
signal peptide and pro-domain were amplified from cDNA by PCR. The forward primer 2.6 
contained a 5’ attB1 Gateway cloning sequence; the reverse primer 2.7 included the TEV, 
6His and V5 sequences. The CK was separately amplified with a forward primer 2.8 
containing the TEV, 6His and V5 sequences complementary to the pro-domain reverse 
primer; the reverse primer 2.9 included a 3’ attB2 sequence. The two fragments were joined 
by overlapping PCR, and the insert was incorporated into pDONR by gateway BP cloning 
(Fig 2.30). To identify the correct clone, restriction digests were carried out with XhoI and 
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BamHI, and EcoRV (Fig 2.31A). To confirm the clone, the entire coding region was 
sequenced, which revealed no mutations (Fig 2.31B). The resulting construct (DNT2 Pro-
domain – TEV-6His-V5 – CK) was then transferred to pActin-gw by Gateway LR cloning. 
 
2.3 Cell culture 
2.3.1 S2 cell culture 
Drosophila S2 cells (Invitrogen) were maintained in 25cm2 flasks (BD), in Insect-Xpress 
medium (Lonza) supplemented with 1x penicillin/streptomycin/L-glutamine mix (Lonza) and 
10% foetal calf serum (Lonza) (complete medium). Cells were grown at 27°C in air (CO2 ≈ 
0%). S2 cells stably transfected with a Drosomycin-Luciferase reporter of Dif activation (cell 
line 648-1B6, a gift from Prof Nick Gay, University of Cambridge, via Dr Lynne Prince, 
University of Sheffield) were maintained in complete medium supplemented with the 
selective antibiotic, 1μg/ml puromycin (Invitrogen) (Weber et al., 2003). 
2.3.2 Transfection 
Cells density was measured using a haemocytometer (Sigma), and cells were seeded at 3x106 
per well of a 6-well plate in 2ml complete medium, and left to grow to confluence overnight. 
Cells were transfected with TranIT-2020 (Mirus), according to the manufacturer’s instruction. 
The transfection mix contained 2-3μg of DNA, 250μl serum-free medium (SFM), and 3μl 
transfection reagent for each well. This was incubated in eppendorf tubes at room temperature 
for 30 minutes, after which 350μl SFM was added. Cells were washed with SFM, and the 
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Fig 2.26 - Cloning strategy for DNT2 CK
DNT2 CK was amplified by PCR from a cDNA template, with 6His, Thrombin (Tbn)
and restriction enzyme sequences included in the primers. The insert and the
vector were cut by restriction digest, and the insert was ligated in with T4 Ligase.
Triangles indicate restriction enzyme sites.
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Fig 2.27 - Identification of DNT2 CK clone
A
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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Predicted       MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSRTKRQSPGRSTLCQTTSQ 60 
Cloned          MTILCWLALLSTLTAVNADYKDDDDKRPHAHHHHHHLVPRGSRTKRQSPGRSTLCQTTSQ 60 
                ************************************************************ 
 
Predicted       FITPQAALNSRGNWMFVVNEQNTARQMVKAELCASNTCSNLCELPNGYNSRCEQKFVQKR 120 
Cloned          FITPQAALNSRGNWMFVVNEQNTARQMVKAELCASNTCSNLCELPNGYNSRCEQKFVQKR 120 
                ************************************************************ 
 
Predicted       LIALQGNGQNLYTDTFWFPSCCVCTIAAN 149 
Cloned          LIALQGNGQNLYTDTFWFPSCCVCTIAAN 149 
                ***************************** 
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Fig 2.28 - Cloning strategy for full-length DNT2
Full-length DNT2 was amplified by PCR from a cDNA template, with 6His, TEV and
restriction enzyme sequences included in the primers. The insert and the vector
were cut by restriction digest, and the insert was ligated in with T4 Ligase. Triangles
indicate restriction enzyme sites.
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Fig 2.29 - Identification of full-length DNT2 clone
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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P-PH
Gentamycin
   Resistance
pUC origin
KspI
EcoRI
KspI
NotI
DNT2 FL
Predicted       MTKSIKRPPPFSCKQVLLTYVILAYTVAAHSSPPPCGLYGAPPCQFLPAPPGQTPTCARP 60 
Cloned          MTKSIKRPPPFSCKQVLLTYVILAYTVAAHSSPPPCGLYGAPPCQFLPAPPGQTPTCARP 60 
                ************************************************************ 
 
Predicted       GKTYCEHADNYPTYLIKSLVRKWGYEAATLLVDETWEDFAAVAWHDTPVFYDPKSIFPPR 120 
Cloned          GKTYCEHADNYPTYLIKSLVRKWGYEAATLLVDETWEDFAAVAWHDTPVFYDPKSIFPPR 120 
                ************************************************************ 
 
Predicted       DPAAQDFNGYSYQTPFGGNPQRPSGGGNPLFVSNPSTEAPTYLLYTSSGGGHRSGHRYNS 180 
Cloned          DPAAQDFNGYSYQTPFGGNPQRPSGGGNPLFVSNPSTEAPTYLLYTSSGGGHRSGHRYNS 180 
                ************************************************************ 
 
Predicted       QGGGTSSSGGHLYINQSDKSTPYNATLWLKRLVRDLSRKQRQPDEVQAEVVEPVNEQTEE 240 
Cloned          QGGGTSSSGGHLYINQSDKSTPYNATLWLKRLVRDLSRKQRQPDEVQAEVVEPVNEQTEE 240 
                ************************************************************ 
 
Predicted       AEEQDNPAEDHPQSKRDVSLNMDLLDIVGVEAPNPLKKRSRTKRQSPGRSTLCQTTSQFI 300 
Cloned          AEEQDNPAEDHPQSKRDVSLNMDLLDIVGVEAPNPLKKRSRTKRQSPGRSTLCQTTSQFI 300 
                ************************************************************ 
 
Predicted       TPQAALNSRGNWMFVVNEQNTARQMVKAELCASNTCSNLCELPNGYNSRCEQKFVQKRLI 360 
Cloned          TPQAALNSRGNWMFVVNEQNTARQMVKAELCASNTCSNLCELPNGYNSRCEQKFVQKRLI 360 
                ************************************************************ 
 
Predicted       ALQGNGQNLYTDTFWFPSCCVCTIAANENLYFQGHHHHHH 400 
Cloned          ALQGNGQNLYTDTFWFPSCCVCTIAANENLYFQGHHHHHH 400 
                **************************************** 
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Fig 2.30 - Cloning strategy for DNT2 for S2 cell expression
pDONR - DNT2 Full length
DNT2 signal peptide + pro-domain was amplified by PCR, as was the CK region, from
cDNA. TEV cleavage, 6His, V5 and Gateway attB cloning sequences were included in
the primers. The two fragments were ligated by PCR, and amplified as a whole. The
complete insert was then cloned into DONR using the Gateway system. Crosses indicate
Gateway cloning sequences.
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Fig 2.31 - Identification of DNT2 clone for S2 expression
(A) Restricition digests were used to identify the correct clone. Enzyme sites are shown on
the map, DNA fragments are shown on the right. Predicted sizes are given below each
lane. (B, opposite) The sequenced gene region, compared to predicted sequence. Protein
domains, epitope tags and protease recognition sequences are indicated.
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attL2
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Kanamycin
   Resistance
DNT2 Pro
DNT2 CK
Predicted       MTKSIKRPPPFSCKQVLLTYVILAYTVAAHSSPPPCGLYGAPPCQFLPAPPGQTPTCARP 60 
Cloned          MTKSIKRPPPFSCKQVLLTYVILAYTVAAHSSPPPCGLYGAPPCQFLPAPPGQTPTCARP 60 
                ************************************************************ 
 
Predicted       GKTYCEHADNYPTYLIKSLVRKWGYEAATLLVDETWEDFAAVAWHDTPVFYDPKSIFPPR 120 
Cloned          GKTYCEHADNYPTYLIKSLVRKWGYEAATLLVDETWEDFAAVAWHDTPVFYDPKSIFPPR 120 
                ************************************************************ 
 
Predicted       DPAAQDFNGYSYQTPFGGNPQRPSGGGNPLFVSNPSTEAPTYLLYTSSGGGHRSGHRYNS 180 
Cloned          DPAAQDFNGYSYQTPFGGNPQRPSGGGNPLFVSNPSTEAPTYLLYTSSGGGHRSGHRYNS 180 
                ************************************************************ 
 
Predicted       QGGGTSSSGGHLYINQSDKSTPYNATLWLKRLVRDLSRKQRQPDEVQAEVVEPVNEQTEE 240 
Cloned          QGGGTSSSGGHLYINQSDKSTPYNATLWLKRLVRDLSRKQRQPDEVQAEVVEPVNEQTEE 240 
                ************************************************************ 
 
Predicted       AEEQDNPAEDHPQSKRDVSLNMDLLDIVGVEAPNPLKKRSRTKRQENLYFQGHHHHHHGK 300 
Cloned          AEEQDNPAEDHPQSKRDVSLNMDLLDIVGVEAPNPLKKRSRTKRQENLYFQGHHHHHHGK 300 
                ************************************************************ 
 
Predicted       PIPNPLLGLDSTSPGRSTLCQTTSQFITPQAALNSRGNWMFVVNEQNTARQMVKAELCAS 360 
Cloned          PIPNPLLGLDSTSPGRSTLCQTTSQFITPQAALNSRGNWMFVVNEQNTARQMVKAELCAS 360 
                ************************************************************ 
 
Predicted       NTCSNLCELPNGYNSRCEQKFVQKRLIALQGNGQNLYTDTFWFPSCCVCTIAAN 414 
Cloned          NTCSNLCELPNGYNSRCEQKFVQKRLIALQGNGQNLYTDTFWFPSCCVCTIAAN 414 
                ****************************************************** 
 
TEV 6His V5 
V5 DNT2 CK 
DNT2 SP + Pro 
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600μl transfection mix was gently added. The transfection was incubated at 27°C for 4 hours, 
after which the transfection mix was replaced with complete medium. 
2.3.3 Luciferase reporter assay 
Luciferase reporters were used to test the activation of Drosophila NFκB homologues, Dorsal 
and Dif. To test for Dorsal, a snail-Luciferase reporter construct was transiently transfected 
into S2 cells (a gift from Prof Albert Courey, UCLA) (Ratnaparkhi et al., 2008). Dorsal 
cDNA was also added to cells expressing the snail-Luciferase reporter to augment the signal 
(a gift from A Courey) (Chen et al., 1999, Ratnaparkhi et al., 2008). S2 cells stably 
transfected with Drosomycin-Luciferase were used to assay Dif activation. In all luciferase 
experiments, pAct-Renilla was co-transfected (a gift from Dr Saverio Brogna, University of 
Birmingham). This served as an internal control for cell number and transfection efficiency. 
Cells were transfected and treated according to the experimental conditions (see Chapter 6). 
Because they grew at a lower density than standard S2 cells, Drosomycin-Luciferase cells 
were pelleted from a 2ml culture and re-suspended in 400μl medium immediately before the 
Luciferase assay was performed. To determine the amount of Luciferase reporter present in 
the cells, and therefore the activity of NFκB, the Dual-Glo Luciferase Assay System 
(Promega) was used. 50μl of cell suspension was transferred in triplicate to an opaque 96-well 
plate. 40μl of the supplied Firefly Luciferase Substrate was added, incubated for 10 minutes at 
room temperature, and luminescence was measured using a SPECTRAFluro Plus (Tecan). 
40μl Stop & Glo substrate was then added, which quenched the activity of Firefly Luciferase 
and served as the substrate for the control Renilla Luciferase. The plate was incubated at room 
temperature for 10 minutes before luminescence was measured. The relative Luciferase 
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activity was determined by dividing the Firefly measurement by the Renilla measurement for 
each well. All experiments were repeated at least three times in triplicate. 
2.4 Protein biochemistry 
2.4.1 Protein purification from Baculovirus 
Protein purification from Baculovirus was carried out in collaboration with Dr Jukka Aurikko 
and Prof Nick Gay, Department of Biochemistry, University of Cambridge. Large-scale 
production of DNT protein was produced in insect cells using Baculovirus constructs 
described in Table 2.2, transferred to Bacmid DNA as described in Section 2.2.6. For each 
construct, 1l Sf9 insect cells (Invitrogen) were cultured in Sf900 II serum-free medium 
(Invitrogen), supplemented with 1x Penicillin/Streptomycin mix (Invitrogen) and 0.1% 
Pluronic F-68 (Invitrogen) to reduce shearing forces. Cells were cultured shaking at 120rpm, 
28°C. Once the cells reached a density of 1x106/ml, Baculovirus was added, and the cells 
were cultured further until the protein was ready to be harvested. The multiple of infection 
(MOI) and the length of culture time were according to the optimal conditions determined 
from samples obtained from the Baculovirus Facility, Department of Biochemistry, 
University of Cambridge (see Chapter 6). At the end of the culture period, cells were 
separated from the supernatant by centrifugation at 6000rpm, 4°C, for 15 minutes. The 
supernatant was then filtered to 0.2μm using a Sartobran P Capsule (Sartorius). 
The filtered cell supernatant contained salts that would interfere with Ni-NTA affinity 
purification, so the solution was buffer-exchanged using a Centramate Tangential Flow 
Filtration System (Pall) into a final volume of 400ml PBS, 20mM imidazole (Sigma). The 
His-tagged DNT proteins were purified from the buffer-exchanged solution using 2ml 
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NiNTA-Agarose beads (Qiagen), incubating at room temperature, rolling for 1 hour. The 
beads were collected using the supplied column and washed twice with PBS, 350mM NaCl, 
25mM imidazole. Protein was eluted in 2ml PBS, 500mM imidazole. To remove the 
imidazole, the protein was dialysed overnight at 4°C into PBS with a Spectra/Por MWCO 
3500 (Spectrum) membrane. Protein concentration was measured using the Bradford assay: 
10μl protein solution, 790μl water and 200μl BioRad Protein Assay Reagent were mixed, and 
absorbance at 595nm was recorded using a BioPhotometer (Eppendorf).  
2.4.2 Protein purification from S2 cells 
Small-scale quantities of DNT protein were produced using S2 cells cultured in 6-well plates, 
according to a protocol developed by Dr Chris Arnot and Prof Nick Gay, Department of 
Biochemistry, University of Cambridge. An entire 6-well plate was transfected with the 
relevant pActin-DNT plasmid (Table 2.2), and incubated for 36 hours following the addition 
of complete medium after transfection. The cell supernatant was separated from the cells by 
centrifugation at 5000rpm for 5 mins, was filtered to 0.2μm (Acrodisc, Pall), and was buffer-
exchanged to PBS, 20mM imidazole using a Vivaspin6 5000MWCO Concentrator (Sartorius) 
at 4°C. His-tagged protein was purified from the solution using NiNTA spin columns 
(Qiagen). The columns were equilibrated to PBS, 10mM imidazole, and the protein was 
bound by centrifuging at 1000rpm. The column was washed twice in PBS, 20mM imidazole, 
350mM NaCl, and the DNT protein was eluted into 600μl PBS, 500mM imidazole. Purified 
protein was buffer-exchanged to PBS using a Vivaspin6 5000MWCO concentrator. 
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2.4.3 SDS-PAGE 
Protein samples were prepared by boiling at 100°C for 5 minutes in SDS loading buffer 
(100mM Tris pH 6.8, 4% SDS, 20% glycerol, 1 granule bromophenol blue (Sigma), 5% β-
mercaptoethanol (Sigma), in water), chilling on ice for 2 minutes, then centrifuging for 3 
minutes at 13000rpm. Samples were loaded into a 5% stacking gel (5% acrylamide (29:1) mix 
(National Diagnostics), 125mM Tris pH6.8, 0.1% SDS, 0.1% ammonium persulfate (National 
Diagnostics), 0.1% TEMED (Sigma)). Protein samples were run through a 12% resolving gel 
(12% acrylamide mix, 375mM Tris pH8.8, 0.1% SDS, 0.1% ammonium persulfate, 0.04% 
TEMED). The Prestained Protein Marker, Broad Range (NEB) or the Precision Plus Protein 
Prestained Standards (BioRad) were used as molecular weight markers on protein gels. Gels 
were run on at 100V, until the dye front reached the end of the gel. Gels were made and run 
using the mini-PROTEAN 3 system (BioRad). To identify protein bands, gels were stained 
with SimplyBlue SafeStain (Invitrogen) according to instructions. 
2.4.4 Edman (N-terminal) sequencing 
Edman degeneration was used to determine the N-terminal sequences of proteins. Proteins 
were blotted from unstained protein gels onto PVDF membranes (GE Healthcare) pre-soaked 
in methanol. Blotting took place in an Xcell SureLock Mini-Cell (Invitrogen) at 30V for 1 
hour. The PVDF membrane was briefly stained with 0.1% Coomassie Blue R, 50% methanol 
in water, then destained in 10% acetic acid and 50% methanol. Stained membranes were 
given to the Protein and Nucleic Acid Chemistry (PNAC) facility at the Department of 
Biochemistry, University of Cambridge. The facility then returned the amino acid sequence 
found at the N-terminal of blotted proteins.  
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2.4.5 Western blot 
Proteins were transferred from poly-acrylamide gels onto a nitrocellulose membrane using an 
Xcell SureLock Mini-Cell at 30V for 1 hour. Membranes were then blocked for 1 hour in 
blocking solution (5% non-fat milk powder, 0.05% Tween-20 (Sigma) in PBS) at room 
temperature. Primary antibodies (Table 2.10) were diluted in blocking solution, and incubated 
with the membrane overnight at 4°C. After washing 3x10 minutes in PBS, 0.05% Tween-20, 
HRP-conjugated secondary antibody was diluted in blocking solution and incubated for 2 
hours at room temperature (Table 2.10). Secondary antibody then was washed 3 x 10 minutes 
with PBS + 0.05% Tween-20. Chemiluminescence was detected by mixing equal volumes of 
SuperSignal West Pico (Thermo) Substrate and Enhancer, and adding it to the membrane. 
After 5 minutes, luminescence was detected either using Amersham Hyperfilm ECL (GE 
Healthcare) autoradiography, or with the G:BOX Chemi (Syngene) and GeneSnap software. 
2.4.6 Trypsin proteolysis 
Trypsin proteolysis was done in collaboration with J Aurikko. Trypsin was used to cleave and 
degrade the DNT2 pro-domain, leaving the Cys-knot intact. The concentration of DNT2 was 
determined (see above), and a 1:100 dilution of Trypsin (Promega) was added to the protein 
solution. Proteolysis took place at 37°C for 30 minutes. DNT2 protein was re-purified from 
the proteolysis reaction using NiNTA-agarose (see above).  
2.4.7 Fast Protein Liquid Chromatography (FPLC) 
FPLC was carried out in collaboration with J Aurikko. DNT2 protein was purified using 
FPLC with size exclusion. The sample of DNT2 purified by NiNTA affinity was loaded onto 
a HighLoad 16/60 Superdex 200 column (GE Healthcare) after overnight equilibration with 
Antibody Donor Dilution Use Source Catalogue 
Number 
Primary Antibodies 
anti-GFP Rabbit 1:1000 Immunohistochemistry Invitrogen A11122 
anti-FasII Mouse 1:4 Immunohistochemistry Developmental Studies 
Hybridoma Bank 
1D4 
anti-cleaved 
Caspase-3 
Rabbit 1:50 Immunohistochemistry Cell Signaling #9661 
anti-active 
Caspase-3 
Rabbit 1:250 Immunohistochemistry Abcam Ab13847 
anti-β-Gal Mouse 1:750 Immunohistochemistry Sigma G4644 
anti-His tag Mouse 1:4000 Western Blot BD Pharmingen 552565 
anti-V5 tag Mouse 1:5000 Western Blot Invitrogen 46-0705 
anti-HA tag Mouse 1:100 Immunocytochemistry Roche 12CA5 
anti-Dorsal Mouse 1:100 Immunocytochemistry Developmental Studies 
Hybridoma Bank 
7A4 
anti-DIG 
AP-conjugated 
Sheep 1:1000 In Situ Hybridisation Roche 11093274910 
Secondary Antibodies 
anti-Rabbit-Alexa488 1:250 Immunohistochemistry Invitrogen 
anti-Mouse-Alexa488 1:250 Immunocytochemistry Invitrogen 
anti-Mouse-Alexa546 1:250 Immunohistochemistry Invitrogen 
anti-Mouse-Alexa647 1:250 Immunocytochemistry Invitrogen 
anti-Mouse-Biotin 1:300 Immunohistochemistry Vector Laboratories 
anti-Rabbit-Biotin 1:300 Immunohistochemistry Vector Laboratories 
anti-Mouse-HRP 1:5000 Western Blot Vector Laboratories 
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PBS. Proteins were eluted according to size (largest proteins first) and detected by UV 
absorbance at 280nm using an Äkta FPLC (GE Healthcare), eluting with PBS at a flow rate of 
1ml/min. 1ml fraction samples were analysed by SDS-PAGE and Coomassie staining. 
2.5 Immunohistochemistry and immunocytochemistry 
2.5.1 Fixation 
Drosophila embryos, larval and adult brains, and S2 cells were fixed prior to immunostaining. 
To collect samples from all embryonic stages, embryos were collected on grape juice agar 
plates for 17 hours at 25°C. Embryos were rinsed in water, dechorionated in a 16% sodium 
hypochlorite solution, and washed thoroughly in water. Embryos were fixed in 3ml 4% 
formaldehyde (Sigma) in PBS, plus 3ml Heptane, for 20 minutes at room temperature. The 
formaldehyde was replaced with methanol, and the embryos were devitillinised by gently 
vortexing for 30 seconds. The fixed embryos were washed several times in methanol, and 
stored at -20°C. 
Wandering larvae were collected, and anaesthetised in ice-cold PBS. Adult flies older than 
one day were collected under CO2, briefly rinsed in ethanol, and transferred to ice-cold PBS. 
For 20 minutes, larval and adult brains were dissected in cold PBS and transferred 
immediately to 250μl 4% formaldehyde in PEM (0.1M PIPES, 2mM EGTA, 1mM MgSO4 in 
water). After 20 minutes, the accumulated brains were transferred to a fresh 250μl of 4% 
formaldehyde, and fixed for 50 minutes at room temperature. Samples were rinsed twice in 
PBS, 0.3% Triton-X-100, then washed twice in PBS, 0.3% Triton-X-100 for 10 minutes. 
Samples were blocked for 1 hour in PBS, 0.3% Triton-X-100, 10% Normal Goat Serum 
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(S1000, Vector Labs, containing 0.08% sodium azide). Samples were stored in blocking 
solution at 4°C. 
When used for immunocytochemistry, S2 cells were transfected and cultured on pre-boiled 
glass coverslips (VWR) in a 6-well plate. Before fixing, the culture medium was removed, 
and cells were washed with cold PBS, 0.1% Tween-20 for 5 minutes. Cells were fixed with 
4% formaldehyde in PBS for 15 minutes at room temperature, washed in PBS, and finally 
blocked in PBS, 4% BSA (Sigma). 
2.5.2 Immunolabelling 
For detection of D42- and Toll-7-Gal4-driven GFP, and for FasII, embryos were stained with 
antibodies, and labelling was developed with HRP. Embryos were re-hydrated in PBS + 0.1% 
Triton-X-100 (PBTx) over 1 hour. Primary antibodies were added in PBTx (Table 2.10), and 
incubated overnight at 4°C. Primary antibody was removed, and embryos were washed 6 x 10 
minutes in PBTx. The appropriate biotinylated secondary antibody was added, and incubated 
for 2 hours at room temperature (Table 2.10). Secondary antibody was removed, and the 
embryos were washed 6 x 10 minutes in PBTx. Samples were then incubated for 30 minutes 
with Vecastain ABC reagent (Vector Labs), comprising 5μl Solution A, 5μl Solution B in 
990μl PBS. The ABC reagent was removed, and embryos were washed 6 x 10 minutes in 
PBTx. Embryos were transferred to a 24-well plate, and the PBTx was replaced with 300μl 
Diaminobenzidine (DAB) solution (Sigma, 1 tablet in 1ml PBTx). To develop the staining, 
3μl of a 3% hydrogen peroxide solution was added (Sigma), and the embryos were observed 
for the emergence of the staining pattern. When required, 5μl of an 8% NiCl2 (Sigma) 
solution was added, to result in a black staining. The reaction was stopped with thorough 
washing with PBTx. For double labellings, the process was repeated, allowing the second 
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reaction to develop in the absence of NiCl2 (brown). Stained embryos were incubated 
overnight in 50% glycerol in PBTx at 4°C, transferred to 70% glycerol, and stored at 4°C. 
Embryos were mounted in 70% glycerol. 
For detection of antigens with confocal microscopy, embryos, larval and adult brains, and S2 
cells were fluorescently labelled. Embryos were re-hydrated as above. All samples were 
incubated overnight in the appropriate primary antibody at 4°C (Table 2.10). Primary 
antibody was removed, and samples were washed 6 x 10 minutes in PBTx. Fluorescently-
labelled secondary antibody was added, and from this point onwards, samples were kept in 
the dark. Embryos were incubated in secondary antibody for 2 hours at room temperature, 
larval and adult brains overnight at 4°C (Table 2.10). Secondary antibody was removed, and 
samples were washed 6 x 10 minutes in PBTx. Finally, all PBTx was removed, and samples 
were stored in Vectashield mounting medium (Vector Labs) at 4°C. For staining with anti-
cleaved Caspase-3, embryos were first blocked in 1% BSA in PBTx, and were then stained in 
multiple small aliquots, in 50μl volumes of primary antibody. Samples were then pooled for 
further staining with secondary antibody and second primary antibody if necessary. To ensure 
adequate fixing for Caspase samples, the formaldehyde was relatively new for each batch of 
experiments. 
Coverslips of S2 cells were gently transferred to a sheet of Parafilm and placed in a humid 
chamber. 60μl of primary antibody was added to each coverslip, and the coverslips were 
incubated overnight on a platform rocker at 4°C. The primary antibody was washed from the 
cells by returning the coverslips to the 6-well plate, and adding PBTx 3 x 10 minutes. 
Coverslips were placed back in the humid chamber, and 60μl secondary antibody was added, 
and incubated in the dark, rocking for 2 hours at room temperature. Coverslips were again 
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washed 3 x 10 minutes, gently dried, and mounted onto slides with Vectashield + DAPI 
(Vector Labs). 
2.5.3 In situ hybridisation 
Anti-sense RNA probes were used for in situ hybridisation experiments. The pDONR vector 
includes a T7 RNA polymerase promoter, downstream of the cloning insertion site, therefore 
Toll-7 and Toll-6 entry clones were used as templates to make probes. Since both genes are 
intronless, the entry clones are cDNA (see Chapter 3). 10μg of pDONR entry clone was 
linearised by a restriction enzyme that cut in the 5’ end of the c DNA: pDONR-Toll-7 was 
linearised with HindIII, pDONR-Toll-6 with SmaI, in 50μl water, including 5μl 10x 
restriction buffer and 2μl enzyme. Digestions were carried out overnight at 37°C. DNA was 
recovered with the phenol/chloroform method. 50μl of DNA was added to 50μl phenol 
(Sigma), 49μl chloroform (Fisher) and 1μl iso-amylalcohol (Fisher). The samples were 
vortexed, centrifuged for 5 minutes at 13000rpm, and the aqueous layer was kept. DNA was 
precipitated by adding 5μl 3M sodium acetate and 150μl ethanol, and chilling for 30 minutes 
at -80°C. DNA was pelleted at 13000rpm for 10 minutes, washed in 80% ethanol, and 
dissolved in 20μl water. 
Probes were generated in 20μl transcription reactions, including 1μg template DNA, 2μl DIG 
RNA labelling mix (Roche), 2μl T7 RNA polymerase (USB), 2μl transcription buffer, 1μl 
RNasin (Promega) in water. The reaction was incubated at 37°C for 2 hours. Transcription 
was terminated with 1μl DNAse treatment at room temperature for 15 minutes, and 
inactivated at 65°C for 15 minutes. To purify the RNA probe, 2.5μl 4M LiCl, 0.25μl glycogen 
(Sigma), and 75μl ethanol were added, and RNA was precipitated overnight at -20°C. The 
probe was pelleted at 13000rpm for 15 minutes, washed with ethanol, air dried, and dissolved 
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in 50μl water with 1μl RNasin. Probes were stored at -20°C. Immediately before use, the 
required volume of probe was denatured at 95°C for 10 minutes and then placed in an 
ice/ethanol bath for 10 minutes. 
Embryos, larval CNS and adult brain preps were fixed as above, except that the formaldehyde 
was replaced with a 4% paraformaldehyde (BDH) solution, dissolved in PBS. Embryos were 
gently re-hydrated into PBS, 0.1% Tween-20 (PBTw) over 1 hour, by washing for 15 minutes 
in 70%, 50%, 30% and 0% methanol in PBTw. All samples were further fixed for 30 minutes 
with 4% paraformaldehyde in PBTw, and washed 3 x 5 minutes in PBTw. Samples were 
treated with 125ng/ml Proteinase K in PBTw for 90 seconds at room temperature, and then 
rinsed twice with 0.2% glycine (Fisher) solution. Samples were then washed 2 x 5 minutes 
before being fixed again for 30 minutes with 4% paraformaldehyde, and washed again 5 x 5 
minutes in PBTw. Samples were rinsed with 50% hybridisation buffer (HB: 50% formamide 
(MP Biomedicals), 5x SCC buffer, 0.1% Tween-20, 50μg/ml Heparin (Sigma), and 100μg/ml 
denatured salmon tested DNA (Sigma) in water) in PBTw, and then incubated in HB at 55°C 
for one hour. The probe was titrated at 1:100, 1:40 and 1:20 in HB at 55°C, added to the 
samples, and hybridisation proceeded overnight at 55°C. Samples were washed for 20 
minutes in HB, then 50% HB in PBTw, then 5 x 20 minutes in PBTx, all at 55°C. Alkaline 
phosphatase (AP)-conjugated anti-DIG was pre-absorbed with the same tissue as the in situ 
hybridisation sample at a 1:100 dilution, rocking at room temperature for 1 hour, and added to 
the samples at a final dilution of 1:1000 in PBTw. Samples were incubated for 1 hour at room 
temperature, and then washed 4 x 20 minutes in PBTw. Samples were then washed 3 x 5 
minutes in staining solution (SS: 100mM NaCl, 50mM MgCl, 100mM Tris pH9.5, 0.1% 
Tween-20). Samples were transferred to a 24-well plate, and developed with 500μl SS with 
2.7μl 100mg/ml NBT and 2.1μl 50mg/ml BCIP. Once the samples were suitably developed, 
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they were washed thoroughly with PBTw, cleared overnight in 50% glycerol in PBTw at 4°C, 
and then stored in 70% glycerol at 4°C. Samples were mounted and imaged soon after 
developing. 
2.6 Microscopy and imaging 
Embryos, and larval and adult CNS samples stained with HRP or AP were mounted whole 
onto glass slides (VWR). Samples were examined using an Axioplan 2 light microscope 
(Zeiss) with a 20x lens and a 40x (oil) DIC lens, using Nomarski optics. Dissected embryo 
samples were also examined with a 63x (oil) DIC lens. Images were taken using a JVC 3CCD 
camera and Image Grabber software (NeoTech). All images were processed with Photoshop 
software (Adobe), and figures were compiled with Illustrator (Adobe). 
Fluorescent images of larval and adult brains stained with anti-GFP were acquired using a 
Leica SP2 AOBS laser scanning confocal microscope using a 20x (oil) lens. Images of fixed 
and fluorescently labelled S2 cells were taken using the 63x (oil) lens on the Leica SP2, at 
200Hz and 1024x1024 pixel resolution. Fluorescent images were processed in ImageJ 
software (NIH). 
For apoptosis experiments, embryos stained with anti-cleaved Caspase-3 were scanned using 
a Radiance 2000 confocal microscope (BioRad). Embryos were oriented so that the ventral 
nerve cord was closest to the lens, and was horizontal in the centre of the field of view. A 60x 
(oil) lens was used, with 1.6x zoom, 166lps scanning speed and 512x512 pixel resolution. A 
0.25μm z-axis step was used to produce cubic voxels (0.25μm3). Gain was maintained at 52.5, 
offset -0.4 and iris 1.5. The laser power was minimally adjusted to ensure consistency 
between samples. 
67 
 
2.7 Phenotypic analysis 
2.7.1 Adult locomotion 
Locomotion phenotypes in adult flies were assessed using the assay developed by Dr Ben 
Sutcliffe, Dr Manual Forero and Dr Alicia Hidalgo in our Lab (Sutcliffe, 2010). All films 
were recorded at the same time of day (before 11am). Adult, male, 5-day old flies were 
collected under CO2 anaesthesia, their wings were cut with micro scissors, and they were 
allowed to recover for at least 30 minutes. A petri dish (26mm high, 46mm diameter) was 
placed on a LP812 light box (Jessops), and a Moticam 2000 (Motic) with a 16mm lens was 
held 95 mm over the light box and dish. Video was captured with Motic MC Camera 1.1 and 
Motic Images Plus 2.0 ML software. Flies typically climbed onto the rim of the dish, and 
walked round and round, and were filmed for 1 minute. Using VirtualDub software 
(www.virtualdub.org), the first 400 frames were decompressed and saved in AVI format. 
Frames where the fly had left the arena were discarded. These films were converted to a stack 
of 400 greyscale TIFF images using ImageJ. The converted films were then processed with 
the FlyTracker plug-in for ImageJ, developed by M Forero, a modification of the Mtrack2 
plug-in from Dr Nico Stuurman, UCSF. Running the program produces a plotted trajectory of 
the fly’s path, a stack of 400 images with the fly’s coordinates given for each frame, and a 
spread sheet giving the fly’s speed and distance travelled between frames. By inserting 
additional formulae, the direct (averaged) distance was determined, as well as the proportion 
of time the fly was at rest and the speed at which it travelled when moving (Sutcliffe, 2010). 
A fly was determined to be at rest if it travelled more slowly than 1.5mm/second in any frame.  
68 
 
2.7.2 Axon guidance 
Fixed, late stage 17 embryos were stained with anti-FasciclinII (FasII) and examined by light 
microscopy, to visualise developing motor axons (see above). The ISNb nerve branch was 
examined in the first 5 abdominal segments (A1-A5) on each side of the embryo. Axonal 
projections were scored three times for the existence of any targeting phenotype. Because the 
variability in axon projections was often subtle, and scoring proficiency improved over time, 
the frequencies obtained on the third time of scoring were used. 
2.7.3 Automatic quantification of apoptotic cells 
Stacks of confocal images of anti-Caspase 3-labelled embryos were processed using the 
DeadEasy Caspase plug-in for ImageJ, developed in our lab by Dr Manuel Forero (Forero et 
al., 2009). DeadEasy Caspase produced a parallel stack to the raw data, with identified cells. 
The processed stack was compared to the original images, to ensure that cells had been 
accurately counted, that the background was not producing false positive results, and to 
identify where signal in the epidermis, axons and gut was affecting the cell count. Identified 
cells that were not within the ventral nerve cord were excluded by creating a region of interest 
(ROI) to include only the CNS nerve cord. To remove false positives arising in the epidermis 
and gut, the ventral-most and dorsal-most slices were processed separately, and areas of non-
neuronal signal were manually blacked out before running DeadEasy Caspase. To remove 
false positives arising from axons, the identified ‘cells’ in the processed stack were blacked-
out, using the Fill tool on ImageJ. The remaining cells were re-counted using the DeadEasy 
Background Correction tool, devised by M Forero. Finally, labelled dMP2 cells were 
subtracted, since they are subject to cell-autonomous programmed cell death in stage 17 
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embryos (Miguel-Aliaga and Thor, 2004). These were identified as large paired cells located 
close to the midline, in the dorsal cortex of the ventral nerve cord. 
2.8 Statistical analysis 
Data were collated and analysed using Excel (Microsoft), and statistical tests were carried out 
using PASW Statistics 18 (IBM). The null hypothesis was for all cases that there was no 
difference between experimental samples and controls. Data for lethality, axon targeting, and 
Dorsal localisation were categorical, therefore χ2 tests were performed. Continuous numerical 
data were obtained from apoptosis and luciferase assays, and tested for normality, using the 
shape of the distribution, skewedness and kurtosis. A one-way ANOVA was performed on the 
data, and a Student’s t-test (independent samples, 2 tails) was used for pair-wise comparisons. 
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CHAPTER 3 
TOLL-7 AND TOLL-6 ARE EXPRESSED IN THE 
DROSOPHILA NERVOUS SYSTEM 
 
3.1 Introduction 
In order to characterise the functions of Toll-7 and Toll-6, and to test whether they can serve 
as DNT receptors, it was crucial to investigate first where the genes are expressed. The aims 
of this chapter were to determine the expression patterns of Toll-7 and Toll-6 by in situ 
hybridisation and by driving GFP expression in Toll-7- and Toll-6-expressing cells using the 
Gal4 system. To make RNA probes for in situ hybridisation, it was first necessary to generate 
cDNA clones; to drive GFP expression, suitable Gal4 lines needed to be obtained.  
It has been reported previously that Toll-7 and Toll-6 are the only paralogues (other than Toll) 
with expression in the embryonic nervous system (Kambris et al., 2002). However, whether 
expression persists in the larva and adult is unknown. 
Neurotrophins are target-derived signalling molecules that act on neurons (Bibel and Barde, 
2000). Accordingly, vertebrate neurotrophin expression is found in organs receiving 
innervation, including the heart, epidermis, muscle and liver (Maisonpierre et al., 1990a). 
Vertebrate neurotrophin receptors are primarily expressed in neurons, although they can also 
be detected in non-neuronal tissues, including muscle, the heart and the kidneys, and in a wide 
range of immune cells (Shelton et al., 1995, Vega et al., 2003). 
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DNT1 and DNT2 are expressed in the central nervous system, epidermis and muscle (Zhu et 
al., 2008, Sutcliffe et al., Submitted). For Toll-7 and Toll-6 to function as DNT receptors, they 
should show complementary patterns of expression. 
3.2 Results 
I have taken two approaches to describe the expression of Toll-7 and Toll-6: in situ 
hybridisation of mRNA, and using GFP reporters.  In situ hybridisation labelled the cell 
bodies expressing Toll-7 and Toll-6. To generate the RNA probes, each of the cDNAs was 
cloned. To drive GFP in a Toll-7 pattern, a Toll-7-Gal4 line was made. To drive GFP 
expression in a Toll-6 pattern, I made use of the published D42-Gal4 line, which carries a 
Gal4 enhancer trap 7kb upstream of Toll-6, and has been previously published as a Toll-6 
reporter (Yeh et al., 1995, Sanyal, 2009). 
3.2.1 Generation of Toll-7 cDNA 
The Toll-7 gene is intronless (Fig 3.1A). It was therefore possible to amplify the full-length 
coding sequence directly from the genomic DNA by PCR. Toll-7 coding DNA was amplified 
from the genomic DNA of yw flies, incorporating 5’ attB1 and 3’ attB2 sites for Gateway 
cloning (primers 7.8 and 7.9, Table 2.3, materials and methods). The DNA fragment was 
cloned into pDONR221 using Gateway BP Clonase, and the correct clone was identified by 
restriction digests: digestions by ApaI, and EcoRV (Fig 3.1B). To confirm the clone, the 
entire coding region was sequenced, and compared to the reference sequence obtained from 
FlyBase (FBgn0034476) (Fig 3.1C). The sequence revealed three mutations. The two point 
mutations identified were valine to isoleucine at position 251, and leucine to methionine at 
position 259. These are fairly conservative changes, and lie close together in the extracellular 
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domain of Toll-7. There is also a deletion of a glutamine residue close to the C-terminus of 
the protein. This falls within a short poly-glutamine tract (positions 1414-1426) reducing it 
from 13 to 12 consecutive glutamine residues. The PCR amplification of Toll-7 was carried 
out multiple times, and the observed base pair changes were reasonably reproducible, 
compatible with naturally occurring polymorphisms. An antisense RNA probe was 
transcribed from pDONR-Toll-7 using the 3’ T7 RNA Polymerase promoter sequence found 
in pDONR (see section 2.5.3, materials and methods). The Toll-7 coding sequence was later 
transferred to pAct-gw-HA by LR gateway cloning. This resulted in an expression clone 
suitable for constitutive expression of Toll-7 in cultured cells under the actin promoter, and 
placed an HA tag at the C-terminal. 
3.2.2 Generation of a Toll-7-Gal4 reporter 
Since no Gal4 line was available, to drive expression of GFP in a Toll-7 pattern, it was 
necessary to generate a promoter-Gal4 fusion construct. To do this, the upstream regulatory 
DNA of Toll-7 was cloned into pPTGAL, which contains the Gal4 coding sequence and P-
element sequences for transgenesis (Sharma et al., 2002). Upstream of Toll-7 is 10kb of 
intergenic DNA. Since this is too large for cloning and transgenesis, I amplified the 5kb 
immediately upstream of Toll-7’s start codon (Fig 3.2A). 5kb of intergenic DNA upstream of 
Toll-7 was amplified from yw genomic DNA by PCR, incorporating 5’ NotI and 3’ BamHI 
restriction sites, using primers 7.15 and 7.14 (Table 2.3, materials and methods). After 
restriction digestion, the fragment was ligated into pPTGAL, placing it immediately upstream 
of the Gal4 coding sequence. To identify the correct clone, restriction digests were carried 
out, with NotI and BamHI, and ScaI (Fig 3.2B). I sent the finished plasmid to BestGene Inc 
for transformation into yw flies. On receipt of transformed larvae, I mapped the chromosomal 
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Fig 3.1 - Toll-7 cDNA was cloned into pDONR
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(A) The FlyBase map of the Toll-7 locus indicated that the gene does not contain introns.
(B) Toll-7 was cloned into pDONR, and restriction digests were used to identify the correct
clone. Enzyme sites are indicated on the map, DNA fragments are shown to the right.
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region, compared to the predicted Toll-7 sequence. Mutated residues are highlighted in
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N-terminal (NT) to Leucine-rich repeats (LRR).
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Tl7_Reference      MAAILLLLLGFSWSLAVESALAPKESESSASAMLGAGTGAAATVSLSGDYSSLLSNVPAA 60 
Tl7_Cloned         MAAILLLLLGFSWSLAVESALAPKESESSASAMLGAGTGAAATVSLSGDYSSLLSNVPAA 60 
                   ************************************************************ 
 
Tl7_Reference      SPVPANPSQPSGPANQCSWSYNGTSSVHCALRLIERQPGLDLQGADGSSQLTIQCSELYL 120 
Tl7_Cloned         SPVPANPSQPSGPANQCSWSYNGTSSVHCALRLIERQPGLDLQGADGSSQLTIQCSELYL 120 
                   ************************************************************ 
 
Tl7_Reference      FESTLPVAVFARLQTLEALRLDSCKLLQLPNNAFEGLATLKSLRLSTHNSEWGPTRTLEL 180 
Tl7_Cloned         FESTLPVAVFARLQTLEALRLDSCKLLQLPNNAFEGLATLKSLRLSTHNSEWGPTRTLEL 180 
                   ************************************************************ 
 
Tl7_Reference      FPDSLGGLKQLTDLDLGDNNLRQLPSGFLCPVGNLQVLNLTRNRIRTAEQMGFADMNCGA 240 
Tl7_Cloned         FPDSLGGLKQLTDLDLGDNNLRQLPSGFLCPVGNLQVLNLTRNRIRTAEQMGFADMNCGA 240 
                   ************************************************************ 
 
Tl7_Reference      GSGSAGSELQVLDASHNELRSISESWGISRLRRLQHLNLAYNNLSELSGEALAGLASLRI 300 
Tl7_Cloned         GSGSAGSELQILDASHNEMRSISESWGISRLRRLQHLNLAYNNLSELSGEALAGLASLRI 300 
                   ********** ******* ***************************************** 
 
Tl7_Reference      VNLSNNHLETLPEGLFAGSKELREIHLQQNELYELPKGLFHRLEQLLVVDLSGNQLTSNH 360 
Tl7_Cloned         VNLSNNHLETLPEGLFAGSKELREIHLQQNELYELPKGLFHRLEQLLVVDLSGNQLTSNH 360 
                   ************************************************************ 
 
Tl7_Reference      VDNTTFAGLIRLIVLNLAHNALTRIDYRTFKELYFLQILNLRNNSIGHIEDNAFLPLYNL 420 
Tl7_Cloned         VDNTTFAGLIRLIVLNLAHNALTRIDYRTFKELYFLQILNLRNNSIGHIEDNAFLPLYNL 420 
                   ************************************************************ 
 
Tl7_Reference      HTLNLAENRLHTLDDKLFNGLYVLSKLTLNNNLISVVEPAVFKNCSDLKELDLSSNQLNE 480 
Tl7_Cloned         HTLNLAENRLHTLDDKLFNGLYVLSKLTLNNNLISVVEPAVFKNCSDLKELDLSSNQLNE 480 
                   ************************************************************ 
 
Tl7_Reference      VPRALQDLAMLRTLDLGENQIRTFDNQSFKNLHQLTGLRLIDNQIGNITVGMFQDLPRLS 540 
Tl7_Cloned         VPRALQDLAMLRTLDLGENQIRTFDNQSFKNLHQLTGLRLIDNQIGNITVGMFQDLPRLS 540 
                   ************************************************************ 
 
Tl7_Reference      VLNLAKNRIQSIERGSFDKNFELEAIRLDRNFLADINGVFATLVSLLWLNLSENHLVWFD 600 
Tl7_Cloned         VLNLAKNRIQSIERGSFDKNFELEAIRLDRNFLADINGVFATLVSLLWLNLSENHLVWFD 600 
                   ************************************************************ 
 
Tl7_Reference      YAFIPSNLKWLDIHGNYIEALGNYYKLQEEIRVKTLDASHNRITEIGPMSIPNTIELLFI 660 
Tl7_Cloned         YAFIPSNLKWLDIHGNYIEALGNYYKLQEEIRVKTLDASHNRITEIGPMSIPNTIELLFI 660 
                   ************************************************************ 
 
Tl7_Reference      NNNLIGNVQPNAFVDKANLARVDLYANQLSKLQLQQLRVAPVVAPKPLPEFYLGGNPFEC 720 
Tl7_Cloned         NNNLIGNVQPNAFVDKANLARVDLYANQLSKLQLQQLRVAPVVAPKPLPEFYLGGNPFEC 720 
                   ************************************************************ 
 
Tl7_Reference      DCTMDWLQRINNLTTRQHPRVMDMANIECVMPHARGAAVRPLSGLRPQDFLCRYESHCFA 780 
Tl7_Cloned         DCTMDWLQRINNLTTRQHPRVMDMANIECVMPHARGAAVRPLSGLRPQDFLCRYESHCFA 780 
                   ************************************************************ 
 
Tl7_Reference      LCHCCDFDACDCEMTCPSNCTCYHDQIWSTNVVDCGGQQTTELPRRVPMDSSVVYLDGNN 840 
Tl7_Cloned         LCHCCDFDACDCEMTCPSNCTCYHDQIWSTNVVDCGGQQTTELPRRVPMDSSVVYLDGNN 840 
                   ************************************************************ 
 
Tl7_Reference      FPVLKNHAFIGRKNLRALYVNGSQVAAIQNRTFASLASLQLLHLADNKLRTLHGYEFEQL 900 
Tl7_Cloned         FPVLKNHAFIGRKNLRALYVNGSQVAAIQNRTFASLASLQLLHLADNKLRTLHGYEFEQL 900 
                   ************************************************************ 
 
Tl7_Reference      SALRELYLQNNQLTTIENATLAPLAALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLG 960 
Tl7_Cloned         SALRELYLQNNQLTTIENATLAPLAALELIRIDGNRLVTLPIWQMHATHFGTRLKSISLG 960 
                   ************************************************************ 
 
Signal Peptide 
CRC-CT
CRC-NT LRR
LRR
Tl7_Reference      RNQWSCRCQFLQALTSYVADNALIVQDAQDIYCMAASSGTGSAALEDSSSNSGSLEKREL 1020 
Tl7_Cloned         RNQWSCRCQFLQALTSYVADNALIVQDAQDIYCMAASSGTGSAALEDSSSNSGSLEKREL 1020 
                   ************************************************************ 
 
Tl7_Reference      DFNATGAACTDYYSGGSMLQHGIPESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 1080 
Tl7_Cloned         DFNATGAACTDYYSGGSMLQHGIPESYIPLLAAALALLFLLVVIAMVFAFRESLRIWLFA 1080 
                   ************************************************************ 
 
Tl7_Reference      HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 1140 
Tl7_Cloned         HYGVRVFGPRCEESEKLYDAVLLHSAKDSEFVCQHLAAQLETGRPPLRVCLQHRDLAHDA 1140 
                   ************************************************************ 
 
Tl7_Reference      THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 1200 
Tl7_Cloned         THYQLLEATRVSRRVVILLTRNFLQTEWARCELRRSVHDALRGRPQKLVIIEEPEVAFEA 1200 
                   ************************************************************ 
 
Tl7_Reference      ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 1260 
Tl7_Cloned         ESDIELLPYLKTSAVHRIRRSDRHFWEKLRYALPVDYPTFRGNNYTLELDHHNHERVKQP 1260 
                   ************************************************************ 
 
Tl7_Reference      ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 1320 
Tl7_Cloned         ASPGLLYRQAPPPAYCGPADAVGIGAVPQVVPVNASVPAEQNYSTATTATPSPRPQRRGE 1320 
                   ************************************************************ 
 
Tl7_Reference      QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 1380 
Tl7_Cloned         QPGSGSGGNHHLHAQYYQHHGMRPPSEHIYSSIDSDYSTLDNEQHMLMMPGAPGGLAMEA 1380 
                   ************************************************************ 
 
Tl7_Reference      AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQQPNPTAVSGQQQGPH 1440 
Tl7_Cloned         AQRAQTWRPKREQLHLQQAQAGTLGSKASQAAHQQQQQQQQQQQQ-PNPTAVSGQQQGPH 1439 
                   ********************************************* ************** 
 
Tl7_Reference      VQAYLV 1446 
Tl7_Cloned         VQAYLV 1445 
                   ****** 
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location of the transgene, established a balanced stock, and used the resultant line to drive 
GFP expression (using protocol G, see Fig 2.5 materials and methods). 
3.2.3 Toll-7 expression in the embryonic nervous system 
To identify cells expressing Toll-7 in embryos, in situ hybridisation was carried out. Toll-7 
mRNA was detected in the CNS of stage 13 embryos, in a segmentally repeating pattern (Fig 
3.3A-B). At this stage, there was expression in stripes in the lateral epidermis (Fig 3.3C). In 
dissected stage 13 embryos, Toll-7 was seen in the CNS, and also three bilateral clusters of 
cells in the thoracic region, which are the precursors of the leg imaginal discs (Fig 3.3D-F). 
The expression of Toll-7 at stage 14 was similar to that at stage 13 (Fig 3.3G-K); and CNS 
cells at the midline were also detected (Fig 3.3L). At stage 15, Toll-7 expression was seen in 
the CNS and in lateral epidermal stripes (Fig 3.4A-C). Dissected stage 15 embryos showed a 
CNS pattern of Toll-7 expression, including in midline cells, as well as expression in the 
epidermis and leg imaginal disc precursors (Fig 3.4D-F). By stage 17, Toll-7 expression was 
largely restricted to the CNS (Fig 3.4G-I). In late embryos, Toll-7 mRNA was also detected in 
the denticles (Fig 3.4J). 
I next examined the morphology of cells using the Toll-7-Gal4 line to drive expression of 
GAP-GFP. In stage 13 embryos, clusters of segmentally repeating CNS cell bodies were 
labelled (Fig 3.5A). The labelling of axonal projections identified cells as neurons (Fig 3.5B). 
Midline cells were labelled dorsally to the VNC, and their large projections identified them as 
dorsal median (DM) cells (Fig 3.5C). In stage 14, GFP was expressed in more CNS cell 
bodies, and the longitudinal projections thickened (Fig 3.5D-F). The DM cells were also 
labelled (Fig 3.5G). In stages 15 to 17, increasing numbers of CNS cells were labelled, GFP 
expression increased in the longitudinal fascicles, and DM cells were labelled (Fig 3.6A-F). In 
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stage 15, ISN axons were labelled (Fig 3.6G), and in stage 17, the ISNb motor axons were 
labelled (Fig 3.6H). Outside of the nervous system, GFP labelled the ring gland (Fig 3.6I) and 
the fat body (Fig 3.6J) of stage 17 embryos. 
3.2.4 Toll-7 expression in the larval CNS 
In situ hybridisation was carried out to characterise expression of Toll-7 in the larval CNS. In 
the VNC, expression was most apparent in the thoracic region, particularly in three bilateral 
clusters which could correspond to the motor neurons for the developing legs (Fig Fig 3.7A-
B). Toll-7 was also expressed in the central brain, and there was strong expression in the optic 
lobe in a pattern that included the medulla or lamina, and possibly also the precursor cells of 
the outer proliferation centre (Fig 3.7C-E). In the eye imaginal disc, expression was only 
detected in the morphogenetic furrow (Fig 3.7F). 
Using Toll-7-Gal4 to drive GAP-GFP, cells were labelled both in the central brain and along 
the VNC (Fig 3.8A-B). The entire neuropile of the VNC was labelled, and the labelling of 
individual axons identified the expressing cells as neurons (Fig 3.8C). There was very little 
expression of GFP in the optic lobe, but in the eye imaginal disc, photoreceptors were labelled 
with GFP (Fig 3.8D). 
3.2.5 Toll-7 expression the adult brain 
Expression of Toll-7 in the adult brain was also determined by in situ hybridisation. Toll-7 
mRNA was detected in the medulla of the optic lobe (Fig 3.9A). In the central brain, Toll-7 
was detected in cells surrounding the antennal nerve, antennal lobe and ventrolateral 
protocerebrum (Fig 3.9B), and in cells surrounding the ellipsoid and fan-shaped bodies of the 
central complex (Fig 3.9C-D). 
Stage 13
Stage 14
Fig 3.3 - Toll-7 is expressed in stage 13-14 embrynic CNS
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D E F
G H I
J K L
In situ hybridisation showing the distribution of Toll-7 mRNA. (A-C) Whole mount stage
13 embryo showing Toll-7 expression in the CNS (arrows) and in the lateral epidermis
(arrow heads). (D-F) Dissected stage 13 embryo showing Toll-7 in a segmentally repeating
pattern in the CNS (arrows) and in the primordial leg imaginal discs (white arrows). (G-I)
Whole mount stage 14 embryos with Toll-7 mRNA detected in the CNS (arrows) and lateral
and dorsal epidermis (arrow heads). (J-L) Dissected stage 17 embryo showing expression
in the CNS (arrows) and leg imaginal disc precursors (white arrows). Cells at the midline are
detected (white arrow heads). Ventral midline of dissected samples indicated by red arrow
heads, anterior is left.
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Stage 17
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Fig 3.4 - Toll-7 is expressed in stage 15-17 embryonic CNS
In situ hybridisation showing the distribution of Toll-7 mRNA. (A-C) Whole mount stage
15 embryo showing Toll-7 epxression in the CNS (arrows), and in lateral epidermis stripes
(arrow heads). (D-E) Dissected stage 15 embryo with Toll-7 expressed in the CNS (arrows)
including midline cells (white arrow heads), lateral epidermis (arrow heads), and the leg
imaginal disc primordia (white arrows). (G-H) Whole mount stage 17 embryo showing CNS
expression (arrows). (I-J) Dissected stage 17 embryos showing CNS expression, and mRNA
detected in the denticles (green arrows). Ventral midline on dissected samples indicated
by red arrows heads, anterior is left.
Stage 13
Stage 14
Fig 3.5 - Toll-7 Gal4 > UAS-GAP-GFP labels stage 13-14 embryonic CNS
UAS-GAP-GFP driven by Toll-7-Gal4, anti-GFP labelling with nickel-enhanced HRP.
(A-C) Dissected stage 13 embryo showing expression in clusters of CNS cells with
lonitudinal projections (arrow), and the dorsal median (DM) cells (white arrow heads).
(D-F) Dissected stage 14 embryo with clusters of CNS cells and longitudinal projections
expressing GFP (arrow). (G) GFP labels the DM cells (white arrow head). Ventral
midline indicated with red arrow heads, anterior is left.
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Fig 3.6 - Toll-7 Gal4 > UAS-GAP-GFP labels stage 15-17 embryonic CNS
UAS-GAP-GFP driven by Toll-7 Gal4, anti GFP labelling with HRP, with (A-H) and without
(I-J) nickel enhancment. (A-C) Dissected stage 15, and  (D-F) dissected stage 17 embryos
showing expression in clusters of cells in the CNS, longitudinal fascicles (arrows), and in
the dorsal median (DM) cells (white arrow heads). (G) Dissected stage 15 embryo showing
the labelled projection of the ISN dorsolaterally along the body wall (blue arrow).
(H) Dissected stage 17 embryo showing GFP expression in the ISNb motor axon (blue
arrow head). (I) Dorsal view of whole-mount stage 17 embryo, showing GFP expression
in the ring gland (red arrow). (J) Lateral view of a whole-mount stage 17 embryo, showing
GFP in the fat body (green arrow). Ventral midline indicated with red arrows heads,
anterior is left.
A B C
D E F
G H
I J
Fig 3.7 - Toll-7 is expressed in the larval CNS
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In situ hybridisation showing the distribution of Toll-7 mRNA in the larval CNS. (A, B) Toll-7
is expressed more prominently in the thoracic VNC, including three cluster of cells on each
side (white arrows). (C-E)  Toll-7 is expressed in the optic lobes, including the medulla or
lamina (blue arrow) and and the outer proliferation centre (blue arrow head). (F) Expression
of Toll-7 is limited to the morphogenetic furrow of the eye disc (arrow).
Fig 3.8 - Toll-7 Gal4 > UAS-GAP-GFP labels the larval CNS
A B
C D
UAS-GAP-GFP drriven by Toll-7 Gal4, anti-GFP detected with fluorescence. GFP labels
(A) cell bodies and (B) the neuropiles of the central brain and VNC. (C) Individual
axons/axon bundles are detected (arrows). (D) Expression is seen in the photoreceptors
in the eye imaginal disc (white arrow head).
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Toll-7>GAP-GFP was also used to identify cells in the adult brain. GFP labelled cells of the 
medulla in the adult optic lobe, and they could be seen projecting to the central brain (Fig 
3.10A). Posterior to the medulla, the lobula was also detected (Fig 3.10B). In the central 
brain, there were extensive projections within the ventrolateral protocerebrum, and also the 
superior medial protocerebrum (Fig 3.10C). The fan-shaped body was very strongly labelled 
with GFP (Fig 3.10D). 
3.2.6 Generation of Toll-6 cDNA 
Like Toll-7, the Toll-6 gene is intronless, so it was possible to amplify the coding DNA 
directly from genomic DNA of yw flies by PCR (Fig 3.11A). The full-length coding sequence 
was amplified by PCR incorporating 5’ attB1 and 3’ attB2 sites for Gateway cloning (primers 
6.11 and 6.12, Table 2.4, materials and methods). The fragment was cloned into pDONR221 
using Gateway BP Clonase, and the correct clone was identified by restriction digests: 
digestion by AatII and XhoI, and BglII (Fig 3.11B). To confirm the clone, the entire coding 
region was sequenced, and compared to the reference sequence obtained from FlyBase 
(FBgn0036494) (Fig 3.11C). The sequence revealed two point mutations: threonine  to 
alanine at position 252, and serine to threonine at position 1263. These are conservative 
changes of small amino acids. Thr252Ala falls between LRRs in the extracellular domain, 
Ser1263Thr is intracellular, but lies outside the signalling TIR domain. It is therefore not 
anticipated that these mutations will substantially alter the structure or function of the protein. 
As with Toll-7 the PCR amplification of Toll-6 was carried out multiple times, and the 
observed base pair changes were reasonably reproducible, compatible with naturally 
occurring polymorphisms. An antisense RNA probe was transcribed from pDONR-Toll-6 
using the 3’ T7 RNA Polymerase promoter sequence found in pDONR (see section 2.5.3, 
Fig 3.9 - Toll-7 is expressed in the adult brain
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In situ hybridisation showing the distribution of Toll-7 mRNA. (A) Toll-7 is expressed in
the medulla (M) of the optic lobe. (B) Toll-7 expression is detected in cells surrounding
the antennal nerve (AN), the antennal lobe (AL), and the ventrolateral protocerebrum
(VLP). (C) Signal is seen surrounding the fan shaped body and (D) the ellipsoid body of
the central complex (CC).
Fig 3.10 - Toll-7 Gal4 > UAS-GAP-GFP labels the adult brain.
A B
C
D
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VLP
SMP
UAS-GAP-GFP driven by Toll-7-Gal4, anti-GFP labelling with fluorescence. (A-B) GFP
is expressed in the medulla (M) and lobula (Lo) of the optic lobe, with projections to
the central brain (blue arrow). (C) GFP labels projections in the ventrolateral
protocerebrum (VLP) and the superior medial protocerebrum (SMP). (D) Toll-7 is
expressed in cells of the fan shaped body (FB).
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materials and methods). The Toll-6 coding sequence was later transferred to pAct-gw-HA by 
LR gateway cloning. This resulted in an expression clone suitable for constitutive expression 
of Toll-6 in cultured cells under the actin promoter, and placed an HA tag at the C-terminal. 
3.2.7 Toll-6 expression in the embryonic CNS 
To identify Toll-6-expressing cells in embryos, in situ hybridisation was carried out. Toll-6 
expression was seen in in early embryos in epidermal stripes (Fig 3.12A-B). Toll-6 mRNA 
was detected in stage 13 embryos in segmentally repeating patterns in the developing CNS 
(Fig 3.12C-D), and also in the dorso-lateral epidermis (Fig 3.12E). In stage 14 embryos, the 
expression in the CNS became stronger, and Toll-6 was found at the dorsal margins of the 
epidermis (Fig 3.12F-J). The CNS expression of Toll-6 increased in stage 15 embryos (Fig 
3.12A-B). Expression outside the CNS was restricted to small clusters of cells lying laterally 
to the VNC in each segment, which may be a subset of PNS, epidermis or muscle (Fig 3.13A-
B). In stages 16 and 17, Toll-6 was expressed throughout the CNS, including in paired cells 
close to the midline which could be the dMP2s (Fig 3.13C-F). By Stage 17, expression of 
Toll-6 was restricted to the CNS and the small, segmentally repeating clusters of cells (Fig 
3.13G-H). 
To label the cell membranes of cells that putatively express Toll-6, I used the D42-Gal4 line 
to drive expression of GAP-GFP. In stage 13 embryos, GFP labelled the CNS (Fig 3.14A) and 
also a lateral stripe of cells (Fig 3.14B). In stage 14, cells in the ventral epidermis were also 
labelled (Fig 3.14C-E). In the stage 14 VNC, GFP was expressed in cell bodies and axonal 
projections, identifying cells as neurons (Fig 3.14F-G). In stage 15 embryos, GFP labelled a 
subset of cells in the CNS (Fig 3.15A-B). Neuronal projections along the longitudinal 
connectives and into the periphery were labelled (Fig 3.15C-D). In stage 17 embryos, CNS 
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Tl6_Reference      MIYYMLLILPVVLAQDQQHTTESLSTKHHQQQQLSHSNAIMGEAGVSNSQLMQPSTPART 60 
Tl6_Cloned         MIYYMLLILPVVLAQDQQHTTESLSTKHHQQQQLSHSNAIMGEAGVSNSQLMQPSTPART 60 
                   ************************************************************ 
 
Tl6_Reference      LRPLTAGAGGDPSLYDAPDDCHFMPAAGLDQPEIALTCNLRTVNSEFDTTNFSVIPAEHT 120 
Tl6_Cloned         LRPLTAGAGGDPSLYDAPDDCHFMPAAGLDQPEIALTCNLRTVNSEFDTTNFSVIPAEHT 120 
                   ************************************************************ 
 
Tl6_Reference      IALHILCNDEIMAKSRLEAQSFAHLVRLQQLSIQYCKLGRLGRQVLDGLEQLRNLTLRTH 180 
Tl6_Cloned         IALHILCNDEIMAKSRLEAQSFAHLVRLQQLSIQYCKLGRLGRQVLDGLEQLRNLTLRTH 180 
                   ************************************************************ 
 
Tl6_Reference      NILWPALNFEIEADAFSVTRRLERLDLSSNNIWSLPDNIFCTLSELSALNMSENRLQDVN 240 
Tl6_Cloned         NILWPALNFEIEADAFSVTRRLERLDLSSNNIWSLPDNIFCTLSELSALNMSENRLQDVN 240 
                   ************************************************************ 
 
Tl6_Reference      ELGFRDRSKEPTNGSTESTSTTESAKKSSSSSTSCSLDLEYLDVSHNDFVVLPANGFGTL 300 
Tl6_Cloned         ELGFRDRSKEPANGSTESTSTTESAKKSSSSSTSCSLDLEYLDVSHNDFVVLPANGFGTL 300 
                   *********** ************************************************ 
 
Tl6_Reference      RRLRVLSVNNNGISMIADKALSGLKNLQILNLSSNKIVALPTELFAEQAKIIQEVYLQNN 360 
Tl6_Cloned         RRLRVLSVNNNGISMIADKALSGLKNLQILNLSSNKIVALPTELFAEQAKIIQEVYLQNN 360 
                   ************************************************************ 
 
Tl6_Reference      SISVLNPQLFSNLDQLQALDLSMNQITSTWIDKNTFVGLIRLVLLNLSHNKLTKLEPEIF 420 
Tl6_Cloned         SISVLNPQLFSNLDQLQALDLSMNQITSTWIDKNTFVGLIRLVLLNLSHNKLTKLEPEIF 420 
                   ************************************************************ 
 
Tl6_Reference      SDLYTLQILNLRHNQLENIAADTFAPMNNLHTLLLSHNKLKYLDAYALNGLYVLSLLSLD 480 
Tl6_Cloned         SDLYTLQILNLRHNQLENIAADTFAPMNNLHTLLLSHNKLKYLDAYALNGLYVLSLLSLD 480 
                   ************************************************************ 
 
Tl6_Reference      NNALIGVHPDAFRNCSALQDLNLNGNQLKTVPLALRNMRHLRTVDLGENMITVMEDSAFK 540 
Tl6_Cloned         NNALIGVHPDAFRNCSALQDLNLNGNQLKTVPLALRNMRHLRTVDLGENMITVMEDSAFK 540 
                   ************************************************************ 
 
Tl6_Reference      GLGNLYGLRLIGNYLENITMHTFRDLPNLQILNLARNRIAVVEPGAFEMTSSIQAVRLDG 600 
Tl6_Cloned         GLGNLYGLRLIGNYLENITMHTFRDLPNLQILNLARNRIAVVEPGAFEMTSSIQAVRLDG 600 
                   ************************************************************ 
 
Tl6_Reference      NELNDINGLFSNMPSLLWLNISDNRLESFDYGHVPSTLQWLDLHKNRLSSLSNRFGLDSE 660 
Tl6_Cloned         NELNDINGLFSNMPSLLWLNISDNRLESFDYGHVPSTLQWLDLHKNRLSSLSNRFGLDSE 660 
                   ************************************************************ 
 
Tl6_Reference      LKLQTLDVSFNQLQRIGPSSIPNSIELLFLNDNLITTVDPDTFMHKTNLTRVDLYANQIT 720 
Tl6_Cloned         LKLQTLDVSFNQLQRIGPSSIPNSIELLFLNDNLITTVDPDTFMHKTNLTRVDLYANQIT 720 
                   ************************************************************ 
 
Tl6_Reference      TLDIKSLRILPVWEHRALPEFYIGGNPFTCDCNIDWLQKINHITSRQYPRIMDLETIYCK 780 
Tl6_Cloned         TLDIKSLRILPVWEHRALPEFYIGGNPFTCDCNIDWLQKINHITSRQYPRIMDLETIYCK 780 
                   ************************************************************ 
 
Tl6_Reference      LLNNRERAYIPLIEAEPKHFLCTYKTHCFAVCHCCEFDACDCEMTCPTNCTCFHDQTWST 840 
Tl6_Cloned         LLNNRERAYIPLIEAEPKHFLCTYKTHCFAVCHCCEFDACDCEMTCPTNCTCFHDQTWST 840 
                   ************************************************************ 
 
Tl6_Reference      NIVECSGAAYSEMPRRVPMDTSELYIDGNNFVELAGHSFLGRKNLAVLYANNSNVAHIYN 900 
Tl6_Cloned         NIVECSGAAYSEMPRRVPMDTSELYIDGNNFVELAGHSFLGRKNLAVLYANNSNVAHIYN 900 
                   ************************************************************ 
 
Tl6_Reference      TTFSGLKRLLILHLEDNHIISLEGNEFHNLENLRELYLQSNKIASIANGSFQMLRKLEVL 960 
Tl6_Cloned         TTFSGLKRLLILHLEDNHIISLEGNEFHNLENLRELYLQSNKIASIANGSFQMLRKLEVL 960 
                   ************************************************************ 
 
Signal Peptide 
CRC-CT
CRC-NT
LRR
LRR
Tl6_Reference      RLDGNRLMHFEVWQLSANPYLVEISLADNQWSCECGYLARFRNYLGQSSEKIIDASRVSC 1020 
Tl6_Cloned         RLDGNRLMHFEVWQLSANPYLVEISLADNQWSCECGYLARFRNYLGQSSEKIIDASRVSC 1020 
                   ************************************************************ 
 
Tl6_Reference      IYNNATSVLREKNGTKCTLRDGVAHYMHTNEIEGLLPLLLVATCAFVAFFGLIFGLFCYR 1080 
Tl6_Cloned         IYNNATSVLREKNGTKCTLRDGVAHYMHTNEIEGLLPLLLVATCAFVAFFGLIFGLFCYR 1080 
                   ************************************************************ 
 
Tl6_Reference      HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 1140 
Tl6_Cloned         HELKIWAHSTNCLMNFCYKSPRFVDQLDKERPNDAYFAYSLQDEHFVNQILAQTLENDIG 1140 
                   ************************************************************ 
 
Tl6_Reference      YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 1200 
Tl6_Cloned         YRLCLHYRDVNINAYITDALIEAAESAKQFVLVLSKNFLYNEWSRFEYKSALHELVKRRK 1200 
                   ************************************************************ 
 
Tl6_Reference      RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 1260 
Tl6_Cloned         RVVFILYGDLPQRDIDMDMRHYLRTSTCIEWDDKKFWQKLRLALPLPNGRGNNNKRVVSG 1260 
                   ************************************************************ 
 
Tl6_Reference      CLSGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 1320 
Tl6_Cloned         CLTGRTPSVNMYATSHEYQAGNGGVIPPPSARYADCGSNNYATINECAAAGGGRGYKPIP 1320 
                   ** ********************************************************* 
 
Tl6_Reference      TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 1380 
Tl6_Cloned         TSASAAAAACKFNTMNQLSKKQQRDLSVAGMAKTLEHQHHHNHQANRRSQHEYAVPSYLP 1380 
                   ************************************************************ 
 
Tl6_Reference      SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 1440 
Tl6_Cloned         SAAPAYDSVDYAKQQIRNNANCECVNLGTAKRAAGKNPASGLPSSFSSNFVPPGGASYNC 1440 
                   ************************************************************ 
 
Tl6_Reference      KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 1500 
Tl6_Cloned         KKSCSCIGDDELLCSCGGGGGIGVNLLESGTQSSVTMSSSSNNSRQPELTHYESNLSLND 1500 
                   ************************************************************ 
 
Tl6_Reference      DEDEDHDQQKNLWA 1514 
Tl6_Cloned         DEDEDHDQQKNLWA 1514 
                   ************** 
 
Transmembrane
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expression of GFP increased, as was the labelling of the neuropile (Fig 3.15E-H). Also in 
stage 17, GFP labelled muscles (Fig 3.15E-F). 
3.2.8 Toll-6 expression in the larval CNS 
To determine whether Toll-6 is expressed in the larval CNS, in situ hybridisation was again 
performed. In the VNC, there was expression throughout the cortex ventrally, and also in cells 
lying close to the midline dorsally (Fig 3.16A-B). There were high levels of expression in the 
central brain (Fig 3.16C). In the optic lobes, Toll-6 was expressed in the lamina and possibly 
the lamina precursor cells (Fig 3.16D), and weakly in the medulla (Fig 3.16E). In the eye disc, 
Toll-6 mRNA was strongly detected in the morphogenetic furrow (Fig 3.16F), but there was 
no clear expression in the developing retina. 
GAP-GFP expression was driven by D42-Gal4, to further characterise Toll-6 expressing cells. 
In the ventral nerve cord, GFP labelled large paired cells dorsally (Fig 3.17A), and many 
axons of the dorsal neuropile (Fig 3.17B). More ventrally in the neuropile, individual axons 
were detectable (Fig 3.17C), confirming that these cells were neurons. GFP was expressed in 
the central brain, but not in the optic lobes (Fig 3.17D). In the eye imaginal disc, developing 
photoreceptors were not labelled (Fig 3.17E). 
3.2.9 Toll-6 expression in the adult brain 
The distribution of Toll-6 mRNA in the adult brain was also determined. In the optic lobes, 
expression was seen in the medulla and more proximally in the lobula (Fig 3.18A). Toll-6 was 
detected in cells surrounding various central neuropiles, including the antennal nerve and 
between the ventolateral protocerebrum and antennal lobe (Fig 3,18B). Toll-6 was also 
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Fig 3.12 - Toll-6 is expressed in early embryos, and in the stage 13-14 embryonic CNS
In situ hybridisation showing the distribution of Toll-6 mRNA. (A-B) Whole mount stage 6
embryo, showing Toll-6 expression in epidermal stripes. (C-E) Whole mount stage 13 embryo
with Toll-6 expression in the CNS (arrows) and in lateral stripes (arrow head). (F-H) Whole
mount and (I-J) dissected stage 14 embryos with Toll-6 expressed in the CNS (arrows) and
in the dorsal epidermis (arrow heads). Ventral midline on dissected samples is indicated
(red arrow head), anterior is left.
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Fig 3.13 - Toll-6 is expressed in stage 15-17 embryonic CNS
In situ hybridisation showing the distribution of Toll-6 mRNA. (A-B) Dissected stage 15
embryo showing Toll-6 expression in the CNS and clusters of cells lateral to the VNC
(white arrows). Stage 16 (C-D) and stage 17 (E-F) dissected embryos showing CNS
expression. Paired cells close to the midline are detected (white arrow heads), as are 
lusters of cells outside the CNS (white arrows). (G-H) Whole mount stage 17 embryos
showing expression in the CNS (arrow) and in cells clusters outside the CNS (white
arrows). Red arrow heads indicate ventral midline of dissected samples, anterior is left.
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Fig 3.14 - D42-Gal4 > UAS-GAP-GFP labels stage 13-14 embryonic CNS
UAS-GAP-GFP driven by D42-Gal4, anti-GFP labelling with HRP. (A-B) Whole mount stage
13 embryo showing GFP expression in the CNS (arrow) and the lateral epidermis (arrow
head). (C-E) Whole mount stage 14 embryo showing expression in the CNS (arrow), the
ventral epidermis (blue arrow), and in the lateral epidermis (arrow head). (F-G) Dissected
stage 14 embryos showing GFP labelling cells of the CNS (arrows), including axons
projecting longitudinally to the adjacent segment (green arrow). Ventral midline
indicated by the red arrow heads, anterior is left.
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Fig 3.15 - D42-Gal4 > UAS-GAP-GFP labels stage 15-17 embryonic CNS
UAS-GAP-GFP driven by D42-Gal4, anti GFP detected with HRP. (A-B) Whole mount
stage 15 embryo showing GFP expression in the CNS (arrows). (C-D) Dissected stage
15 embryos showing expression in the longitudinal fascicles (green arrow) and axons
entering or leaving the CNS (green arrow head). (F-G) Whole mount stage 17 embryo
showing GFP is expressed in a subset of muscles (white arrows) and in the CNS (arrow).
(H-I) Dissected stage 17 embryo showing GFP labelled longitudinal fascicles (green
arrow) and axons entering or leaving the periphery (green arrow head). Ventral midline
of dissected samples is indicated (red arrow heads), anterior is left.
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Fig 3.16 - Toll-6 is expressed in the larval CNS
A B
C D
E F
In situ hybridisation showing the distribution of Toll-6 mRNA. (A) Toll-6 is expressed widely
in the ventral VNC cortex. (B) In the dorsal VNC, cells close to the midline are detected
(arrows). (C) Toll-6 is expressed throughout the larval central brain. (D-E) In the optic lobes,
Toll-6 is expressed in cells contributing to the lamina (white arrow) and the medulla (white
arrow head). (F) In the eye disc, expression is restricted to the morphogenetic furrow
(green arrow).
Fig 3.17 - D42-Gal4 > UAS-GAP-GFP labels neurons in the larval CNS
A B C
D E
UAS-GAP-GFP driven by D42-Gal4, anti-GFP labelling with fluorescence. (A-C) GFP
labels the larval VNC, including cells close to the dorsal midline (arrows), the neuropile
(blue arrows), and individual axons (blue arrow head). (D) GFP is detected in the central
brain, but not the optic lobes. (E) No expression is seen in the eye imaginal disc.
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detected in cells surrounding the ellipsoid body and the calyx of the mushroom body (Fig 
3.18C-D). 
Finally, D42-Gal4 was used to drive expression of GAP GFP, to label cell membranes. GFP 
labelled cells of the medulla, which were seen projecting to the central brain, as were cells of 
the lobula, which projected to the contralateral brain (Fig 3.19A-B). Projections were also 
seen in parts of the antennal lobe and the suboesophageal ganglion (Fig 3.19C). Posteriorly, 
there were GFP+ cells close to the calyx, though the mushroom body itself was not labelled 
(Fig 3.19D). 
3.2.10 Expression of mCD8-GFP 
As well as using GAP-GFP to label cells with D42-Gal4 and Toll-7-Gal4, an alternative 
membrane-targeted GFP was also used: mCD8-GFP. In the embryos, the patterns of labelling 
were the same as with GAP-GFP. In the larval brain, mCD8-GFP driven by Toll-7-Gal4 
labelled cell bodies and axons in the VNC (Fig 3.20A). GFP was seen throughout the central 
brain and optic lobes, in a glial pattern, without obvious cell bodies or axons (Fig 3.20A). 
D42>mCD8-GFP in the larval CNS also labelled cells bodies and axons of the VNC (Fig 
3.20B). In the central brain, there was strong GFP expression, and cells were also detected in 
the optic lobes (Fig 3.20B). Using both Toll-7-Gal4 and D42-Gal4 to drive expression of 
mCD8-GFP in the adult brain resulted in a broad pattern of labelling, with a large number of 
cells and brain region expressing GFP (Fig 3.20C-D). 
3.3 Discussion 
I have cloned the coding sequences of Toll-7 and Toll-6 to generate cDNA for each gene, and 
from these generated RNA probes and carried out in situ hybridisation. I have also generated 
MLo
AN
AL
VLP
EB Ca
Fig 3.18 - Toll-6 is expressed in the adult brain
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In situ hybridisation showing the distribution of Toll-6 mRNA. (A) Toll-6 is expressed in
the medulla (M) and lobula (Lo). (B) Toll-6 expression in the central brain surrounds the
antennal nerve (AN), antennal lobe (AL), and the ventrolateral protocerebrum (VLP).
(C) Signal is seen around the ellipsoid body (EB). (D) Toll-6 is dected on the posterior
brain, close to the calyx (Ca).
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Fig 3.19 - D42-Gal4 > UAS-GAP-GFP labels the adult brain
A B
C D
UAS-GAP-GFP driven by D42-Gal4, anti-GFP  labelling with fluorescence. (A-B) GFP is
expressed in the medulla (M) and lobula (Lo) of the optic lobe, with projections to the
contralateral brain (blue arrow). (C) GFP labels central brain projection in the antennal
lobe (AL) and the suboesophageal ganglion (SOG). (D) On the posterior brain, cells are
detected around the calyx.
Toll-7 Gal4 > mCD8 GFP
Toll-7 Gal4 > mCD8 GFP D42-Gal4 > mCD8 GFP
D42-Gal4 > mCD8 GFP
Fig 3.20 - Labelling of cells with mCD8 GFP
A B
C D
UAS-mCD8-GFP driven by Toll-7-Gal4 (A, C), or by D42-Gal4 (B, D). (A) Expression is
seen throughout the brain hemispheres and in the VNC of the larval CNS. (B) There
is expression in a large number of central brain cells, as well as in the VNC. (C, D) GFP
is expressed broadly throughout the adult brain, in many central and optic lobe domains.
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a Toll-7-Gal4 fly line, and used this and the D42-Gal4 line to examine the morphology of 
cells by expressing GAP-GFP. In embryos, Toll-7 and Toll-6 are expressed in the epidermis 
and CNS, with expression of both genes largely restricted to the CNS in late embryos. 
Expression of both Toll-7 and Toll-6 continues in the larval and adult CNS. GFP driven by 
Toll-7-Gal4 and D42-Gal4 labels CNS cell bodies and axons from embryos to adults, 
indicating that expressing cells include neurons. 
In situ hybridisation identifies the endogenous expression of a gene. However, signal is 
restricted to the location of the mRNA: in neurons this is typically the soma. To characterise 
the cell type, double in situ experiments, or co-immunostaining for glial or neuronal markers 
could have been carried out.  
Using Gal4 to drive membrane-targeted GFP can reveal the morphology of cells that normally 
express Toll-7 or Toll-6. Given the amplification effect of the Gal4/UAS system, it can 
increase the sensitivity of detection. However, there are two drawbacks of this method. 
Firstly, the regulation of Gal4 is not identical to that of the gene of interest. In Toll-7-Gal4, 
only a portion of the upstream intergenic region was cloned into a pPTGAL: regulatory 
elements may have been missed that lie outside of the amplified fragment. And following 
transformation, the position in the genome of the Toll-7-Gal4 construct may influence the 
expression of Gal4. In the D42-enhancer trap, the Gal4-P-element is placed 7kb upstream of 
Toll-6, and oriented on the minus strand (Sanyal, 2009). Therefore, the positional effects of 
enhancers and repressors could be lost. Since completing this work, the Drosophila genome 
has been re-annotated. A new gene is reported 4kb upstream of Toll-6, which lies closer to the 
D42-Gal4 insertion site. However, it is unclear whether this new sequence encodes a protein, 
or what its function might be. Secondly, GFP may still be detectable in cells even if Toll-7 or 
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Toll-6 are no longer expressed. This perdurance is due to the amplifying effect of Gal4 and 
the stability of GFP within the cell. The temporal information about expression could be lost. 
To overcome the limitations of the in situ hybridisation or GFP labelling methods, I combined 
the results of both to determine the expression of Toll-7 and Toll-6. There was frequently 
overlap of in situ and GFP expression patterns, allowing the morphology of cells expressing 
GFP to be matched to the cell bodies with mRNA detected. 
In embryos, in situ hybridisation of Toll-7 mRNA and Toll-7>GFP both strongly labelled the 
CNS. Both the in situ and the GFP expression patterns were segmentally repeating from stage 
13, and the CNS labelling became stronger as the embryo developed. The midline cells 
labelled by in situ could be the same midline DM cells labelled by GFP. This large overlap in 
patterns suggests that Toll-7-Gal4 is recapitulating the endogenous expression of Toll-7 
mRNA in the CNS, and that Toll-7 is expressed in neurons. Outside of the CNS, the patterns 
of labelling dis not overlap as clearly. Toll-7>GFP did not label the precursors to the leg 
imaginal discs, as seen with the in situ. Conversely, the strong expression of GFP in the fat 
body and the ring gland was not evident with in situ hybridisation. In the larval CNS, there 
were similar patterns of labelling with in situ and Toll-7>GFP in the VNC and in the central 
brain. Again, the overlapping expression suggests that Toll-7-Gal4 broadly reflected the 
endogenous expression of Toll-7. However, Toll-7 mRNA detected in the optic lobes was not 
reflected by GFP expression, and the photoreceptors that are labelled by GFP lacked signal in 
the in situ. In the adult brain, the in situ and Toll-7>GFP patterns again complemented each 
other. In the central brain, there was extensive overlap of detection, particularly in the 
ventrolateral protocerebrum and the central complex. In the optic lobes, mRNA and GFP were 
both detected in the medulla, although the Toll-7>GFP expression in the lobula is not evident 
in the in situ. On the whole, Toll-7-Gal4 drove expression of GAP-GFP in a cell population 
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that broadly corresponded to that detected by in situ hybridisation. This was particularly the 
case in the CNS, although there were exceptions outside of the nervous system. Therefore, it 
is likely that the cells detected by in situ were the same as those labelled by GAP-GFP, and 
that they include neurons. 
Toll-6 mRNA was detected in the embryonic CNS, in segmentally repeating stripes at stage 
13 increasing to broad expression throughout the VNC at stage 17. This pattern was mirrored 
by D42-Gal4-driven GAP-GFP expression, which also labelled the embryonic CNS with 
increasing intensity as it developed. However, the expression of GFP did not become as 
widespread as was seen with the in situ, suggesting that a subset of Toll-6-expressing cells 
were labelled using D42-Gal4. The labelling by GFP of axons indicates that these cells 
included neurons. Outside the embryonic CNS, Toll-6 mRNA was detected in clusters of cells 
that run parallel to the VNC. D42>GFP labelled as sub-set of muscle cells, also running 
parallel to the VNC. However, the labelled muscles lie more laterally than the clusters of cells 
identified by in situ, so it is unlikely that the expression patterns overlap in this instance. In 
the larval CNS, there is a high degree of overlapping expression in the central brain and VNC. 
Both Toll-6 mRNA and D42>GFP were detected in these regions, and both methods detected 
pairs of cells close to the dorsal midline. Therefore, it is likely that the same cells were being 
detected. Moreover, neither Toll-6 mRNA nor D42>GAP-GFP were detectable in the 
developing retina. However, the labelling by in situ hybridisation of the optic lobes was not 
reflected by GFP expression. In the adult brain, the pattern of Toll-6 mRNA and D42>GAP-
GFP were largely complementary. The same patterns were observed in the optic lobes, with 
both the medulla and the lobula labelled. In the central brain, there was overlapping 
expression around the antennal nerve and the antennal lobe. Also, cells surrounding the calyx 
were seen with both methods, although no axons were labelled in the mushroom body with 
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GFP. However, the mRNA detected around the ellipsoid body is not reflected by GFP 
expression. Similarly to Toll-7-Gal4, D42 drove expression in many regions that are labelled 
by Toll-6 in situ hybridisation, particularly in the nervous system. It is therefore likely that 
both methods were detecting the same cells. Given their morphology, these cells include 
neurons. 
Both UAS-GAP-GFP and UAS-mCD8-GFP were used to label cells, by crossing lines to Toll-
7-Gal4 and D42-Gal4. Both of these GFP proteins are targeted to the membrane, but their 
patterns of labelling were different in the larval and adult CNS. GAP-GFP is a modified GFP 
construct, which contains the membrane-anchoring sequence from the GAP-43 protein 
(Moriyoshi et al., 1996). mCD8-GFP is a fusion protein of GFP and mouse CD8, a trans-
membrane lymphocyte marker (Lee and Luo, 1999). In the larval VNC, both versions of GFP 
labelled cell bodies and axons (compare Fig 3.20A with Fig 3.8, and Fig 3.20B with Fig 
3.17). However, the larval brains were differently labelled. With Toll-7-Gal4, GAP-GFP only 
labelled cell bodies and axons in the central brain, whereas mCD8-GFP labelled the entire 
hemispheres, in an apparently glial pattern. With D42-Gal4, GAP-GFP was only expressed in 
the central brain, but mCD8-GFP was more widely expressed, and was detected in cells of the 
optic lobes. However, the optic lobe expression of mCD8-GFP does not reflect the Toll-6 in 
situ pattern. In the adult brain, Toll-7>GAP-GFP labelled smaller populations of cells than 
Toll-7>mCD8-GFP (compare Fig 3.20C with Fig 3.10). mCD8-GFP was not detected in the 
fan-shaped body, whereas it was labelled with GAP-GFP and Toll-7 in situ hybridisation. 
Similarly with D42-Gal4, the discrete labelling with GAP-GFP contrasted with the broad 
expression of mCD8-GFP in the adult brain (compare Fig 3.20D with Fig 3.19). Since the 
Gal4 drivers were the same, the differences in expression are most likely due to the different 
versions of GFP. The differences could be due to the length of time the two proteins last 
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within the cell. It is possible that mCD8-GFP can last longer, and therefore remain at the cell 
membrane after the expression of Gal4 has been switched off. This could explain why mCD8-
GFP labels more cells than GAP-GFP. Alternatively, GAP-GFP could be more rapidly 
degraded, and its does not reach high enough levels in all cells to be detected. In this chapter, 
I have used GAP-GFP to label cells, since the patterns of expression more closely reflected 
the in situ patterns. It is intriguing that the two versions of GFP should behave differently, and 
this fact should be noted in the future when examining gene expression. 
The expression of Toll-7 and Toll-6 in the adult brain suggests they could play a role in 
various brain functions. They were found in a number of key brain areas that are involved in 
the processing and integration of sensory input: the antennal lobe (olfactory), the 
suboesophageal ganglion (gustatory), and the ventrolateral protocerebrum (auditory, 
chemosensory and visual) (Masse et al., 2009, Miyazaki and Ito, 2010, Kamikouchi et al., 
2006, Miyamoto and Amrein, 2008, Otsuna and Ito, 2006). Toll-7 and Toll-6 were also 
expressed in cells associated with higher brain functions, such as the central complex (central 
control of locomotion) and the Kenyon cells of the mushroom body (olfactory learning) 
(Strauss and Heisenberg, 1993, Masse et al., 2009). This suggests that, beyond development, 
Toll-7 and Toll-6 could be involved in higher neuronal functioning. 
It was important to describe the expression of Toll-7 and Toll-6, and to determine whether the 
patterns are consistent with them serving as DNT receptors. Both Toll-7 and Toll-6 are 
expressed in embryonic CNS neurons, and Toll-7>GAP-GFP labelled the ISNb motor axon at 
is muscle target. This complements the embryonic expression of the DNTs, which are found 
in the muscle (Zhu et al., 2008). In the larval CNS, DNT1 is expressed in the VNC and the 
central brain (Sutcliffe, 2010), areas that are overlapped by both Toll-7 and Toll-6. DNT2 is 
expressed in the eye imaginal disc, and DNT1 in the optic lobe, which is complemented by the 
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expression of Toll-7 and Toll-6 in the optic lobe. Similarly, in the adult visual system, DNT2 
is expressed in the retina and DNT1 in the lamina (Sutcliffe, 2010, Zhu et al., 2008). Toll-7 
and Toll-6 are expressed in the medulla, and Toll-6 also in the lobula complex, which are 
downstream of the DNT-expressing tissues. Moreover, Toll-7>GFP and D42>GFP both 
reveal axons projecting from the optic lobes into the central brain. Toll-7 and Toll-6 are 
expressed in neurons, including those that project to DNT-expressing tissues, and others that 
overlap with DNT-expressing neurons. Therefore, the expression patterns of Toll-7 and Toll-6 
are compatible with them serving as DNT receptors. 
Toll-6 and Toll-7 are broadly expressed in the Drosophila CNS, in patterns that are consistent 
with them interacting with the DNTs. In the following chapters I will look at the functional 
interactions between the Tolls and the DNTs, and the CNS functions of Toll-7 and Toll-6. 
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CHAPTER 4 
TOLL-7 AND TOLL-6 GENETICALLY INTERACT 
WITH THE DNTS 
 
4.1 Introduction 
Toll-7 and Toll-6 are expressed in the Drosophila CNS from embryos to the adult, in patterns 
that often complement the expression of DNT1 and DNT2. The aims of this chapter were to 
test if these two protein families interact in flies, by using two conventional genetic 
approaches. Firstly, genetic interactions between the mutant alleles of the Tolls and the DNTs 
were analysed. Secondly, genetic rescue experiments were carried out to attempt to rescue the 
lethality of spz2 and DNT141DNT2e03444 double mutants. 
For this, it was important to generate loss of function, null alleles for Toll-7 and Toll-6. Since 
fly lines were available with P-element transposons close to the start of each gene, mutants 
could be generated by P-element excision (Adams and Sekelsky, 2002). P-elements are 
transposable elements, that are often found near to the 5’ end of genes (Spradling et al., 1995). 
Inducing the excision of a P-element (so-called ‘hopping-out’) can lead to a number of 
possible outcomes, which can have varying effects on the function of the nearby gene (Adams 
and Sekelsky, 2002). This can be done by expressing Δ2-3 Transposase, which induces the 
mobilisation of P-elements from the genome (Robertson et al., 1988). One possible outcome 
is an imprecise excision, when some of the genomic DNA flanking the insertion is also 
removed (Daniels et al., 1985, Salz et al., 1987). This creates a small deletion in the 
chromosome. Screening by PCR can identify flies carrying deletions that, if large enough, 
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could have resulted in the loss of part or all of the gene’s coding sequence. Sequencing can 
then be used to confirm the precise nature of the lesion. 
Mutant alleles of DNT1 and DNT2 interact in vivo, and this can be seen by looking at lethality 
(Sutcliffe, 2010). DNT141DNT2e03444 mutants can be maintained as a viable homozygous 
stock. However, DNT141DNT2eo3444 homozygotes are semi-lethal as progeny of a 
heterozygous stock, when balanced over the TM6B chromosome and maintained at 18°C. 
Under these conditions, there are very few homozygous, Tb+ pupae (survival index ≈ 0). With 
DNT141/TM6B and DNT2e03444/TM6B single mutants, homozygous Tb+ pupae can be counted 
at near wild-type rates (survival index ≈ 1). The genetic interaction between DNT1 and DNT2 
was revealed by a survival index <1. Thus, by counting the number of TM6B and Tb+ pupae 
in combinations of Toll-7, Toll-6 and DNT double mutants, kept at 18°C, potential genetic 
interactions can be tested. For details on how the survival index is calculated, see section 
2.1.5, materials and methods. In addition to DNT141 and DNT2e03444 there is a hypomorphic 
allele of spz. The spz2 allele encodes a protein with a single amino acid substitution in the pro-
domain (Weber et al., 2007), and around 7% of flies pupate as homozygotes. It is unknown 
whether DNT1, DNT2, Toll-7 or Toll-6 also genetically interact with spz. 
Genetic rescue experiments provide further information about the relationships between 
genes, and shared signalling pathways. And a key experiment to test whether Toll-7 and Toll-
6 are receptors for DNT1 and DNT2 is to test if overexpression of constitutively active forms 
of the receptors can rescue the mutant phenotypes of the DNT mutants. Toll-7 and Toll-6 are 
paralogues of Toll, and share the same general protein structure. Therefore the molecularly 
characterised constitutively active Toll receptors, which signal in the absence of ligand, can be 
used as a guide to generate activated Toll-7 and Toll-6. The deletion of the entire extracellular 
domain results in a constitutively active Toll receptor: TollΔLRR (Winans and Hashimoto, 
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1995). Truncating Toll-7 and Toll-6 in the same way may also produce activated receptors. 
Alternatively, the Toll10b mutant allele encodes a protein with an amino acid substitution of 
cysteine to tyrosine in the extracellular domain (Schneider et al., 1991). This cysteine is 
within the Cys-rich cluster lying closest to the membrane, and is thought to play a role in 
inhibiting Toll signalling in the absence of ligand (Hu et al., 2004). The auto-inhibition is 
released when the cysteine is mutated. The cysteine is in a conserved position in Toll-7 and 
Toll-6, and it is anticipated that mutating the equivalent residue in these genes will create 
constitutively active receptors.  
4.2 Results 
4.2.1 Generation of Toll-7 null alleles by P-element imprecise excision 
A P-element mobilisation and PCR screen was carried out by Janine Fenton, the technician in 
our lab, before I arrived. GE17034 flies carry a P-element 383bp upstream of the ATG start 
codon of Toll-7. The P-element was mobilised by expressing Δ2-3 transposase, and the 
mutated chromosome was recovered and balanced stocks were established, using genetic 
protocol H (Fig 2.6, materials and methods).  P-element mobilisation of these flies generated 
129 lines representing unique excision events, identified as white-eyed males. 72 of these 
lines were screened by PCR using primers 7.1-7.7 (Table 2.3, materials and methods), 
identifying 6 as potential mutants, including Toll-7P8 and Toll-7P114. A region of genomic 
DNA was amplified by PCR, with forward primer 7.2 and reverse primer 7.4, which are 
located either side of the original P-element insertion site. In wild-type flies, these primers 
amplify a 2.1kb fragment of DNA. The amplified fragments in these mutants were smaller 
(Toll-7P8 = 1.2kb, Toll-7P114 = 1.6kb), indicating a deletion of the genome (Fig 4.1A). To 
molecularly characterise the break-points in these mutant lines, the genomic DNA fragment 
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was sequenced by J Fenton. In both cases, the deletion removed the ATG start codon of Toll-
7, the signal peptide, and the first few amino acids (Fig 4.1B). They are therefore protein null 
alleles, and will be used throughout this work. 
4.2.2 Generation of Toll-6 null alleles by P-element imprecise excision 
A P-element mobilisation was carried out with the help of Janine Fenton and Sarah Quail, an 
undergraduate student. GE26951 flies carry a P-element 154 base-pairs upstream of the ATG 
start codon of Toll-6, which was excised using Protocol I (Fig 2.7, materials and methods). 
505 stocks were established from white-eyed males, representing unique excision events of 
the GE26951 P-element. Of these lines, 366 were screened by PCR for a deletion in the 
genomic DNA using primers 6.1-6.10 (Table 2.4, materials and methods). 10 lines were 
identified as potential mutants, including Toll-626 and Toll-631. A region of genomic DNA 
was amplified by PCR, with forward primer 6.2 and reverse primer 6.8, which are located 
either side of the original P-element insertion site. In wild-type flies, these primers amplify a 
3.4kb fragment of DNA. The fragment amplified in these mutants were smaller (Toll-626 = 
1.9kb, Toll-631 = 1.6kb), indicating a deletion in the genome (Fig 4.2A). To molecularly 
identify the break-points in these lines, genomic DNA fragment was sequenced by J Fenton. 
In both cases, the deletion eliminates the initiating ATG start codon for Toll-6, and uncovers 
the sequences encoding the signal peptide and the first few amino acids (Fig 4.2B). These are 
therefore protein null alleles. 
4.2.3 Genetic interactions between Toll-7, Toll-6, DNT1 and DNT2 
Using the survival index to measure viability, I tested whether there are functional 
interactions between the DNTs and Toll-7 and Toll-6. DNT141, Toll-7P8 and Toll-7P114 single 
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Fig 4.1 - Toll-7 mutagenesis by imprecise P-element excision
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Mutant alleles of Toll-7 were generated by P-element mobilisation. (A) PCR of genomic
DNA revealed two lines with deletions. (B) Sequencing confirmed that the deletions
uncovered the start codon of Toll-7 and the first few amino acids. Primer sites used
in (A) are indicated by green arrows. The forward primer was 7.2, located 1kb upstream
of the start of Toll-7; the reverse primer was 7.4, located 1kb into the Toll-7 gene.
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Fig 4.2 - Toll-6 mutagenesis by imprecise P-element excision
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Mutant alleles of Toll-6 were generated by P-element mobilisation. (A) PCR of genomic
DNA revealed two lines with deletions. (B) Sequencing confirmed that the deletions
uncovered the start codon of Toll-6 and the first few amino acids. Primer sites used
in (A) are indicated by green arrows. The forward primer is 6.2, located 2kb upstream
of the start of Toll-6; the reverse primer is 6.8, located 1.9kb into the Toll-6 coding sequence.
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mutants showed a reduced viability to approximately half that of controls (Fig 4.3A). The 
DNT2e03444 mutant showed slightly reduced viability compared to controls, while Toll-626 and 
Toll-631 mutant alleles showed no effect on viability (Fig 4.3A). 
I next looked at various combinations of alleles for Toll-6, Toll-7 and the DNTs. As 
previously reported (Sutcliffe, 2010), DNT2e03444DNT141/TM6B double mutants had a greatly 
reduced viability. Similarly, Toll-7P8Toll-626/SM6aTM6B and Toll-7P114Toll-631/SM6aTM6B 
double mutants were semi-lethal, with a very low survival index (Fig 4.3B). Loss of the two 
receptors phenocopied the loss of the two DNTs. I observed a similar reduction in viability in 
DNT141Toll-626/TM6B and Toll-7P114;DNT2e03444/SM6aTM6B double mutants (Fig 4.3B). This 
suggests removing one DNT and one Toll is the equivalent of removing both DNTs or both 
Tolls, that there could be two ligand-receptor pairs. This could indicate functional interactions 
between DNT1 and Toll-7, and between DNT2 and Toll-6. The survival index of the 
DNT2e03444Toll-626/SM6aTM6B double mutants was similar to DNT2e03444/TM6B and Toll-
631/TM6B single mutants (Fig 4.3A, B). This is consistent with the notion that these genes are 
components in the same signalling pathway. Toll-7P114;DNT141/SM6aTM6B double mutants 
showed a strongly reduced viability (Fig 4.3B). This was much lower than either of the single 
mutants, and could point to promiscuity of binding. 
Finally, I combined alleles of DNT1, DNT2, Toll-7 and Toll-6 with spz. The spz2 allele had a 
low survival index (Fig 4.3C). The combination of spz2 and DNT2e03444 showed a slightly 
reduced viability, while spz2DNT141 double mutants were fully lethal (Fig 4.3C). When 
placed in a spz2 mutant background, both Toll-7P8 and Toll-626 mutant alleles were lethal (Fig 
4.3C). This is consistent with Toll-6 and Toll-7 playing roles in DNT signalling. 
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4.2.4 Rescue of Toll-7Toll-6 mutant lethality by activated Toll-7 and Toll-6 
Two versions of constitutively active Toll-7 and Toll-6 receptor constructs were made, 
following the example of the activated Toll constructs: TollΔLRR and Toll10b. For details on 
how the constructs were generated, see section 2.2.9, materials and methods. Similarly to 
TollΔLRR, the extracellular domain of Toll-7 and Toll-6 was deleted, yielding Toll-7ΔLRR and 
Toll-6ΔLRR. The constructs were placed into expression clones downstream of UAS, with an 
attB sequence in the clone for φC31-mediated fly transgenesis. Toll10b is a constitutively 
active Toll allele, with a cysteine to tyrosine point mutation in the extracellular domain. The 
equivalent cysteine residue was mutated in Toll-7 (Cys 993) and Toll-6 (Cys 1020), yielding 
Toll-7Cys-Tyr and Toll-6Cys-Tyr constructs. These were placed into P-element-containing 
expression clones downstream of UAS, for Transposase-mediated fly transgenesis. 
Expression of the constitutively active receptors in flies was driven using the Gal4/UAS 
system (see methods). 
I first asked whether activated Toll-7 and Toll-6 constructs can rescue the receptor double 
mutant phenotype. Toll-7P8Toll-626 double mutants display a semi-lethal phenotype at 18°C in 
an SM6aTM6B-balanced stock. I expressed either Toll-7ΔLRR, Toll-6ΔLRR or Toll-7Cys-Tyr in 
cholinergic neurons with the ChaGal4 driver, in a Toll-7P8;Toll-626/SM6aTM6B double 
mutant background. The ChaGal4 driver was used, because it drives expression in a large 
proportion of neurons. The pan-neuronal elavGal4 driver could not be recombined with Toll-6 
mutant alleles, and was therefore not used in rescue experiments with Toll-7Toll-6 double 
mutants. Toll-6ΔLRR and Toll-7ΔLRR partially, but significantly, rescued the lethality of the 
receptor double mutants; expressing Toll-7Cys-Tyr rescued the mutants slightly more than the 
ΔLRR receptors (Fig 4.4). Unfortunately, I was unable to generate the fly stocks to test the 
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effect of Toll-6Cys-Tyr on lethality. Expressing activated receptors in neurons partially rescued 
the Toll-7P8Toll-631 double mutant lethality, indicating that to some extent, this is a nervous 
system phenotype and that the receptors are functional. 
4.2.5 Rescue of DNT mutant lethality by activated Toll-7 and Toll-6 
I next tested whether expressing activated Toll-7 or Toll-6 receptors could rescue the semi-
lethal phenotype of the DNT141DNT2e03444 double mutant. Activated receptor constructs were 
expressed in all neurons with the elavGal4 driver, in a DNT2e03444DNT141/TM6B double 
mutant background. Toll-7ΔLRR and Toll-6ΔLRR rescued the lethality of DNT1DNT2 double 
mutant (Fig 4.5A). Toll-7Cys-Tyr and Toll-6Cys-Tyr also rescued the DNT1DNT2 double mutant 
lethality, above the rescue by ΔLRR constructs (Fig 4.5A). Moreover, neuronal expression of 
UAS-Toll10b, the Toll equivalent of the Cys-Tyr constructs, also rescued the DNT1DNT2 
double mutant lethality. These rescues indicate that Toll-7 and Toll-6 share a common 
function with the DNTs, and are acting downstream of the ligands. 
Spz is also a DNT, so I asked whether activating Toll-7 or Toll-6 in neurons could rescue the 
lethality of spz mutants. Therefore activated receptors were expressed in all neurons in a spz2 
mutant background. Toll-7ΔLRR and Toll-6ΔLRR both rescued the semi-lethality of spz2 (Fig 
4.5B). This result, together with the rescue of DNT141DNT2e03444 lethality will Toll10b, shows 
that activated receptors can substitute for each other, and suggests that DNTs and Tolls share 
the same signalling pathways. 
4.3 Discussion 
In this chapter (with the help of Janine Fenton and Sarah Quail) I have generated null mutants 
of Toll-7 and Toll-6 by imprecise excision of P-elements. Using genetic interactions, I have 
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shown that Toll-7Toll-6 double mutants phenocopy DNT1DNT2 double mutants, and that the 
genes interact in vivo. These experiments suggest an interaction between Toll-7 and DNT1, 
and Toll-6 and DNT2. I have also generated constitutively active receptor constructs by 
removing the extracellular domain or mutating a conserved cysteine residue, and have 
obtained transgenic flies to express the activated receptors using the Gal4/UAS system. I 
finally showed that expressing constitutively active receptors in the nervous system rescues 
the semi-lethal phenotype of Toll-7Toll-6, DNT1DNT2, and spz mutants. 
DNT1DNT2 mutants are viable, and can survive as a homozygous stock. The semi-lethal 
phenotype is revealed when heterozygous flies balanced with TM6B are crossed and 
maintained at 18°C. The lower temperature apparently sensitises the alleles, resulting in the 
observed lethality. It is unusual for temperature-sensitive effects to manifest at lower 
temperature: most conditional alleles show their phenotype at higher temperatures. However, 
temperature can have broad, non-specific effects on neuronal structure and function, beyond 
specific temperature-sensing pathways. At the NMJ, higher temperatures promote axonal 
branching, synaptic transmission and corresponding enhancement of locomotion (Sigrist et 
al., 2003, Zhong and Wu, 2004). These effects, as well as temperature-dependent plastic 
changes in the central brain, are correlated with changes in ion channel activity and cAMP 
signalling (Peng et al., 2007). It is possible that the 18°C condition is restricting neuronal 
function, and that this is enhancing the interaction between DNTs and Tolls. Lower 
temperatures have also been shown to enhance phenotypes of NFκB mutant alleles in flies 
(Ayyar et al., 2007). Spz is known to signal through the NFκB paralogues Dorsal and Dif 
(Manfruelli et al., 1999, Meng et al., 1999). Therefore the low temperature-sensitivity of 
NFκB may be contributing to the lethal phenotype seen with this assay. Although it is not 
entirely clear why lower temperature sensitises this phenotype, it has been a useful assay to 
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employ. The results are reproducible (Sutcliffe, 2010), and have revealed functional 
interactions between Toll-7 and Toll-6 and the DNTs. 
Looking at various double mutant combinations of DNT1, DNT2, Toll-6 and Toll-7, I have 
seen a genetic interaction between the ligands and the receptors. To some extent, the data 
suggest that there are two parallel signalling pathways. Removing both ligands causes the 
same lethal phenotype as removing both receptors (Fig 4.6A). Lethality is also seen on 
removing DNT1 and Toll-6, or DNT2 and Toll-7 (Fig 4.6B). Therefore, in a DNT1 mutant 
background, loss of Toll-6 phenocopies loss of DNT2; in a DNT2 mutant background, loss of 
Toll-7 phenocopies loss of DNT1. This is consistent with DNT1 and Toll-7 acting as one 
ligand receptor pair, DNT2 and Toll-6 acting as another pair. Moreover, removing DNT2 and 
Toll-6 does not enhance the phenotype of DNT2 or Toll-6 single mutants, consistent with 
them acting in the same pathway. The semi-lethal interaction of Toll-7 with DNT1, however, 
demonstrates that this represents a simplified model. The fact that the Toll-7DNT1 double 
mutant phenotype is stronger than the single mutants could be explained by promiscuity in 
ligand-receptor interactions. This is seen in some other contexts, including the binding of 
vertebrate neurotrophins to the Trk family of receptors (Reichardt, 2006). The spz2 allele 
interacts differently with DNT2e03444 and Toll-626, which further suggests that the relationships 
between the ligands and receptors are not straight-forward pairings. 
The Toll-7Toll-6 double mutant semi-lethality over SM6aTM6B at 18°C is partially rescued 
by expressing Toll-7ΔLRR, Toll-6ΔLRR and Toll-7Cys-Tyr in neurons. This means that, to some 
extent, the lethality is due to a loss of Toll-7 and Toll-6 in the nervous system. However, the 
rescue is not to control viability. This could because ChaGal4, specific to cholinergic 
neurons, is not driving expression in all the neurons required for survival. It is possible that a 
higher degree of rescue might have been reached if the activated receptors were expressed in 
DNT1 DNT1
DNT1 DNT1
DNT2 DNT2
DNT2 DNT2
Toll-7 Toll-6 Toll-7 Toll-6
Toll-7 Toll-6 Toll-7 Toll-6
Fig 4.6 - Semi-lethal combinations of alleles indicate functional
 interactions between DNTs and Tolls
A
B
Various combinations of mutant alleles of DNT1, DNT2, Toll-6 and Toll-7 result in a semi-lethal
phenotype. (A) Loss of both ligands and loss of both receptors results in the same phenotype.
(B) Loss of DNT1 and Toll-6, or loss of DNT2 and Toll-7, effectively knocks out both signalling
pathways, and results in a semi-lethal phenotype.
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an alternative or larger subset of neurons. Unfortunately, the pan-neuronal elavGal4 driver did 
not recombine with null alleles of Toll-6. Additionally, the levels of expression are likely to 
exceed the endogenous activation of Toll-7 and Toll-6 in vivo, which may disrupt normal 
neuronal functions. Finally, signalling outside the nervous system may also be important for 
viability, and the partial rescue of survival could reflect this. 
Some conclusions can be drawn from the small, but significant rescues of the Toll-7Toll-6 
double mutant lethality. The rescues indicate that the ΔLRR activated receptor constructs are 
functional, and that removing the extracellular domain is an effective strategy to activate the 
receptors. Moreover, as shown by the rescue with Toll-7Cys-Tyr activated receptor, conserved 
cysteine residues close to the membrane could be involved in silencing the unbound receptor. 
The greater effect of Toll-7Cys-Tyr than Toll-7ΔLRR suggests that the mutated receptor might be 
more effective in signalling than the truncated form. The fact that Toll-7 and Toll-6 could be 
constitutively activated in the same way as Toll, suggests that the Toll paralogues share 
common activation mechanisms.  
Activating Toll-7 or Toll-6 in neurons partially rescues the lethality of DNT1DNT2 double 
mutants and spz mutants. This again demonstrates that the lethality phenotype is due, at least 
in part, to neuronal dysfunction. The incomplete rescue could again be due to insufficient or 
dysregulated expression of the activated receptors. The rescue of DNT1DNT2 double mutants 
was stronger than the rescue of the Toll-7Toll-6 double mutants, which might reflect the use of 
the more widely expressing elavGal4 driver, compared to ChaGal4 used earlier. However the 
endogenous control of expression levels was lost, and any non-neuronal requirements of Toll-
7 and Toll-6 were not met. Another explanation of the incomplete rescue could be that Toll-7 
and Toll-6 are not the only DNT receptors, and that activation of additional receptors may be 
required to fully rescue the DNT mutant phenotype. The Cys-Tyr activated receptors appeared 
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to more strongly rescue DNT1DNT2 double mutant lethality than the ΔLRR receptors, similar 
to the effect seen in Toll-7Toll-6 double mutants. Intriguingly, the rescue by Toll10b was more 
similar to the ΔLRR versions of Toll-7 and Toll-6 than the Cys-Tyr receptors. This could be 
due to a positional effect of UAS-Toll10b in the genome, or could point to differences in 
signalling between Toll, Toll-7 and Toll-6. 
The significant rescues of DNT mutant lethality phenotypes by constitutively active Toll-7 
and Toll-6 show that the receptors share a common signalling pathway with the DNTs: 
activating signalling compensates for a loss of the ligands. Toll is known to signal through the 
NFκB homologues Dorsal and Dif (Moussian and Roth, 2005, Meng et al., 1999). Since 
activated Toll, Toll-6 and Toll-7 all rescue DNT mutant lethality, it is likely that Toll-7 and 
Toll-6 also signal through NFκB. These rescues also show that the receptors are acting 
downstream of the DNTs. Spz binds to Toll to activate signalling (Weber et al., 2003). 
Activating Toll-7 and Toll-6 rescues the spz phenotype, and Toll10b rescues the DNT1DNT2 
phenotype. It has also been shown that neuronal expression of DNT1 and DNT2 rescues the 
spz lethality, and that expressing spz rescues the DNT2DNT1 phenotype (Sutcliffe, 2010). 
These results are compatible with promiscuous or redundant relationships between the ligands 
and the receptors. 
Lethality is a gross, non-specific phenotype, and doesn’t indicate what molecular or cellular 
processes are disrupted. Therefore, in the following chapter, I will examine what are the CNS 
functions of Toll-7 and Toll-6, and whether these are compatible with them serving as DNT 
receptors. 
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CHAPTER 5 
TOLL-7 AND TOLL-6 FUNCTION IN THE 
NERVOUS SYSTEM 
 
5.1 Introduction 
In the previous chapters, I have shown that Toll-7 and Toll-6 are expressed in the Drosophila 
nervous system, and that the receptors genetically interact with the DNTs. The aims of this 
chapter were to characterise the functions of Toll-7 and Toll-6 in the nervous system, testing 
for phenotypes also found in DNT mutants. I tested for locomotion phenotypes, and the roles 
of the receptors in axon targeting and cell survival. Finally, rescue experiments tested whether 
constitutively active receptors can rescue the cell death phenotype of the DNTs. 
Drosophila behaviour has long been used as a read-out of nervous system function 
(Heisenberg, 1997). Adult locomotion lends itself to the investigation of gene function, since 
it can be easily tested, and requires the coordination of a large number of inputs and outputs. 
Locomotion phenotypes can result from dysfunction in a wide range of processes, from 
neuromuscular communication to central control mechanisms. Locomotion is disrupted if 
there are changes to the muscle (Gilsohn and Volk, 2010), or if there is dysfunction in the 
motor neuron at the NMJ (Wan et al., 2000, Wagh et al., 2006). Sensory input, including 
visual and proprioceptive signal, are required for normal locomotion (Keller et al., 2002). 
Control of motor neuron excitability influences the ability of flies to move normally (Ping et 
al., 2011). And in the brain, the Central Complex plays a pivotal role in the central control of 
locomotion, including initiation, speed and direction (Strauss and Heisenberg, 1993, Strauss, 
2002). And beyond the function of specific genes, the fly’s sex, age, food availability, light 
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levels all influence the level of activity (Martin et al., 1999). Therefore, I will test if Toll-7 
and Toll-6 mutants show locomotion phenotypes. 
Motor neurons send their axons out of the CNS to their targets – muscle. Once a motor axon 
has found its target, it establishes synapses (the NMJ), and the contraction of the muscle is 
brought under neuronal control. The embryonic development of the muscle and the targeting 
of motor axons occur simultaneously, and muscles form independently of innervation (Bate, 
1993, Broadie and Bate, 1993). Motor neurons reach their muscle targets in a series of steps. 
Firstly, pioneer motor axons exit the VNC and project to the periphery towards the muscle, 
follower neurons then fasciculate along the pioneer axons to establish the segmental and 
intersegmental nerves, and finally axons branch off to target to specific muscle fibres where 
an NMJ is established (Sánchez-Soriano and Prokop, 2005, Landgraf and Thor, 2006). The 
projection of motor axons from the CNS does not require muscle, but synaptogenesis does 
depend on the normal differentiation of muscle fibres (Prokop et al., 1996). Looking for 
defects in the intersegmental nerve b (ISNb) frequently identifies genes that play a role in 
axon targeting (Dorsten and VanBerkum, 2008, Meyer and Moussian, 2009). ISNb is made 
up of the motor axons from the RP1, RP3, RP4, RP5 and V neurons, and they target the 
ventral longitudinal muscles 6, 7, 12, and 13 (Landgraf et al., 1997). These RP neurons all 
originate from the same neuroblast (NB3-1), while the V neuron is the only motor neuron 
originating from NB5-2 (Schmid et al., 1999). The dendritic arbours of motor neurons are 
myotopically mapped, and the dendrites corresponding to the ISNb axons are found together 
in the adjacent anterior hemisegment (Landgraf et al., 2003). Motor neurons can be labelled 
with anti-Fasciclin II (FasII) antibodies. FasII is a highly specific marker of the axons and 
growth cones of a subset of motor neurons, including the ISNb nerve branch, and does not 
label sensory or interneurons (Van Vactor et al., 1993). Therefore, staining with anti-FasII can 
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reveal misrouting phenotypes of the ISNb nerve branch as it targets the embryonic muscle. 
Thus, I will test if motor axon targeting required Toll-7 and Toll-6 
One of the fundamental aspects of neuronal development is whether the cell should survive or 
die. Apoptosis is a form of programmed cell death and is characterised by the condensation of 
the nucleus and other organelles, and the membrane-bound fragmentation of the cell (Kerr et 
al., 1972). Apoptosis is genetically controlled, and involves a host of pro-apoptotic genes, 
initiator and effector Caspases, and inhibitors (Xu et al., 2009). The process in flies broadly 
reflects the apoptosis pathways in vertebrates, though species differences include the relative 
importance of Cytochrome C involvement (Kornbluth and White, 2005). Caspase-3 is the 
most potent effector of cell death, and is homologous to DrICE in flies (Degterev et al., 2003, 
Xu et al., 2009). Antibodies raised against the activated vertebrate Caspase-3 also recognise 
activated Drosophila DrICE (Muro et al., 2006, Bond et al., 2008). Apoptosis is an important 
feature of nervous system development across species (Buss et al., 2006), and in flies 25-50% 
of cells in the developing CNS are lost in this way (White et al., 1994, Rogulja-Ortmann et 
al., 2007). Therefore, I will test whether apoptosis levels change in Toll-7 and Toll-6 mutants, 
and whether activated forms of the receptors can rescue the excess cell death of DNT mutants. 
DNT mutant flies show locomotion defects, and mutant embryos show axon targeting defects 
and increased neuronal cell death (Zhu et al., 2008, Sutcliffe et al., Submitted). To test if the 
Tolls can function as DNT receptors, it is important to investigate whether Toll-7 and Toll-6 
mutants show similar phenotypes to the DNT mutants. 
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5.2 Results 
5.2.1 Toll-7 and Toll-6 are required for normal locomotion behaviour 
I tested the locomotion phenotype of adult flies using the paradigm developed by Ben 
Sutcliffe, Manuel Forero and Alicia Hidalgo (Sutcliffe et al., Submitted). Adult flies had their 
wings clipped, and were allowed to recover for 30 minutes. They were filmed for one minute 
after being placed in the centre of a petri dish, and the films were processed using FlyTracker 
software. The software produced a plotted trajectory of the fly’s path, and also a detailed read-
out of various behavioural parameters. Flies were controlled for age, sex and food quality. 
Filming was always carried out at the same time of day, between 9.30am and 11.00am. 
When placed in the petri dish, yw control flies invariably walked to the edge, climbed the 
walls of the dish, and walked on the rim of the dish. This produced a characteristic circular 
trajectory (Fig 5.1A). When tested in the same way, the trajectories of Toll-7P8/P114 and 
Toll-626/31 single mutants showed that they travel a much shorter distance than the controls, 
over an equal period of time (Fig 5.1B, C). Toll-7P8/P114;Toll-626/31 double mutants behaved 
similarly to the single mutants (Fig 5.1D). Mutant flies would not always travel far enough to 
reach the rim, but would remain on the bottom of the petri dish. They rarely completed a full 
circuit of the dish, so the circular trajectory of the controls was lost. When the total distance 
travelled was quantified, all of the mutants showed a greatly reduced path length, compared to 
controls (Fig 5.2A). 
The reduction in distance travelled by the mutants could be attributed to at least two 
behavioural phenotypes. The first is time resting. This was defined as a frame of the film 
where a fly travelled less than 1.5mm, and included frames where a fly was grooming or 
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motionless. When I observed the flies, it was clear that the mutants showed an increase in 
resting behaviour. Quantifying the proportion of time spent resting confirmed this (Fig 5.2B). 
The increased time resting was accompanied by an additional phenotype: mutant flies walked 
more slowly than the yw controls. The average walking speeds of the flies were compared, 
ignoring the frames when the fly was resting. Toll-7P8/P114, Toll-626/31, and Toll-7P8/P114;Toll-626/31 
all travelled at slower average speeds compared to yw (Fig 5.2C). The FlyTracker software 
measured the speed of the flies in each of the frames recorded. I pooled all of these values, to 
produce a histogram showing the distribution of walking speeds for each genotype (Fig 5.2D). 
The single and double mutant flies spent a larger proportion of time walking slowly, whereas 
the controls were able to walk at higher speeds. 
Toll-7 and Toll-6 are therefore required for normal locomotion behaviour. Single and double 
mutant flies did not travel as far as controls in a set period of time, and this was due to an 
increased amount of time at rest, and an inability to walk as quickly as control flies. 
5.2.2 Toll-7 and Toll-6 are required for axon targeting 
To test if Toll-7 and Toll-6 are involved in axon targeting, the ISNb motor axons were 
examined as they target to muscles 6, 7, 12, and 13. Motor axons were stained with anti-FasII, 
and abdominal segments A1 to A5 were examined in late stage 17 embryos, where the 
prototypical axonal pattern consists of three projections. The most lateral of these lies in the 
cleft of muscles 12 and 13; the projection between muscles 13 and 6 is often thicker and 
shorter than the others, and the projection between muscles 6 and 7 is often the faintest (Fig 
5.3A). The phenotypes that I looked for were fan, loss of 1 projection, loss of 2 or more 
projections, and misrouting (Zhu et al., 2008). The fan phenotype is recognised by multiple 
thin projections originating at the cleft of muscles 13 and 6, and along with the loss of 1 
yw
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D
Fig 5.1 - Toll-7 and Toll-6 mutant flies travel less far than control flies
(A-D) Representative trajectories of adult flies of the given genotype, recorded over an
equal amount of time, when placed in the centre of a petri dish. (A) yw control flies
typically travel to the rim of the dish, and continue to walk around it. (B) Toll-7 and
(C) Toll-6 single mutants and (D) double mutants have reduced trajectory lengths.
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projection, does not reproducibly vary between genotypes (Fig 5.3B). Misrouting refers to the 
errant projection of an axon to the wrong muscle, to another nerve, to the next hemisegment, 
or following a path that substantially deviates from the classical pattern. When comparing 
genotypes, misrouting and loss of 2 or more projections were combined, as these were the 
phenotypes that varied according to genotype. 
In yw controls, 20% of hemisegments showed a misrouting phenotype. In Toll-626/31 and 
Toll-631/DfXG4 mutant embryos, there was an increase in the proportion of hemisegments 
showing misrouting (Fig 5.3C, E). While the rate of misrouting increased, the aberrant 
projections looked similar to the misrouted axons seen in controls. In Toll-7P8/P114 and Toll-
7P114/DfBSC22 mutant embryos, a much stronger increase in the proportion of aberrant 
hemisegment was observed (Fig 5.3C, E). To eliminate the contribution of genetic 
background to the phenotypes, two transheterozygote combinations were used for each gene: 
one using different null alleles, the other placing a null allele in trans over a deficiency. The 
fact the same phenotypes were observed in each case confirms that the effects are gene-
specific. Toll-7P8/P114 and Toll-7P114/DfBSC22 mutants showed more severe misrouting 
phenotypes, including projections forming loops and misrouting further from the target, 
which were not seen in control flies. Toll-7P8/P114 and Toll-7P114/DfBSC22 mutants also showed 
the loss of 2 or more projections phenotype, which was never seen in controls. In some 
instances, the entire ISNb nerve branch was missing (Fig 5.3D). This means Toll-7 has the 
greater influence over axon targeting to muscles 6, 7, 12 and 13. Toll-7P8/P114;Toll-626/31 
double mutants also showed the more severe misrouting phenotypes and losses of 2 or more 
projections. In the double mutants, there were significantly more aberrant hemisegments 
compared to Toll-7P8/P114 single mutants (Fig 5.3E). Therefore, Toll-7 and Toll-6 are required 
for the targeting of the ISNb motor axons. 
Fig 5.3 - Toll-6 and Toll-7 promote axon targeting
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5.2.3 Toll-7 and Toll-6 can promote cell survival in the CNS 
To analyse the role of Toll-7 and Toll-6 in cell survival, I carried out an immunofluorescent 
staining of activated Caspase-3, to detect apoptotic cells in the stage 17 embryonic VNC by 
confocal microscopy. To process the stacks of images, I used the DeadEasy Caspase plugin 
from ImageJ (Forero et al., 2009), which produced a parallel stack of white Caspase-positive 
cells on a black background. The software also returned the number of cells counted (Fig 
5.4A, and see section 2.7.3, materials and methods). Since the number of apoptotic cells 
varies greatly between developmental stages, late stage 17 embryos were examined, where 
wild-type samples typically have 110-120 apoptotic cells (Rogulja-Ortmann et al., 2007, 
Sutcliffe, 2010, Pennack, 2008). 
To test whether Toll-7 and Toll-6 are required for cell survival in the Drosophila embryonic 
VNC, I counted Caspase-positive cells in Toll-7 and Toll-6 mutants. Toll-7P8/P114 and Toll-626/31 
mutant embryos both showed an increase in the number of apoptotic cells compared to 
controls (Fig 5.4B, C). The same result was obtained when looking at Toll-7P8/DfBSC22 and Toll-
626/DfXG4 mutants, with alleles in trans over deficiencies, therefore genetic background is 
unlikely to have contributed to the phenotype (Fig 5.4C). The increase in cell death in Toll-6 
and Toll-7 mutants shows that these genes are required for cell survival in the developing 
VNC. 
I next tested whether Toll-7 and Toll-6 were sufficient to maintain cell survival, by expressing 
constitutively active receptors in the all neurons in the developing VNC. First, the Toll-7ΔLRR 
and Toll-6ΔLRR activated receptors were expressed in all neurons using elavGal4, in otherwise 
wild-type embryos. Toll-7ΔLRR had no effect on the number of apoptotic cells, while Toll-6ΔLRR 
increased the amount of cell death in the VNC (Fig 5.5A, C). This result was not consistent 
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with Toll-7 and Toll-6 being able to promote cell survival. I next tested whether Cys-Tyr 
activated receptors could maintain cell survival. Expressing Toll-7Cys-Tyr and Toll-6Cys-Tyr in all 
neurons in otherwise wild-type embryos reduced the amount of cell death compared to yw 
(Fig 5.5B, D). Therefore, activated Toll-7 and Toll-6 prevent naturally occurring cell death, 
indicating that the receptors can promote cell survival. 
5.2.4 Activated Toll-7 and Toll-6 rescue the DNT1 and DNT2 mutant 
phenotypes 
The above analyses show that Toll-7 and Toll-6 mutant phenotypes resemble those of DNT1 
and DNT2 mutants. The crucial test of whether Toll-7 and Toll-6 can function as DNT 
receptors is to test if activated receptors can rescue the phenotype of DNT mutants. DNT1 and 
DNT2 are both required for cell survival, since mutant embryos showed an increase in 
apoptosis (Fig 5.6A, C, see also Zhu et al., 2008). To test whether activated Toll-7 and Toll-6 
receptors could rescue this phenotype, I expressed Toll-7Cys-Tyr in all neurons in DNT141 
mutant embryos, and Toll-6Cys-Tyr in neurons of DNT2e03444/Df6092 mutants. In both cases, the 
amount of cell death was rescued to below control levels (Fig 5.6B, D). The rescue of the cell 
death phenotype is evidence that Toll-7 and Toll-6 functionally interact with the DNTs. 
5.3 Discussion 
I have shown that Toll-7 and Toll-6 mutants exhibit abnormal adult behaviour, and loss of 
these genes causes axon targeting defects and increases cell death in the developing CNS. 
Expression of activated Toll-7 and Toll-6 in neurons reduces the amount of naturally 
occurring cell death, and also rescues the phenotype of the DNT mutants. Therefore, Toll-7 
Fig 5.4 - Toll-7 and Toll-6 are required for cell survival in the embryonic VNC
A
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B
(A) Stage 17 embryonic VNCs were stained with anti-cleaved Caspase-3, and detected
with confocal miscroscopy. DeadEasy software produced a parallel stack of images,
where cells are identified from background, and a count of cell number is given.
(B) Representative samples of yw, Toll-7P8/P114 and Toll-626/31 embryos stained with
anti-cleaved Caspase-3. (C) Toll-7 and Toll-6 mutants show increased apoptosis in the
developing CNS. Mean cells shown +/- SEM, numbers given in bars, *p<0.05 **p<0.01
***p<0.001 Students t-test, numbers given in bars.
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Fig 5.5 - Toll-7 and Toll-6 activated with Cys-Tyr mutations, but not ΔLRR,
   reduce naturally occuring cell death
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Apoptosis was quantified in embryos with neuronal expression of activated Toll-7 and
Toll-6 receptors. Representative samples are shown for (A) elav>Toll-6ΔLRR and (B)
elav>Toll-7Cys-Tyr (C) Toll-7ΔLRR had no effect, while Toll-6ΔLRR increased cell
death in the embryonic VNC. (D) Expressing Toll-6Cys-Tyr and Toll-7Cys-Tyr in all neurons
reduced the number of apoptotic cells. Mean cells shown +/- SEM, numbers given in
bars, *p<0.05 Students t-test. Full genotypes from left to right are (C) yw,
elavGal4 x UASToll-7ΔLRR, elavGal4 x UASToll-6ΔLRR, (D) yw, elavGal4 x UASToll-7Cys-Tyr,
elavGal4 x UASToll-6Cys-Tyr
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Fig 5.6 - Activated Toll-7 and Toll-6 rescue the DNT1 and DNT2 mutant phenotype
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Expression of activated receptors rescues the increased apoptosis seen in DNT mutants.
Representative sampled are shown for (A) DNT155 and (B) DNT1, elav>Toll-7Cys-Tyr. (C) DNT1
and DNT2 mutants have more cell death in the embryonic VNC than yw controls.
(D) Expressing Toll-7Cys-Tyr in all neurons in DNT1 mutants, and Toll-6Cys-Tyr neurons of DNT2
mutants reduces the amount of apoptosis to below control levels. Mean cells shown
+/- SEM, numbers given in bars, *p<0.05 ***p<0.001 Students t-test. Full genotpyes
in (D), from left to right are yw, DNT141elavGal4 x UASToll-7Cys-Tyr;DNT141,
DNT2e03444elavGal4 x Df6092UASToll-6Cys-Tyr/TM6BlacZ.
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and Toll-6 are necessary for normal development and function of the Drosophila CNS, and 
these data are consistent with them serving as DNT receptors. 
I observed a locomotion phenotype in Toll-7 and Toll-6 single and double mutant adult flies, 
but I am unable to attribute the effects to a specific adult function. The phenotype may be due 
to an underlying developmental defect, which is manifested in the behaving adult. Equally, I 
cannot directly attribute the adult phenotype to the specific developmental defects identified 
in mutant embryos, since during metamorphosis, the Drosophila nervous system undergoes 
extensive remodelling (Tissot and Stocker, 2000). Moreover, the axon targeting defects that I 
identified were to muscles that go on to form the larval body wall. The motor neurons that 
target the adult legs first arise in the larva, and the central complex that controls locomotion 
behaviour forms in the pupa (Baek and Mann, 2009, Pereanu et al., 2011). It is therefore 
unclear whether the behavioural phenotypes are due to loss of Toll-7 and Toll-6 in the adult 
CNS, or result from a nervous system that is dysfunctional because of defects in development. 
Adult Toll-7 and Toll-6 mutant flies do not travel as far as yw controls over the same amount 
of time, and this is partly due to a reduction in walking speed. This could be due to a reduced 
contractility of muscle fibres. However, reduced walking speed coupled with increased time 
resting is reminiscent of the behavioural phenotypes of flies with a defective central complex 
(Strauss and Heisenberg, 1993). Both Toll-7 and Toll-6 are expressed in the adult brain, in 
cells surrounding the central complex, and could therefore be important in the central control 
of locomotion. Alternatively, the expression of both genes in a broad range of brain regions 
might point to a more global neurological deficit. Interestingly, Toll-7 is expressed in clusters 
of cells in the larval VNC that could correspond to the developing motor neurons of the leg, 
which are present in larval stages (Truman, 1990). A potential role for Toll-7 in adult motor 
neurons could also be contributing to the locomotion phenotype. 
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Toll-7 and Toll-6 are required for the normal targeting of the ISNb nerve branch to muscles 6, 
7, 12 and 13. Like all neurons, ISNb projections are subject to various long- and short-range 
guidance cues (Tessier-Lavigne and Goodman, 1996, Dickson, 2002). ISNb is also a well-
studied nerve branch, and genes identified that permit axon targeting include extracellular 
matrix components, extracellular proteases, cell recognition molecules, receptor phosphatases, 
and transcription factors (Meyer and Moussian, 2009, Serpe and O'Connor, 2006, Abrell and 
Jäckle, 2001, Sun et al., 2001, Desai et al., 1997, Madden et al., 1999). The role of the Toll 
receptor in axon targeting has also been studied. Toll was reported to act non-cell-
autonomously in neurons to inhibit axon targeting, and to regulate motor neuron number and 
muscle fibre development (Rose et al., 1997, Halfon et al., 1995). However, Toll expression 
has since been demonstrated in embryonic neurons (Sutcliffe et al., Submitted), making it 
likely that Toll also functions cell-autonomously. Toll-7 and Toll-6 are also expressed in 
neurons, and are therefore acting cell-autonomously to promote axon targeting. 
The misrouting phenotypes of Toll-7 and Toll-6 mutants are strongly reminiscent of those 
seen in DNT1 and DNT2 mutants (Zhu et al., 2008). The morphologies of aberrant ISNb 
projections in Toll-7 and Toll-6 mutants were similar to those in DNT mutants: projections to 
incorrect muscles or neighbouring hemisegments, formation of axon loops, and of losses of 2 
or more projections. Loss of DNT1 more severely affected ISNb than loss of DNT2, and 
double mutants showed significantly more misrouting than either single mutant (Zhu et al., 
2008). Toll-7 phenocopies DNT1 in the lethality assay of genetic interaction. Similarly, Toll-7 
mutants show a stronger misrouting phenotype than Toll-6 mutants, and the double mutants 
are still more severe. GFP driven by Toll-7-Gal4 specifically labels the ISNb nerve branch, so 
it is not surprising that Toll-7 mutants show a phenotype in these axons. Therefore, the axon 
guidance phenotypes and lethality phenotypes are in accordance, and point to an interaction of 
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DNT2 with Toll-6 and DNT1 with Toll-7. To strengthen this, the SNa nerve branch could be 
examined for misrouting phenotypes in Toll-7 and Toll-6 mutants. It has been shown that loss 
of DNT2 has a stronger effect on SNa misrouting than loss of DNT1 (Zhu et al., 2008). 
In the previous chapter, I generated two versions of constitutively active Toll-7 and Toll-6: the 
ΔLRR form and the Cys-Tyr form. When rescuing lethality, they behaved similarly. 
However, when they were expressed in neurons in the embryonic CNS, only the Cys-Tyr 
versions were able to reduce the levels of apoptosis. This was an unexpected result, and 
indicates that two types of receptor are not functioning in the same way. This could be due to 
differences in the way the two proteins are expressed: the truncated forms might not be 
optimally transcribed of translated, or they might be accumulating within the cell. 
Alternatively, they might be downregulated or rapidly removed from the membrane before 
they can have an effect on cell survival, but are able still able to influence animal viability. 
Cell survival and animal viability might reflect separate aspects of Toll signalling. 
Importantly, the lethality assay involves counting pupae, which is a much later stage of 
development than the embryos assayed here: this could also affect how the transgenes affect 
different phenotypes. 
During the course of the project, the different activated receptor versions were made at 
different times. Similarly, the generation of fly lines used in cell death rescue experiments 
took some time. Consequently, apoptosis assay experiments were carried out in two batches. 
Inevitably, the properties of the confocal laser change over time, which affects the detection 
of immunolabelling. To negate this effect, a yw control sample was tested for each batch of 
experiments. Both of the control counts of apoptotic cells that I obtained are in accordance 
with the 110-120 range found by other members of the lab (Pennack, 2008, Sutcliffe, 2010). 
The fact that the increases in apoptosis seen in Toll-7P8/P114 and Toll-626/31 compared to their 
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control are mirrored by the increase seen in Toll-7P8/DfBSC22 and Toll-626/DfXG4 compared to 
their own control, further validates this approach. 
Loss of Toll-7 and Toll-6 resulted in increased cell death in the embryonic VNC compared to 
controls; however the changes observed were somewhat modest. It is possible that Toll-7 and 
Toll-6 are compensating for each other in these single mutants, and that the double mutant 
would show a stronger phenotype. This was the case with axon guidance, where the Toll-
7Toll-6 double mutant showed the strongest phenotype. The potential for redundancy could 
also explain why the DNT1 and DNT2 mutants show a greater amount of cell death compared 
to Toll-7 and Toll-6. Similarly, there is more apoptosis in spz2 mutants than in Tollr3/Dfro80b 
mutants (Zhu et al., 2008). Nevertheless, the increases in apoptosis seen here are broadly 
comparable to those produced previously in the lab (Zhu et al., 2008). Equally, the relatively 
subtle effect of activating Toll-7 and Toll-6 is similar to previous results following activation 
of Toll (Zhu et al., 2008). 
There is extensive cell death in the Drosophila embryonic CNS, and in some contexts this 
may be pre-determined (White et al., 1994, Rogulja-Ortmann et al., 2007, Miguel-Aliaga and 
Thor, 2009). This could mean that not all cells are subject to a non-cell-autonomous control of 
survival. However, it is clear that neurotrophism is an important aspect of the development of 
the fly’s CNS (Hidalgo, 2002, Hidalgo et al., 2006, Zhu et al., 2008). Importantly, all results 
here are significant, and the ability of Toll-7 and Toll-6 to modulate neuronal survival 
demonstrates that cell number is plastic. 
Toll-7 and Toll-6 are both necessary and sufficient for cell survival in the developing CNS. 
Toll-7 and Toll-6 show the same loss- and gain-of-function phenotypes as DNT1 and DNT2 
indicating that they serve common functions (Zhu et al., 2008). The rescue of DNT1 and 
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DNT2 by neuronal expression of Toll-7Cys-Tyr and Toll-6Cys-Tyr, respectively, shows that the 
ligands and the receptors share a common signalling pathway. Moreover, the rescue data 
indicate that Toll-7 and Toll-6 act downstream of the DNTs. This is consistent with them 
functioning as DNT receptors. 
Altogether, in this chapter I have shown that Toll-7 and Toll-6 carry out important functions 
in the CNS. During development, they control cell survival and targeting, and they are 
required for locomotion behaviour in the adult. The phenotypes of Toll-7 and Toll-6 mutants 
closely resemble those of DNT1 and DNT2 mutants. In addition, mutant alleles of Tolls and 
DNTs interact, and activated Toll receptors rescues DNT mutant phenotypes. With 
overlapping and complementary patterns of expression, Toll-7 and Toll-6 could function as 
DNT receptors. In the next chapter, I will test this directly, by carrying out signalling assays 
in cell culture. 
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CHAPTER 6 
DNT1 AND DNT2 ACTIVATE NFΚB SIGNALLING 
THROUGH TOLL-7 AND TOLL-6 
 
6.1 Introduction 
Toll-7 and Toll-6 are expressed in the Drosophila CNS, and are required for neuronal survival 
and targeting. The Tolls genetically interact with the DNTs, and constitutively active receptors 
rescue DNT mutant phenotypes. My aims in this chapter were to test in cell culture whether 
Toll-7 and Toll-6 signal through NFκB, and whether they can be activated by DNT1 and 
DNT2. By testing the effect of each DNT on cells expressing either Toll receptor, I aimed to 
test ligand-receptor interactions. 
There are a number of ways to test whether two proteins function as a ligand-receptor pair. 
Competition binding assays can be carried out in cell culture, but this does not prove that 
binding is functional. Similarly, in vitro assays such as surface plasmon resonance can 
demonstrate protein-protein interactions, but again this does not produce functional evidence. 
Testing signalling in cultured cells has the advantage that the read-out of ligand binding 
demonstrates a functional interaction. Given that the read-out of NFκB signalling can also be 
complemented with in vivo tests, this was considered the best approach. I therefore tested 
whether DNT1 and DNT2 can activate NFκB signalling through Toll-7 and Toll-6. 
In order to investigate whether DNT1 and DNT2 can signal through Toll-7 and Toll-6 in 
cultured cells, it is first necessary to obtain recombinant DNT protein. DNT1, DNT2 and Spz 
possess a cystine-knot (CK) domain that is structurally homologous to neurotrophin family, 
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and an N-terminal pro-domain (DeLotto and DeLotto, 1998, Mizuguchi et al., 1998, Zhu et 
al., 2008). To signal, the CK of Spz is cleaved from the pro-domain by Easter or SPE in vivo 
(DeLotto and DeLotto, 1998, Jang et al., 2006), and it is likely that DNT1 and DNT2 
maturation also involves the cleavage of their CK from the pro-domain. DNT1 possesses an 
additional domain C-terminal to the cys-knot (CTD), also called DNT1 CK+3’ (Zhu et al., 
2008, Sutcliffe et al., Submitted). It is unclear whether this extra domain remains with the CK 
or is also endogenously cleaved. Both the CK and the CK + CTD proteins are functional in 
vivo, though they can produce different results in different experimental paradigms (Pennack, 
2008, Sutcliffe, 2010). 
Functional DNT1 and DNT2 CKs can be expressed in vivo under the Gal4/UAS system, as 
can the CK of Spz (Zhu et al., 2008, Hu et al., 2004). However, in cell culture experiments, 
the Spz pro-domain is required for the expression and secretion of a functional protein (Weber 
et al., 2007). Recombinant full-length Spz protein can be produced in E. coli, or by using the 
Baculovirus expression system (Hoffmann et al., 2008, Weber et al., 2003, DeLotto and 
DeLotto, 1998). Alternatively, small quantities of DNT protein can be produced in 
Drosophila S2 cells transfected in a 6-well plate (Arnot et al., 2010). The advantage of 
Baculovirus expression is that it uses insect cells to generate protein which is folded and 
secreted into the cell supernatant, and can be harvested under native conditions. It is therefore 
more likely to yield a protein that shows correct folding. 
During dorsoventral patterning, Toll signalling leads to the activation of Dorsal, an NFκB 
homologue (Moussian and Roth, 2005). In the innate immune response, Toll also activates 
Dif, and Dorsal and Dif can act redundantly in some contexts (Manfruelli et al., 1999, Meng 
et al., 1999). Both dorsal and Dif are expressed in the nervous system (Cantera et al., 1999, 
Mindorff et al., 2007). Toll-7 and Toll-6 share the same intracellular domain as Toll, so it is 
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most likely that they also signal through these NFκB homologues. Indeed, elavGal4>Toll-7ΔLRR 
and elavGal4>Toll-6ΔLRR rescue the spz2 mutant semi-lethality, and elavGal4>Toll10b rescues 
the DNT141DNT2e03444 mutant semi-lethality, providing further evidence that Tolls share 
intracellular signalling pathways (see Chapter 4). 
NFκB signalling can be measured using two methods: testing for nuclear localisation of 
NFκB protein, or with the use of reporter plasmids. When Dorsal is activated, it translocates 
to the nucleus, following the phosphorylation and degradation of Cactus (Rushlow et al., 
1989, Steward, 1989, Roth et al., 1989, Verma et al., 1995). Expressing Toll10b in cell culture 
activates Dorsal, and this can be quantified by visualising the nuclear localisation of Dorsal by 
immunocytochemistry (Kubota et al., 1993). Alternatively, the use of a reporter plasmid can 
be used to quantify NFκB signalling in cultured cells. The most convenient reporter is 
Luciferase, and kits are commercially available for the quantification of Luciferase activity, 
using luminescence as a read-out. To measure Dorsal activity, a number of reporters are 
available, including zen-Luciferase, snail-Luciferase, and twist-Luciferase (Reach et al., 1996, 
Ratnaparkhi et al., 2008). It has been shown previously that the most responsive reporter to 
Dorsal is snail-Luciferase, and the strength of the luminescence signal can be augmented by 
adding dorsal cDNA (Ratnaparkhi et al., 2008). To measure Dif activation, a drosomycin-
Luciferase reporter can be used (Tauszig et al., 2000). An advantage of the drosomycin 
reporter is the availability of a S2 cell line stably-transfected with this plasmid (Weber et al., 
2003). In experiments using either snail-Luciferase or drosomycin-Luciferase, a control 
plasmid is also transfected: actin-Renilla. This plasmid encodes the Renilla Firefly gene, and 
is constitutively expressed under the actin promoter. Renilla Firefly activity is also measured 
by luminescence, but it uses a different substrate and requires different buffer conditions. In 
this way, the Firefly and Renilla readings can be obtained independently. By co-transfecting 
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with actin-Renilla, which does not respond to Dorsal or Dif, experimental Firefly readings 
can be normalised, which takes into account differences in transfection efficiency and cell 
number. 
6.2 Results 
6.2.1 Expression of recombinant DNT1 
To express DNT1 protein using the Baculovirus system, cDNA was first cloned into pFastBac 
vectors, and then shuttled in to the Baculovirus bacmid using the Bac-to-Bac method using 
DH10Bac E. coli (Invitrogen) (see materials and methods). The isolated bacmid was then 
given to the Baculovirus Facility at the Department of Biochemistry, University of 
Cambridge, who carried a time-course of expression from two cell lines. The Baculovirus 
facility then returned samples of cell pellets and supernatants generated during the time-
course. To test for the production of DNT protein, the supernatant samples were tested by 
western blot, probing for the His-tag included in the constructs. Only the supernatants were 
assayed for presence of His-tagged DNT1. For the protein to be functional, it must be folded 
correctly, and subsequently secreted from the cells. Protein that accumulates in inclusion 
bodies is likely to be misfolded, and therefore not suitable for cell signalling assays. Protease 
recognition sequences were included in expression constructs, so that the pro-domain could be 
cleaved from the CK to generate mature DNT proteins. Expression of DNT proteins using 
Baculovirus was undertaken in collaboration with Dr Jukka Aurikko and Prof Nick Gay at the 
Department of Biochemistry, University of Cambridge. 
To produce mature DNT1 protein, I first generated constructs encoding DNT1 CK and DNT1 
CK+CTD. In flies, the CK and the CK+CTD can be expressed without the endogenous pro-
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domain (Zhu et al., 2008). So that the protein would be secreted from cells, and could be 
identified by western blot, an exogenous EGT signal peptide (SP) and protein tags were 
included at the N-terminal. The final constructs therefore encoded: EGT SP–FLAG-His-
Thrombin–DNT1 CK and EGT SP–FLAG-His-Thrombin–DNT1 CK+CTD. However, 
western blot of all the supernatant samples from the time-course failed to detect any His-
tagged DNT protein (Fig 6.1B). Since Spz requires its pro-domain to be expressed in cultured 
cells (Weber et al., 2007), a construct was cloned that contained the endogenous DNT1 Pro-
domain + CK. Evidence from our lab has shown previously that the CTD can be 
spontaneously cleaved in cell culture (Zhu et al., 2008). Therefore, to ensure the His-tag 
remained with the CK, it was placed at the C-terminal of the CK, and the CTD was removed, 
resulting in DNT1 Pro+CK–TEV-His. However, none of the DNT1 Pro+CK time-course 
supernatant samples contained a His-tagged protein detectable by western blot (Fig 6.1B). My 
collaborators routinely produce recombinant Spz using the Baculovirus system, with a 
construct encoding the Spz pro-domain, followed by a His-tag and TEV protease sequence, 
with the Spz CK at the C-terminal (Weber et al., 2003). Using this as a template, the DNT1 
CK+CTD was cloned and substituted for the Spz CK. The resultant construct was: Spz Pro–
His-TEV–DNT1 CK+CTD. However, once again, His-tagged protein could not be detected in 
supernatant samples from the Baculovirus time-course (Fig 6.1B). Another member of the 
Gay lab, Dr Chris Arnot, produced smaller quantities of Spz protein in cells cultured in a 6-
well plate, which were sufficient for signalling assays (Arnot, 2009). I therefore cloned a full-
length DNT1 construct suitable for protein expression from small cultures of S2 cells. The 
final construct contained the endogenous pro-domain, a TEV protease sequence, His and V5 
tags, and the CK + CTD. To test for the production and secretion of DNT1 from S2 cells, a 
sample from transfected cells was tested by western blot, probing for the presence of a       
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V5-tagged protein. V5-tagged DNT1 was detected as a band of ≈40kDa (Fig 6.1C). This size 
is consistent with the CK and the CTD remaining together after expression. The predicted size 
of the CK+CTD according to the amino acid sequence is ≈46kDa, also seen previously in our 
lab (Zhu et al., 2008). The reduced size could reflect a partial proteolysis of the C-terminal of 
the protein, since the V5 tag is attached to the DNT1 CK at its N-terminal. 
6.2.2 Expression of recombinant DNT2 
As with DNT1, constructs encoding DNT2 were generated for expression using the 
Baculovirus system and from S2 cells. To produce mature DNT2, a construct was generated 
that included an EGT signal peptide, FLAG and His tags, and a thrombin protease N-terminal 
to the DNT2 CK. Baculovirus was then made which contained the EGT SP–FLAG-His-
Thrombin–DNT2 CK construct, and given to the Baculovirus facility for generation of time-
course samples. However, none of the supernatant samples yielded a His-tagged protein 
detectable by western blot (Fig 6.2B). Next, a full-length DNT2 construct was made, with C-
terminal TEV and His sequences, which included the endogenous pro-domain. Again, the 
supernatant samples from the Baculovirus time-course were probed by western blot for the 
presence of His-tagged protein. On this occasion, protein was detected as a band of ≈41kDa, 
which corresponds to the size of full-length DNT2 (Fig 6.2B). According to the time course 
samples, the optimum conditions for expression of DNT2 with Baculovirus are using Sf9 
cells, using a multiple of infection of 10, and culturing the cells for 4 days before protein 
purification. Finally, a construct was made for expression of full-length DNT2 from small 
cultures of S2 cells. Similarly to DNT1, this placed TEV and tag sequences between the pro-
domain and CK of the protein, resulting in DNT2 Pro–TEV-His-V5–DNT2 CK. This was 
transfected into S2 cells, and the supernatant was probed for the presence of V5-tagged 
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protein by western blot. V5-tagged DNT2 was detected as a band of ≈13kDa (Fig 6.2C). This 
size corresponds to the tagged DNT2 CK, and suggests that the pro-domain is spontaneously 
cleaved under these culture conditions. 
6.2.3 Expression and purification of DNT2 using Baculovirus 
Protein expression with Baculovirus, and the subsequent investigation of recombinant DNT2 
protein, was carried out in collaboration with Dr Jukka Aurikko and Prof Nick Gay at the 
Department of Biochemistry, University of Cambridge. To produce recombinant DNT2 on a 
large scale, 2l cultures of Sf9 cells were infected, and protein purification was carried out after 
4 days (see Section 2.4.1, materials and methods). To test whether DNT2 was purified, a 
sample of the eluate was run on SDS-PAGE, alongside a sample of the original supernatant. 
All protein was stained with Coomassie. In the original supernatant, there were no specific 
proteins visible. In the purified sample, which had been significantly concentrated from the 
original supernatant, specific protein species were visible. Protein corresponding to full-length 
DNT2 was barely detectable at 41kDa. Instead, proteins of ~13kDa and ~28kDa were seen 
(Fig 6.3A). To identify these proteins, they were blotted to a PVDF membrane and sent for 
Edman sequencing of their N-terminals at the Protein and Nucleic Acid Chemistry Facility, at 
the Department of Biochemistry, University of Cambridge. The N-terminal sequence of the 
28kDa fragment was ‘HSSPPPCGLY’, which is found at the start of the DNT2 pro-domain 
after removal of the signal peptide (Fig 6.3B, C). The N-terminal sequence of the 13kDa 
fragment was ‘S/HPGRXT’, which aligns to ‘SPGRST’, found in DNT2 just upstream of the 
six conserved cysteine residues that comprise the CK (Fig 6.3B, C). These results show that 
the 28kDa protein is the DNT2 pro-domain and the 13kDa protein is the DNT2 CK, and that 
they are most likely spontaneously cleaved under Baculovirus expression conditions. To 
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remove the pro-domain, a sample of the purified DNT2 was treated with 1:100 Trypsin for 
30mins at 37°C. This effectively degraded the pro-domain, and left the 13kDa CK intact (Fig 
6.4A). Under non-reducing conditions, the protein was detected as ~26kDa, indicating that the 
CK normally exists as a disulphide-linked dimer (Fig 6.4A). Trypsin treatment could also 
damage the CK, so an alternative method was sought that could separate the two purified 
domains under less harsh conditions. To do this, the purified protein sample was passed 
through a size-exclusion column. This fractionates the proteins according to molecular 
weight. Protein is detected as it exits the chromatography column by UV absorbance at 
280nm. In the purified sample, DNT2 CK had the lowest molecular weight, and was therefore 
anticipated to elute last. To identify the protein eluting in the final fractions, samples were run 
on SDS-PAGE and stained with Coomassie (Fig 6.4B). The final fractions contained a 
number of protein species, which was contrary to the expectation that proteins would elute 
according to size. The largest protein, approximately 75kDa, was an unidentified contaminant 
that also appeared in the time-course and purified samples. The three strongest bands were 
~41kDa, ~28kDa and ~13kDa (Fig 6.4B). These sizes correspond to the full-length DNT2, the 
pro-domain, and the CK. The proteins ran at the same molecular weight under native 
conditions (through the size-exclusion column), but separated into three species under 
denaturing, reducing conditions (SDS-PAGE). This is consistent with the DNT2 CK being 
cleaved from the pro-domain, but them remaining attached under native conditions. Under 
denaturing conditions, the pro-domain and CK dissociated and were detected separately. 
Some full-length DNT2, which remained uncleaved, was detected as a band at the predicted 
41kDa. This indicates that the fraction collected from the size-exclusion column corresponded 
to ~41kDa, and included cleaved and intact DNT2 protein. Altogether, DNT2 can be 
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produced using Baculovirus. The full-length protein is spontaneously cleaved to yield the pro-
domain, and the dimerising CK. 
6.2.4 Expression of Toll-7 and Toll-6 in S2 cells 
To test whether DNTs can activate Toll-7 or Toll-6 signalling, it is first necessary to express 
the receptors in S2 cells, and test whether they are targeted to the membrane. Wild-type Toll-7 
and Toll-6 receptors with C-terminal HA tags were expressed in cells using the pAct-Toll-7-
HA and pAct-Toll-6-HA plasmids (see Sections 3.2.1 and 3.2.6, Chapter 3). To test whether 
the proteins can be detected at the membrane, S2 cells were transfected, and after 48 hours 
were fixed and labelled with anti-HA. Fig 6.5 shows that, although there was cytoplasmic 
signal, both Toll-7 and Toll-6 localised to the membrane in S2 cells. 
6.2.5 Constitutively active Toll-7 and Toll-6 signal through NFκB 
To confirm that Toll-7Cys-Tyr and Toll-6Cys-Tyr are functional as constitutively active receptors, 
and to test whether they signal through NFκB, I tested whether their expression in S2 cells 
can induce the activation of NFκB reporter plasmids. Activation of Dorsal was tested by 
transfecting S2 cells with the snail-Luciferase reporter, Dif activation was tested in cells 
stably transfected with the drosomycin-Luciferase reporter. Activated receptors were 
transfected using pUAS-Toll-7Cys-Tyr and pUAS-Toll-6Cys-Tyr (see materials and methods). The 
expression of the activated receptors was therefore under the control of Gal4. By co-
transfecting pMT-Gal4, the expression of Gal4 could be activated by adding 1mM CuSO4 to 
the cell medium, which binds the metallothionine promoter. Thus, expression of Toll-7Cys-Tyr 
and Toll-6Cys-Tyr was induced by adding Cu2+ to cultured cells. To test whether the expression 
of activated receptors can activate NFκB, the reporter activity in cells in which expression 
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was induced by Cu2+ was normalised against cells not receiving Cu2+. This generated a 
relative Luciferase value, which indicated the effect of inducing gene expression with Cu2+. 
The relative Luciferase activity of cells transfected with both pMT-Gal4 and pUAS-Toll-7Cys-Tyr 
or pUAS-Toll-6Cys-Tyr was compared to cells transfected with only the pMT-Gal4 or only the 
pUAS plasmid. These singly-transfected cells, and cells transfected with an empty pDONR 
vector, served as negative controls, since there was no expression of activated receptors 
(green bars, Fig 6.6A, B). 
When Toll-6Cys-Tyr and Toll-7Cys-Tyr expression was induced in cells carrying the snail-
Luciferase there was a modest but significant increase in the Luciferase activity compared to 
negative control (Fig 6.6A). Toll-6Cys-Tyr and Toll-7Cys-Tyr also induced the activation of 
drosomycin-Luciferase (Fig 6.6B). The small increase in Luciferase activity in cell expressing 
only pMT-Gal-4 is not significantly different from cells transfected with the empty pDONR 
vector (p=0.17). These results confirm that the Cys-Tyr activated receptors are functional. 
The activation of both NFκB reporters also shows that Toll-7 and Toll-6 can signal through 
Dorsal and Dif. 
6.2.6 DNT1 activates NFκB via Toll-7 
To test whether DNT1 can signal through Toll-7 or Toll-6 to activate Dorsal, recombinant 
protein was added to S2 cells expressing wild-type receptors, and NFκB activity was 
quantified using the snail-Luciferase reporter. The DNT1 CK+CTD protein purified from S2 
cell expression used was. Because the amounts of DNT1 produced by S2 cells was small, and 
consequently the purification process was not highly stringent, a reliable concentration of 
DNT1 protein could not by obtained. Therefore, all of the protein purified from one 6-well 
plate culture was used in each batch of experiments. S2 cells were transfected with Toll-7 or 
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Toll-6 expression plasmids, snail-Luciferase, and the actin-Renilla control plasmid, and 
cultured for 48 hours. dorsal cDNA was co-transfected, to increase the snail-Luciferase 
signal. DNT1 CK+CTD was added to the cells, and the Luciferase assay was carried out after 
24 hours. However, adding DNT1 did not induce the activation of the snail-Luciferase in cells 
expressing Toll-7 or Toll-6 (Fig 6.7). 
An alternative way to test for the activation of Dorsal is to visualise the localisation of Dorsal 
protein within a cell, by immunocytochemistry. S2 cells were transfected with wild-type Toll-
7 or Toll-6, and cultured for 48 hours. Because Dorsal is normally expressed at very low 
levels in S2 cells, dorsal cDNA was co-transfected into cells to be able to detect it by 
immunostaining. DNT1 CK+CTD purified from S2 cell expression was added, and cells were 
fixed and labelled with anti-Dorsal after 90 minutes.  Cells were examined by confocal 
microscopy, and the localisation of Dorsal was recorded. Dorsal was determined to be nuclear 
if there was strong signal in the nucleus (identified by DAPI co-staining), and signal excluded 
from the cytoplasm (Fig 6.8A). The percentage of cells expressing Toll-7 or Toll-6 with 
nuclear Dorsal, compared to non-nuclear, was then recorded. DNT1 CK+CTD slightly 
increased the nuclear localisation of Dorsal in S2 cells expressing Toll-6, although this was 
not statistically significant (Fig 6.8B). In cells expressing Toll-7, DNT1 CK+CTD 
significantly induced the proportion of cells with nuclear Dorsal (Fig 6.8B). This shows that 
DNT1 can activate Dorsal signalling, through at least Toll-7. 
To test whether DNT1 could also activate Dif through Toll-7 or Toll-6, recombinant protein 
was added to cells that carried a Dif reporter plasmid. Wild-type Toll-7 or Toll-6 was 
transfected into stably-transfected drosomycin-Luciferase cells, with the actin-Renilla control 
plasmid. Cells were cultured for 48 hours, and DNT1 CK+CTD purified from S2 cell 
expression was added. After 24 hours, the Luciferase activity was assayed. In cells transfected 
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with the empty pDONR vector or with pAct-Toll-6, DNT1 CK+CTD had no effect. In cells 
expressing Toll-7, DNT1 CK+CTD produced a significant increase in Luciferase activity 
compared to cells treated with PBS (1.9-fold increase in luminescence, p<0.05) (Fig 6.9). This 
shows that DNT1 can activate Dif signalling through Toll-7. 
6.2.7 DNT2 activates NFκB via Toll-7 and Toll-6 
To test whether DNT2 can also activate NFκB through Toll-7 or Toll-6, the stably-transfected 
drosomycin-Luciferase cell line was used to test for activation of Dif. DNT2 CK, purified 
from Baculovirus was used. Since the protein was produced in large amounts, and was 
relatively pure, a reliable concentration of DNT2 protein could by obtained, and therefore a 
set amount of DNT2 could be added to cells. S2 cells, stably transfected with drosomycin-
Luciferase, were also transfected with pAct-Toll-7 or pAct-Toll-6, as well as the actin-Renilla 
control plasmid. After 48 hours, 50nM DNT2 CK was added, and Luciferase activity was 
determined after a further 24 hours. Adding DNT2 CK to cells transfected with the empty 
pDONR vector, but without Toll-7 or Toll-6, increased the amount of Luciferase activity 
compared to PBS-treated cells (Fig 6.9). This suggests that DNT2 can activate Dif through 
proteins endogenously expressed in S2 cells. When either wild-type Toll-7 or Toll-6 was 
expressed in S2 cells, addition of DNT2 CK also resulted in a strong induction of the 
Luciferase reporter (Fig 6.9). Moreover, adding DNT2 CK increased Luciferase activity more 
in cells expressing either Toll-7 or Toll-6, compared to cells transfected with pDONR. This 
indicates that DNT2 can signal through Toll-7 and Toll-6 to activate Dif. 
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6.3 Discussion 
In this chapter, I have used cell culture to demonstrate that Toll-6 and Toll-7 can signal 
through NFκB. Expressing DNT1 using Baculovirus and in S2 cells revealed that the pro-
domain and the CTD are both required for the secretion of DNT1 from cultured cells. It is 
likely that DNT1’s pro-domain is also spontaneously cleaved, and that the CTD remains 
attached to the CK (see also Zhu et al., 2008). Using the Baculovirus expression system, I 
have produced recombinant DNT2 protein. Similarly to DNT1, the pro-domain is required for 
secretion of DNT2 from cultured insect cells. The CK is spontaneously cleaved from the pro-
domain in vitro, though biochemical data are consistent with the two peptides remaining 
associated under native conditions. DNT1 signalled through Toll-7 to induce the nuclear 
localisation of Dorsal and the activation of a Dif reporter plasmid. DNT2 signalled through 
both Toll-7 and Toll-6 to activate Dif signalling.  
Expressing constitutively active Toll-7 and Toll-6 in S2 cells lead to the activation of 
reporters of both Dorsal and Dif activity. The effects seen were modest, although they were 
significant. Given more time, I could have better optimised the conditions for this experiment; 
it is likely that transfection conditions could be improved, particularly given the large number 
of plasmids involved in each transfection. One strategy to improve this could be to establish 
cells lines stably transfected with all of the common plasmids, reducing the amount of DNA 
needed for transient transfections. It is interesting to note that Toll-7Cys-Tyr produced a stronger 
effect than Toll-6Cys-Tyr. It is not clear why the two paralogues should have behaved 
differently in this context, when they produced similar results in the rescue of cell death and 
lethality. It is known that Toll can activate both Dif and Dorsal, and the choice of NFκB 
paralogue used depends on the context (Manfruelli et al., 1999, Meng et al., 1999). Equally, 
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Toll-9 has also been shown to activate Dif (Ooi et al., 2002), and Toll-8 (Tollo) can interact 
with Relish (Ayyar et al., 2007). It is therefore not surprising that Toll-6 and Toll-7 can signal 
through NFκB. Whether the receptors employ Dif or Dorsal in vivo is likely to depend on the 
cell type and context. 
The effects on NFκB signalling of DNT1 and DNT2 are not comparable. DNT2 was obtained 
using the Baculovirus system, in large quantities with high purity. DNT1 was obtained from 
small-scale cultures of S2 cells, and was not purified in sufficient quantities to be visible on a 
Coomassie-stained protein gel. Producing recombinant DNT1 protein was not as simple as 
initially anticipated. By the time the optimum arrangement of protein domains was discovered 
for expression in S2 cells, there was not enough time to express it in larger quantities using 
Baculovirus. I would anticipate that, had I obtained Baculovirus-expressed DNT1, the data 
relating to the effect of DNT1 on S2 cells may have been statistically significant, less 
equivocal, and comparable to those obtained with DNT2. However, in the attempt to express 
and purify DNT ligands, some of their biochemical characteristics have been revealed. 
In vivo, functional CK isoforms of Spz, DNT1 and DNT2 can be expressed without the 
endogenous pro-domain (Hu et al., 2004, Zhu et al., 2008). However, attempts to directly 
produce DNT1-CK and DNT2-CK in cultured insect cells using the Baculovirus system did 
not yield any protein. Mature DNT2 was only purified from culture supernatant when the full-
length construct was expressed. In the case of DNT1, the endogenous pro-domain and CTD 
were both required for the expression and secretion of the mature protein. The requirement of 
the pro-domain for secretion in the Baculovirus expression paradigm is also seen with Spz 
(Weber et al., 2007). Similarly, the pro-domain is necessary for the expression and secretion 
of the Spz homologue, NGF, from cultured cells (Suter et al., 1991). Moreover, the secretion 
of different vertebrate neurotrophins is regulated by their pro-domains: mature NGF is 
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secreted from cultured cells when expressed with its endogenous pro-domain, but is retained 
in cells when fused to the BDNF pro-domain (Nomoto et al., 2007). This suggests that the 
secretion of Spz homologues can be regulated by interactions with the pro-domain, and may 
explain why DNT1 CK+CTD was not detectable when fused to the Spz pro-domain. 
DNT expression clones were generated that included either a TEV or Thrombin protease 
recognition sequence. It was anticipated that the pro-domain would remain attached to the 
CK, and that a directed proteolysis would be required to yield mature DNT protein, since this 
is the case with Spz (Weber et al., 2003). However, biochemical analysis of purified DNT 
proteins suggest that the pro-domains are spontaneously cleaved from these Spz paralogues. 
When full-length DNT1 was expressed in S2 cells, the size of the V5-tagged protein detected 
by Western blot corresponded to the cys-knot plus much of the CTD. While both the pro-
domain and the CTD are required for protein secretion, the persistence of the CTD suggests 
that it could play a role in DNT1 signalling. The long CTD is unique to DNT1 within the Spz 
family, however it is conserved between invertebrate species, which could also indicate that it 
is functionally important (Parker et al., 2001, Wilson, 2009). In vivo, both DNT1 CK and 
DNT1 CK+CTD can promote cell survival (Zhu et al., 2008). However, in axon targeting, at 
the larval NMJ, and in behavioural assays, expression of DNT1 CK+CTD gave clearer 
phenotypes (Pennack, 2008, Sutcliffe, 2010). Therefore, the CTD of DNT1 is functionally 
important, and is a characteristic unique to DNT1 within the neurotrophin family. 
When full-length DNT2 was expressed using Baculovirus, the CK was spontaneously cleaved 
from the pro-domain, which separated on a reducing, denaturing gel. Under native conditions, 
through a size-exclusion column, the cleaved pro-domain and cys-knot eluted in the same 
fractions as the intact full-length DNT2. This suggests that after cleavage, the pro-domain and 
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cys-knot could remain attached. Similarly, the pro-domain and CK of Spz remain together 
after cleavage, and separate on binding to Toll (Weber et al., 2007). In Spz, this is due 
interaction of charged residues on the pro-domain and CK (Arnot et al., 2010), though it is 
unclear if the same happens with DNT2. 
The effect of DNT1 on Luciferase reporters in S2 cells was very weak. As mentioned above, 
this is probably due to the quality of the recombinant DNT1 protein obtained. There was only 
enough time to produce DNT1 on a small scale, using S2 cells. The total amount of DNT1 
secreted into the cell medium would have been relatively small from the outset. And the 
methods of purifying protein from these small volumes were more likely to result in protein 
loss, compared to Baculovirus-expressed protein: for example, using NiNTA spin columns 
with small volumes, compared to 1 hour incubation with NiNTA-agarose with Baculovirus. 
Moreover, although the purification process isolated DNT1 from most of the protein 
contaminants in the supernatant, the level of purity was likely to be much lower than 
Bacolvirus-produced DNT2. To mitigate this, each time the experiment was repeated, a fresh 
batch of DNT1 was produced, and all of the protein was used up on each occasion. In this 
way, the maximum amount of DNT1 was added to the cells as was possible. However, either 
because of a small amount of DNT1, or a larger amount of contaminating protein, the effects 
seen with DNT1 are much smaller than those of DNT2. Given more time, I would return to 
the Baculovirus system to produce DNT1 in large quantities. This would be likely to greatly 
improve the strength of the response of Luciferase reporters in S2 cells to DNT1. Because the 
effects of DNT1 were less robust than those of DNT2, I looked at an additional measure of 
NFκB activation. The induction of nuclear localisation of Dorsal protein, together with the 
activation of the drosomycin-Luciferase reporter, show that DNT1 can activate NFκB 
signalling through Toll-7. 
125 
 
DNT2 is able to significantly activate drosomycin-Luciferase in S2 cells, even when no Toll 
receptor was transfected. The same effect is seen when Spz is added to S2 cells that have not 
been transfected with Toll, and is due to endogenous Toll expression in this cell line (Weber 
et al., 2003). DNT2 rescues Spz mutant lethality, which could point to promiscuity in 
DNT/Toll binding (Sutcliffe, 2010). Therefore, DNT2 could be signalling through Toll to 
activate NFκB, or through promiscuous binding to an additional, endogenously expressed 
receptor. To test these hypotheses, experiments could be repeated that included RNAi 
targeting each of the receptors. 
DNT2 activated Dif signalling in cells transfected with Toll-7 and Toll-6, at significantly 
higher levels than in untransfected cells. This indicates DNT2 signals through Toll-7 and 
Toll-6 to activate NFκB. Activation of both receptors by DNT2 suggests that there is 
promiscuity of binding between the DNTs and the Tolls. However, the DNT2 results do not 
provide any evidence of for a specific relationship to Toll-7 or Toll-6. And the results with 
DNT1 are not strong enough to rule out similarly promiscuous binding. One way to approach 
this question would be to assess the binding affinities of the DNTs to Toll-7 and Toll-6. To do 
this would require DNT1 protein of a comparable amount and purity to DNT2, that is, 
expressed using Baculovirus. With high-quality DNT1, binding affinities could be tested in 
vitro using surface plasmon resonance, or in culture by producing dose-response curves for 
NFκB activation. However, the specificity of binding and NFκB activation in cell culture 
would not necessarily reflect all of the in vivo signalling events. In the fly, whether a DNT 
binds to a Toll will depend on their expression patterns and amount of protein available to 
signal. Also, the endogenous signalling pathway will depend on the presence of Dif, Dorsal, 
or some other factor, within the cell. 
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In this chapter, I have demonstrated that DNTs signal through Tolls in cell culture. Together 
with the patterns of expression, genetic interactions, shared phenotypes and rescue 
experiments, my results support a role for Toll-7 and Toll-6 functioning in the CNS as DNT 
receptors. 
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CHAPTER 7 
DISCUSSION 
 
7.1 Summary of results 
The aims of this thesis were to investigate the functions of Toll-7 and Toll-6 in the 
Drosophila CNS, and to test whether they could function as DNT receptors. I first examined 
the expression patterns of Toll-7 and Toll-6 in embryos, and in the larval and adult CNS, by in 
situ hybridisation and by Gal4-driven expression of GAP-GFP. In embryos, Toll-7 mRNA 
was detected in the CNS and in the epidermis, and also in clusters cells in the thorax that are 
most likely the leg primordia. By the end of embryogenesis, Toll-7 expression was largely 
restricted to the leg primordia, and the CNS – where mRNA was most strongly detected. Toll-7 
mRNA was also detected in the larval CNS and the adult brain, both in central brain regions 
and the optic lobes. I generated a Toll-7-Gal4 fly line, and used it to drive expression of 
membrane-targeted GAP-GFP. There was significant overlap of the in situ and GFP 
expression patterns, particularly in the CNS. The labelling of axons by GFP identified cells as 
neurons. Toll-6 mRNA was detected in the embryonic CNS and epidermis. In late embryos, 
Toll-6 expression was distributed in the CNS and small clusters of cells lateral to the VNC, 
which could be epidermis, PNS or muscle. In situ hybridisation revealed expression of Toll-6 
in the larval CNS and in the adult brain, in both the central brain and optic lobes. Using the 
D42 Gal4 driver, which is inserted upstream of Toll-6, to drive expression of GAP-GFP, a 
population of cells was labelled that frequently overlapped with the in situ pattern. Axonal 
projections revealed these cells as neurons. Therefore, these data indicate that Toll-7 and Toll-6 
are expressed in neurons in the Drosophila CNS, from embryos to adults 
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I next investigated the functions of the receptors, and tested whether they can interact with the 
DNTs. To do this, I generated null mutant alleles, with the help of Janine Fenton and Sarah 
Quail, and generated constitutively active receptor constructs for gain-of-function transgenic 
flies. To test for a lethality phenotype, Toll-7 and Toll-6 single and double mutant flies were 
balanced over TM6B or SM6aTM6B as heterozygotes, and kept at 18°C. The survival index of 
the Toll-7P8 and Toll-7P114 mutants was slightly reduced, and that of Toll-626 and Toll-631 
mutants was not reduced, compared to controls; but Toll-7P8Toll-626 and Toll-7P114Toll-631 
double mutants show a semi-lethal phenotype. Similarly, DNT141 single mutants showed a 
reduced survival index and DNT2e03444 showed a wild-type survival index, and the 
DNT141DNT2e03444 double mutants showed a semi-lethal phenotype. I also investigated 
genetic interactions between DNTs and Tolls, by combining Toll-7, Toll-6 and DNT mutant 
alleles. Toll-7P114DNT2e03444 and Toll-626DNT141 double mutants were semi-lethal over TM6B 
at 18°C, suggesting an interaction between Toll-7 and DNT1, and Toll-6 and DNT2. The 
semi-lethality of spz2 mutants was rescued by expressing activated forms of Toll-7 and Toll-6 
in neurons, revealing that Toll-7 and Toll-6 can function like Toll, most likely by activating 
NFκB. Finally, expressing constitutively active Toll-7 and Toll-6 in neurons rescued the 
DNT141DNT2e03444 double mutant semi-lethality. This demonstrates that Toll-7 and Toll-6 can 
function downstream of DNT1 and DNT2, which is consistent with them serving as receptors 
for the DNTs. The rescue of lethality by expressing activated receptors in neurons 
demonstrates that Toll-7 and Toll-6 have important cell-autonomous functions in neurons. 
To investigate the functions of Toll-7 and Toll-6 in the Drosophila nervous system, I tested 
for locomotion, axon targeting and cell survival phenotypes. Toll-7P8/P114 and Toll-626/31 single 
and double mutant adults show locomotion phenotypes: they walk more slowly than controls, 
and spend more time resting. Therefore the receptors are required for normal locomotion in 
129 
 
adults. I next investigated a role for Toll-7 and Toll-6 in axon targeting, by looking at anti-
FasII-labelled ISNb motor axons in single and double mutant embryos. In Toll-626/31 and 
Toll-626/DfXG4 single mutants, there was in increase in the frequency of misrouting phenotypes 
compared to controls. In Toll-7P8/P114 and Toll-7P114/DfBSC22 single mutants, there was increased 
misrouting, and also hemisegments in which all of the stereotypic ISNb projections were lost. 
In Toll-7P8/P114Toll-626/31 double mutants, the misrouting and loss of projection phenotypes 
were further increased. I also tested whether Toll-7 and Toll-6 can regulate cell survival in the 
embryonic CNS. In Toll-7P8/P114, Toll-7P114/DfBSC22, Toll-626/31 and Toll-631/DfXG4 mutants, there 
was an increase in apoptosis in the embryonic VNC, indicating that Toll-7 and Toll-6 are 
required for cell survival. Expressing activated receptors in neurons rescued naturally 
occurring cell death to below control levels, showing that the receptors can promote cell 
survival. And most importantly, the increased cell death phenotype of DNT141 and 
DNT2e03444/Df6092 mutant embryos was rescued by expressing Toll-7Cys-Tyr and Toll-6Cys-Tyr in 
neurons. These results indicate that Toll-7 and Toll-6 are required for normal fly behaviour, 
and axon targeting and cell survival in the developing CNS. The rescue of DNT mutant 
phenotypes by activated receptors is evidence that Toll-7 and Toll-6 functionally interact with 
the DNTs in vivo, and act downstream of the ligands. 
Finally, to test whether DNT1 and DNT2 can signal through Toll-7 and Toll-6, I carried out 
signalling assays in cell culture. To do this, it was first necessary to generate recombinant 
DNT protein. After unsuccessful attempts with the Baculovirus system, recombinant DNT1 
was expressed in S2 cells. For expression and secretion from cells, DNT1’s endogenous pro-
domain and CTD are required, though in cultured cells the pro-domain appeared to be 
spontaneously cleaved, yielding mature DNT1 CK+CTD protein. DNT2 was produced using 
the Baculovirus expression system. As with DNT1, DNT2’s pro-domain was required for the 
130 
 
expression and secretion of DNT2 from insect cells, though it is also cleaved in culture. 
Biochemical analysis is consistent with the pro-domain being spontaneously cleaved from the 
DNT2 CK, but that the two domains remain associated under native conditions. Expressing 
Toll-7Cys-Tyr and Toll-6Cys-Tyr in S2 cells resulted in the activation of Dif and Dorsal. DNT1 
activated the Dif reporter and induced the nuclear localisation of Dorsal, signalling through 
Toll-7. DNT2 strongly activated the Dif reporter, and can signal through Toll-7 and Toll-6. 
Altogether, my data show that Toll-7 and Toll-6 are expressed in the Drosophila CNS; that 
they function to control adult behaviour, axon targeting and cell survival; and that they can 
function both in vivo and in cell culture as DNT receptors. 
7.2 Toll-7 and Toll-6 function in the Drosophila CNS 
Toll-7 and Toll-6 are expressed in the CNS, from embryos to adults. Previous reports have 
shown Toll-7, Toll-6 and Toll are expressed in the CNS; none of the other paralogues have 
been described in the nervous system (Kambris et al., 2002, Zhu et al., 2008). Toll-7Toll-6 
double mutants are semi-lethal, and this phenotype can be partially rescued by expressing 
activated receptors in neurons. This shows that, to some extent, Toll-7 and Toll-6 are required 
in the nervous system for viability. However, the incomplete rescue suggests that the 
receptors might be also required in other tissues. 
Toll-7 and Toll-6 are required for normal adult behaviour. Locomotion is frequently used as a 
phenotypic readout of neuronal function (Strauss, 2002). Although the adult phenotype cannot 
be attributed to an adult function of the genes, the phenotype of slow walking and frequent 
resting are reminiscent of defects in the central complex, where both receptors are expressed 
(Strauss and Heisenberg, 1993, Strauss, 2002). 
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Toll-7 and Toll-6 promote axon targeting and cell survival in the developing CNS, since 
single and double mutants show axon targeting phenotypes and increased apoptosis. Toll-7 
mutants showed a stronger misrouting phenotype of the ISNb motor axons, consistent with 
the expression pattern of Toll-7>GAP-GFP, in which the ISNb projections were specifically 
labelled. Toll-7 and Toll-6 mutants show an increase in apoptotic cell number in the 
developing CNS, and expressing Toll-7Cys-Tyr and Toll-6Cys-Tyr in neurons rescued naturally 
occurring cell death. Toll mutants also show axon targeting defects in embryos and larvae 
(Rose et al., 1997, Halfon et al., 1995). Halfon et al. reported the loss of the innervation of 
muscles 6 and 7, which coincided with loss of the corresponding RP3 neurons. Increased 
neuronal apoptosis in Toll mutants has also been shown (Zhu et al., 2008). Altogether, Toll, 
Toll-7 and Toll-6 share common functions, and play important roles in the development of the 
Drosophila nervous system. 
Drosophila motor neurons project to their muscle targets in a well-defined and highly 
stereotypic pattern (Landgraf et al., 1997, Landgraf and Thor, 2006). It is possible that this 
reflects a hard-wired pattern of development, in which genetically-encoded cell-autonomous 
factors determine the survival and targeting of developing motor neurons. However, there is 
evidence that motor neurons may also be subject to trophic and tropic regulation. In wild-type 
embryos, Eve+ and HB9+ motor neurons can undergo apoptosis (Rogulja-Ortmann et al., 
2007). And in DNT mutant embryos, there is a further loss of these motor neurons and their 
peripheral projections (Zhu et al., 2008). In Toll-7 mutants, the increase in CNS apoptosis is 
accompanied by losses in entire ISNb motor nerve branches. This is consistent with Toll-7 
promoting the survival of motor neurons, and could be confirmed by investigating whether 
the exccess apoptotic cells in Toll-7 mutants also express motor neuron markers. Although 
motor neurons can project to the periphery in the absence of muscle, synaptogenesis requires 
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the presence of fully-differentiated muscle, and muscle precursors direct the defasciculation 
and targeting of motor axons (Prokop et al., 1996, Landgraf et al., 1999). When their normal 
targets are ablated, motor axons can ectopically target to alternative muscles (Sink and 
Whitington, 1991, Cash et al., 1992). Conversely, when individual motor neurons are ablated, 
neighbouring axons can innervate the deprived muscle (Chang and Keshishian, 1996). These 
results are consistent with tropic interactions between muscles and motor neurons. The 
robustness of neuronal development in Drosophila is revealed by the stereotypic pattern of 
axonal targeting. Developmental plasticity – the ability of neurons and their targets to signal 
to each other and fine-tune innervation – could represent a key element of the development of 
the Drosophila nervous system. 
Since Toll-7 and Toll-6 are expressed in the larval and adult CNS, it would be interesting in 
the future to investigate the functions of the receptors at these later stages. By expressing 
activated receptors, and by using RNAi to knock-down Toll-7 and Toll-6 after embryonic 
development, larval and adult functions of the receptors could be revealed. For example, it 
would be interesting to examine the roles of Toll-7 and Toll-6 at the larval NMJ. This is a 
model synapse, and has been used to investigate structural plasticity and electrophysiological 
properties of Drosophila neurons, including in DNT mutants (Hebbar et al., 2006, Baines and 
Pym, 2006, Sutcliffe et al., Submitted). 
7.3 Different versions of activated receptors do not function equally 
To test the function of Toll-7 and Toll-6, constitutively active receptor constructs were made, 
following the example of two different published versions of constitutively active Toll 
receptors (Schneider et al., 1991, Winans and Hashimoto, 1995). Toll-7Cys-Tyr and Toll-6Cys-Tyr 
were made by mutating a cysteine residue to tyrosine in the third CRC in the extracellular 
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domain. The equivalent mutation in this conserved cysteine in Toll is responsible for the 
dominant activation seen in the Toll10b allele (Schneider et al., 1991). Toll-7ΔLRR and Toll-6ΔLRR 
were also made, where all of the LRRs and CRCs were deleted. These are equivalent 
deletions to the TollΔLRR construct, which also signals in the absence of ligand (Winans and 
Hashimoto, 1995). It was anticipated that the different versions of each activated receptor 
would produce similar effects in vivo. In the rescue of lethality of both Toll-7Toll-6 and 
DNT1DNT2 double mutants, expression of both Cys-Tyr and ΔLRR receptors resulted in an 
increased survival index; although the Cys-Tyr versions produced the stronger rescue of 
DNT1DNT2 semi-lethality. This suggested that the structural changes thought to be involved 
in Toll activation – that ligand binding releases receptor auto-inhibition (Hu et al., 2004) – are 
shared by Toll-7 and Toll-6. However, only expression of the Cys-Tyr receptors reduced 
naturally occurring cell death in the embryonic CNS. In contrast, expressing Toll-7ΔLRR 
produced no effect, and Toll-6ΔLRR resulted in an increase in the number of apoptotic cells. In 
cell culture, expression of both Toll10b and TollΔLRR results in the activation of the drosomycin-
Luciferase reporter (Sun et al., 2002, Sun et al., 2004, Hu et al., 2004). However, in a 
previous report that generated ΔLRR versions of all Toll paralogues, only TollΔLRR and Toll-5ΔLRR 
were shown to activate drosomycin-Luciferase (Tauszig et al., 2000). It is interesting that 
when I expressed Toll-7Cys-Tyr and Toll-6Cys-Tyr in S2 cells, they were able to activate 
drosomycin-Luciferase. This suggests that different versions of activated Toll-7 and Toll-6 do 
not function in the same way. The constitutive activity of TollΔLRR is partly due to a cysteine 
residue at the protein’s N-terminal: when this is removed or mutated, the level of activity falls 
to below that of Toll10b (Hu et al., 2004). This cysteine is not conserved in Toll-7 or Toll-6, 
and could explain the apparently lower level of activity of the ΔLRR receptors. The different 
in vivo results could be due to differences in how the proteins are expressed at the membrane. 
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If the ΔLRR receptors are less effective at activating cell signalling, they may not be able to 
rescue phenotypes that require stronger levels of signalling, but are still able to rescue 
phenotypes that require weaker signalling. It is possible that this is behind the observed 
differences on cell death and lethality seen when expressing Toll-7ΔLRR and Toll-6ΔLRR in 
neurons. A similar situation exists in the control of neuronal survival and outgrowth by 
NFκB: low levels of NFκB activation can promote neurite outgrowth, whereas stronger 
activation is required to promote cell survival (Gutierrez et al., 2005). Toll-7Cys-Tyr and Toll-
6Cys-Tyr rescued mutant semi-lethality and naturally occurring cell death in vivo, and activate 
NFκB signalling in cultured cells: they therefore represent the more efficient versions of 
constitutively active receptor. 
7.4 Toll-7 and Toll-6 function as DNT receptors 
As well as describing the functions of Toll-7 and Toll-6 in the Drosophila CNS, an aim of my 
thesis was to test whether they can serve as receptors for DNT1 and DNT2. To investigate this 
possibility, I looked at a number of criteria. Firstly, DNTs are expressed in neuronal targets, 
such as muscle, and have non-cell-autonomous effects on neurons (Zhu et al., 2008). Both 
Toll-7 and Toll-6 are expressed in CNS neurons, in patterns that complement and overlap 
expression of the DNTs, such as in motor neurons (Zhu et al., 2008, Sutcliffe et al., 
Submitted). Secondly, DNT mutants have defects in CNS development and function. Like 
DNT1 and DNT2, Toll-7 and Toll-6 are required in neurons for viability at 18°C, where there 
is genetic interaction between the ligands and the receptors. Moreover, both Tolls and DNTs 
are required for normal adult locomotion, they promote axon targeting, and they are necessary 
and sufficient for cell survival. Thirdly, expressing activated forms Toll-7 and Toll-6 in 
neurons rescued DNT1DNT2 double mutant semi-lethality, and also rescued the increased 
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apoptosis seen in the CNS of DNT1 and DNT2 mutants. This indicates that the receptors are 
functioning downstream of the ligands. Fourthly, in cell culture, I showed that DNT1 can 
activate NFκB signalling through Toll-7, and DNT2 through Toll-7 and Toll-6. Altogether, 
these data provide evidence that Toll-7 and Toll-6 can function as DNT receptors, both in vivo 
and in cell culture. 
The possibility exists that are two ligand/receptor pairs. The expression patterns of Toll-7 and 
Toll-6 do not reveal an obvious pairing. The receptors are expressed in broadly overlapping 
patterns, and it is possible that some neurons express both Toll-7 and Toll-6. The strongest 
evidence for specific interactions came from lethality assays. These experiments suggest that 
DNT1 and Toll-7 interact, and that DNT2 and Toll-6 interact. This set of relationships is 
supported by data from axon targeting phenotypes: both DNT1 and Toll-7 have stronger 
misrouting phenotypes in the ISNb projections, whereas DNT2 and Toll-6 have a relatively 
weaker phenotype (for DNT phenotypes, see also Zhu et al., 2008). On the other hand, Toll-
7DNT1 double mutants – putatively two members of one signalling pathway – have a stronger 
lethality phenotype than either single mutant. This suggests there are additional interactions 
between the ligands and the receptors. And in cell death experiments, DNT1 mutants have a 
stronger phenotype than DNT2, whereas Toll-7 mutants have slightly less cell death than Toll-
6. In cell culture, DNT1 appears to function through Toll-7, but it is anticipated that the weak 
effects seen through Toll-6 would become stronger and significant had higher quality, 
Baculovirus-derived protein been available. Using DNT2 from Baculovirus shows that the 
ligand can signal through both Toll-7 and Toll-6. Therefore, it is possible that some 
promiscuity exists in DNT and Toll binding. 
Previous work in our lab has shown that the DNTs are functionally redundant: expressing 
activated spz rescues the DNT1DNT2 mutant phenotype, and activated DNT1 and DNT2 
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rescue spz (Sutcliffe et al., Submitted). Similarly, I have shown that expressing activated Toll-
7 and Toll-6 can partially rescue the spz mutant semi-lethality, and that Toll10b partially 
rescues DNT1DNT2. In vivo, a number of factors most likely determine which DNT signals 
through which receptor. Primarily, the endogenous receptor will be expressed where it can 
detect the relevant DNT. And if there is ligand/receptor promiscuity, binding could be 
influenced by the relative abundance of each DNT. Binding of vertebrate neurotrophins to 
their receptors is also promiscuous, and is regulated by alternative splicing and the co-
expression of additional receptors (Clary and Reichardt, 1994, Strohmaier et al., 1996, Roux 
and Barker, 2002). Although there are no splice variants of intronless Toll-7 and Toll-6, it is 
unknown whether post-translational modifications or co-receptor expression could also 
regulate ligand/receptor specificity between the Tolls and the DNTs. 
To further characterise the biochemical relationships between the DNT1, DNT2, Toll-7 and 
Toll-6, additional experiments could be carried out in cell culture and in vitro. This would 
require much larger amounts of higher purity recombinant DNT1 protein than were produced 
during this thesis. By also expressing Toll-7 and Toll-6 proteins, in vitro experiments using 
surface plasmon resonance could determine the binding affinities of the ligands and the 
receptors. And biophysical techniques, potentially including protein crystallisation, could 
characterise the nature of DNT/Toll binding. 
7.5 Toll-7 and Toll-6 signal through NFκB 
I have shown that Toll-7 and Toll-6 signal through NFκB paralogues, Dorsal and Dif. Toll is 
known to activate both Dorsal and Dif, depending on the signalling context (Manfruelli et al., 
1999, Meng et al., 1999, Moussian and Roth, 2005). Equally, Toll-9 has also been shown to 
activate Dif (Ooi et al., 2002), and Toll-8 (Tollo) can interact with Relish, a third Drosophila 
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NFκB paralogue (Ayyar et al., 2007). And all vertebrate TLRs signal through NFκB (Kawai 
and Akira, 2007). It is most likely that, in vivo, whether Toll-7 and Toll-6 signal through 
Dorsal, Dif or heterodimers will depend on which are present in the cell. Heterodimerisation 
of Dorsal or Dif with Relish, enhances the innate immune response (Han and Ip, 1999, Tanji 
et al., 2010). It would be interesting to test whether DNT/Toll signalling can also activate 
Relish. Although it is most likely that Toll-7 and Toll-6 activate NFκB in vivo, this remains to 
be tested. To do this, NFκB could be activated by expression of dTRAF2 in Toll-7 and Toll-6 
mutants, to rescue lethality or cell death phenotypes (Cha et al., 2003). 
The activation of NFκB by neurotrophins is conserved from flies to humans. Vertebrate 
neurotrophins activate NFκB through Trks and p75NTR, to promote cell survival and neurite 
outgrowth (Foehr et al., 2000, Carter et al., 1996). The activation of NFκB by neurotrophins 
can be measured by nuclear localisation of NFκB protein subunits or with a reporter plasmid, 
and its effect on cell survival and axon growth have been attributed to its actions in the 
nucleus (Foehr et al., 2000, Carter et al., 1996, Gutierrez and Davies, 2011). NFκB regulates 
multiple aspects of neuronal development and function, and is implicated in diseases 
including epilepsy, Alzheimer’s disease and cancer (Mattson and Meffert, 2006). Neuronal 
NFκB can be activated by glutamatergic transmission and increases in intracellular Ca2+, 
which results in the nuclear localisation of NFκB and the regulation of transcription (Guerrini 
et al., 1995, Wellmann et al., 2001, Meffert et al., 2003). NFκB can then regulate synaptic 
plasticity by modifying neuronal structure and receptor expression (Gutierrez et al., 2005, 
Boersma et al., 2011, O'Mahony et al., 2006). NFκB activation is associated with 
transcriptional regulation and the induction of long-term memory in crabs, therefore role of 
NFκB in synaptic plasticity is conserved across animals (Freudenthal and Romano, 2000). In 
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all of these examples, NFκB activation results in its nuclear localisation and the regulation of 
transcription. 
NFκB was the first transcription factor to be found in synapses, but its potential functions 
outside the nucleus remain relatively unexplored (Kaltschmidt et al., 1993). In flies 
misexpression of Dorsal protein in photoreceptors can cause it to ectopically localise to axons, 
which is correlated with axon targeting defects (Mindorff et al., 2007). Indeed, Dorsal has 
been shown to function in muscle to regulate glutamate receptor density, without localising to 
the nucleus to regulate transcription (Heckscher et al., 2007). Moreover, TLR-3 and TLR-8 
can function in vertebrate axons to inhibit outgrowth, and these effects have been shown to be 
independent of NFκB (Cameron et al., 2007, Ma et al., 2006). Therefore, it is possible that 
Toll signalling could regulate multiple aspects of neuronal development and function, through 
canonical NFκB signalling in the nucleus, through alternative NFκB functions near the cell 
membrane, or through as-yet uncharacterised pathways that do not involve NFκB. In the 
future, it would be very interesting dissect the downstream signalling pathways activated in 
DNT/Toll signalling. 
7.6 Crosstalk between the nervous and immune systems 
The characterisation of Drosophila Tolls as DNT receptors raises some important questions 
about the functions of TLRs in the vertebrate nervous system. All human TLRs have been 
detected in neurons (Zhou et al., 2009), and their activation can influence neuronal cell 
number and morphology (Okun et al., 2011). TLRs bind a number of endogenous ligands, 
many of which are released by damaged or necrotic tissue (Sloane et al., 2010). TLRs can also 
be activated by secreted endogenous ligands, such as HMGB1, which can promote neurite 
outgrowth by binding its alternative receptor, RAGE (Yang et al., 2005, Hori et al., 1995). 
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And there is evidence that TLRs could play a role in normal neuronal functioning: TLR3 
knock-out mice show cognitive defects, suggesting signalling is important also in the absence 
of infection (Okun et al., 2010a). However, the endogenous ligands of TLRs in the 
undamaged, ‘sterile’ brain are unknown. Toll and neurotrophin families are found in humans 
and in flies, and Tolls have neuronal functions in both animals. It is therefore compelling to 
test whether vertebrate neurotrophins constitute a family of endogenous vertebrate TLR 
ligands, and to investigate whether the relationship between Tolls and neurotrophins is 
conserved across animals. 
There are reports of cross-talk between the TLR and neurotrophin signalling pathways in 
immune cells. In dendritic cells – initiators of the innate and adaptive immune responses – 
TLR4 signalling can up-regulate the expression of NGF and p75NTR (Jiang et al., 2008). 
NGF/p75NTR signalling can then enhance the maturation of LPS-stimulated dendritic cells, to 
promote the release of cytokines and to activate T-cells of the adaptive immune system (Jiang 
et al., 2007). It would be interesting to test whether TLR signalling in neurons can also 
interact with neurotrophin/p75NTR/Trk signalling pathways, and explore the effect of TLR 
signalling on neuronal function both in health and in inflammation. 
The generation of mature Spz protein is through a proteolytic cascade, which involves 
different zymogens in dorsoventral patterning and immunity; it is unknown what proteases 
normally cleave pro-Spz for it to function as a neurotrophin, or how DNT1 and DNT2 are 
endogenously processed. Proteolytic cascades are also seen in the vertebrate coagulation 
cascade, where circulating factors in the blood are sequentially activated, resulting in the 
formation of a fibrin clot. The key mechanism of vertebrate coagulation – an amplifying 
proteolytic cascade – is also seen in invertebrates. An analogous process occurs in the 
horseshoe crab, but instead of the cascade converging on fibrin activation, Coagulagen is 
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cleaved and goes on to form a clot (Osaki and Kawabata, 2004). In vertebrates, the protease 
Plasmin plays an important role in the control of blood coagulation by breaking down the 
fibrin clot. Plasmin is itself activated by a protease, tissue Plasminogen Activator (tPA). In the 
vertebrate CNS, the tPA/Plasmin proteolytic cascade results in the cleavage of BDNF – a 
structural homologue of Coagulogen (Pang et al., 2004). And this process is directly regulated 
by the secretion of tPA from neurons in response to neuronal activity, which is a key 
mechanism in the regulation of LTP (Nagappan et al., 2009). There is an intriguing similarity 
between the mechanisms that control haemostasis and neurotrophin signalling, at the centre of 
which are Cys-knot proteins. 
Spz plays a central role in the Drosophila innate immune system, and the aggregation of 
Coagulogen is part of the horseshoe crab’s immune response (Bergner et al., 1996). Immune 
functions of Cys-knot proteins are conserved across animals, and neurotrophins are involved 
in multiple aspects of mammalian innate and adaptive immune responses (Vega et al., 2003). 
BDNF is involved in the development of the pre-implantation mouse embryo (Kawamura et 
al., 2007), and Spz has a well-defined role in the establishment of the dorsoventral axis in 
early Drosophila embryos (Moussian and Roth, 2005). And the structure and function of 
vertebrate and Drosophila neurotrophins are conserved. These are disparate functions, and the 
co-option of one signalling pathway to a different physiological system, raises an important 
point. In the end, it is the result of signalling that matters, not the means. It matters far more 
that neurons and immune cells can respond to extracellular signals, than it matters that 
neurotrophins convey those signals. Vertebrate and Drosophila neurotrophins are structural 
homologues; they both promote the survival, targeting and function of neurons; and they 
activate NFκB signalling. In vertebrates, neurotrophins signal through Trk and p75NTR, 
whereas in Drosophila, they signal through Tolls. 
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7.7 Implications 
My thesis has established roles for Toll-7 and Toll-6 in the development and function of the 
Drosophila nervous system. I have also shown that Tolls can function as neurotrophin 
receptors. This introduces a different class of protein to the neurotrophin receptors, which in 
vertebrates includes Trks, p75NTR and Sortilin. It is now compelling to examine whether the 
neurotrophin/Toll relationship is conserved, by testing whether vertebrate neurotrophins can 
bind and signal through TLRs. The characterisation of neuronal functions of Tolls, 
homologues to vertebrate immune receptors, also sheds more light on the link between the 
nervous and immune systems. And in Drosophila, the identification of receptors for DNT1 
and DNT2 allows the continued and more detailed investigation of Drosophila neurotrophin 
signalling. 
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